CA2029569A1 - Benzoxazine derivatives and pharmaceutical compositions containing the same - Google Patents
Benzoxazine derivatives and pharmaceutical compositions containing the sameInfo
- Publication number
- CA2029569A1 CA2029569A1 CA002029569A CA2029569A CA2029569A1 CA 2029569 A1 CA2029569 A1 CA 2029569A1 CA 002029569 A CA002029569 A CA 002029569A CA 2029569 A CA2029569 A CA 2029569A CA 2029569 A1 CA2029569 A1 CA 2029569A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- substituted
- formula
- optionally
- lower alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000005130 benzoxazines Chemical class 0.000 title claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 37
- -1 oxo-substituted nitrogen Chemical class 0.000 claims description 156
- 150000001875 compounds Chemical class 0.000 claims description 155
- 125000000217 alkyl group Chemical group 0.000 claims description 76
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 46
- 125000002947 alkylene group Chemical group 0.000 claims description 43
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 40
- 125000005843 halogen group Chemical group 0.000 claims description 37
- 125000000623 heterocyclic group Chemical group 0.000 claims description 33
- 230000008569 process Effects 0.000 claims description 30
- 125000003545 alkoxy group Chemical group 0.000 claims description 23
- 125000003277 amino group Chemical group 0.000 claims description 22
- 125000003282 alkyl amino group Chemical group 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 13
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 11
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 11
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 11
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 10
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 10
- 125000001769 aryl amino group Chemical group 0.000 claims description 9
- 125000002837 carbocyclic group Chemical group 0.000 claims description 9
- 125000004043 oxo group Chemical group O=* 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000004450 alkenylene group Chemical group 0.000 claims description 8
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 7
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical class [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 7
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 6
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 230000001590 oxidative effect Effects 0.000 claims description 5
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 claims description 4
- 125000000484 butyl group Chemical class [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000005594 diketone group Chemical group 0.000 claims description 4
- 150000004820 halides Chemical class 0.000 claims description 4
- 125000001436 propyl group Chemical class [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000001539 acetonyl group Chemical group [H]C([H])([H])C(=O)C([H])([H])* 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 238000007363 ring formation reaction Methods 0.000 claims description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 3
- ZBHZHRGREIOWJN-UHFFFAOYSA-N 2,2-dimethyl-4-(6-methyl-1-oxidopyridin-1-ium-2-yl)-6-nitro-3h-1,4-benzoxazine Chemical compound CC1=CC=CC(N2C3=CC(=CC=C3OC(C)(C)C2)[N+]([O-])=O)=[N+]1[O-] ZBHZHRGREIOWJN-UHFFFAOYSA-N 0.000 claims description 2
- GOTJEXSHEQBBSV-UHFFFAOYSA-N 2,2-dimethyl-6-nitro-4-(1-oxidopyridin-1-ium-2-yl)-3h-1,4-benzoxazine Chemical compound C12=CC([N+]([O-])=O)=CC=C2OC(C)(C)CN1C1=CC=CC=[N+]1[O-] GOTJEXSHEQBBSV-UHFFFAOYSA-N 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 125000000018 nitroso group Chemical group N(=O)* 0.000 claims description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims description 2
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims description 2
- 125000000815 N-oxide group Chemical group 0.000 claims 3
- USEBNTJCYGURRQ-UHFFFAOYSA-N 2,2-dimethyl-4-(1-oxidopyridin-1-ium-2-yl)-3h-1,4-benzoxazine-6-carbonitrile Chemical compound C12=CC(C#N)=CC=C2OC(C)(C)CN1C1=CC=CC=[N+]1[O-] USEBNTJCYGURRQ-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 9
- 108010083133 potassium channel protein I(sk) Proteins 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 169
- 238000000921 elemental analysis Methods 0.000 description 102
- 238000002844 melting Methods 0.000 description 101
- 230000008018 melting Effects 0.000 description 101
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 95
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 72
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 63
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 61
- 239000000203 mixture Substances 0.000 description 61
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 51
- 239000000243 solution Substances 0.000 description 40
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 35
- 235000002639 sodium chloride Nutrition 0.000 description 35
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 34
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 29
- 239000000543 intermediate Substances 0.000 description 26
- 239000002904 solvent Substances 0.000 description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 239000011541 reaction mixture Substances 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- 239000013078 crystal Substances 0.000 description 18
- 238000001819 mass spectrum Methods 0.000 description 17
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 238000001816 cooling Methods 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 239000000460 chlorine Substances 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 14
- 108091006146 Channels Proteins 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 239000012044 organic layer Substances 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- 229960001866 silicon dioxide Drugs 0.000 description 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 239000002585 base Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000006722 reduction reaction Methods 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- 229910000104 sodium hydride Inorganic materials 0.000 description 10
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 9
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 9
- 239000003960 organic solvent Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000003213 activating effect Effects 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 8
- 238000001953 recrystallisation Methods 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- 101150041968 CDC13 gene Proteins 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 239000005457 ice water Substances 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- QRAOZQGIUIDZQZ-UHFFFAOYSA-N 4-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1,4-benzoxazine Chemical class C=1C=C2N(C)CCOC2=CC=1B1OC(C)(C)C(C)(C)O1 QRAOZQGIUIDZQZ-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- 150000001204 N-oxides Chemical group 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 230000008602 contraction Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000012312 sodium hydride Substances 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 5
- 235000011054 acetic acid Nutrition 0.000 description 5
- 238000007112 amidation reaction Methods 0.000 description 5
- 125000003710 aryl alkyl group Chemical group 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 229910000085 borane Inorganic materials 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 210000004351 coronary vessel Anatomy 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 4
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
- PVTXJGJDOHYFOX-UHFFFAOYSA-N 2h-1,4-benzoxazine Chemical compound C1=CC=C2N=CCOC2=C1 PVTXJGJDOHYFOX-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 238000007126 N-alkylation reaction Methods 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000009435 amidation Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 229960001412 pentobarbital Drugs 0.000 description 4
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- TVZCRIROJQEVOT-CABCVRRESA-N Cromakalim Chemical compound N1([C@@H]2C3=CC(=CC=C3OC([C@H]2O)(C)C)C#N)CCCC1=O TVZCRIROJQEVOT-CABCVRRESA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 3
- 230000006181 N-acylation Effects 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000007868 Raney catalyst Substances 0.000 description 3
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 3
- 229910000564 Raney nickel Inorganic materials 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229950004210 cromakalim Drugs 0.000 description 3
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 150000002832 nitroso derivatives Chemical class 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000011698 potassium fluoride Substances 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 230000001020 rhythmical effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000050 smooth muscle relaxant Substances 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000000304 vasodilatating effect Effects 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- DIJIMOVRKFEFGE-UHFFFAOYSA-N 2,2-dimethyl-3,4-dihydro-1,4-benzoxazine-6-carbonitrile Chemical compound N#CC1=CC=C2OC(C)(C)CNC2=C1 DIJIMOVRKFEFGE-UHFFFAOYSA-N 0.000 description 2
- IMTHKLARQSFDMB-UHFFFAOYSA-N 2,2-dimethyl-6-nitro-3,4-dihydro-1,4-benzoxazine Chemical compound [O-][N+](=O)C1=CC=C2OC(C)(C)CNC2=C1 IMTHKLARQSFDMB-UHFFFAOYSA-N 0.000 description 2
- VBMDIQOUBJVRRS-UHFFFAOYSA-N 2,2-dimethyl-6-nitro-4-(pyridin-2-ylmethyl)-3h-1,4-benzoxazine Chemical compound C12=CC([N+]([O-])=O)=CC=C2OC(C)(C)CN1CC1=CC=CC=N1 VBMDIQOUBJVRRS-UHFFFAOYSA-N 0.000 description 2
- AZCVPOWFCAKLHB-UHFFFAOYSA-N 2,2-dimethyl-6-nitro-4-nitroso-3h-1,4-benzoxazine Chemical compound [O-][N+](=O)C1=CC=C2OC(C)(C)CN(N=O)C2=C1 AZCVPOWFCAKLHB-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- FRYPQGMFDZBQEW-UHFFFAOYSA-N 2-bromo-1-oxidopyridin-1-ium;hydron;chloride Chemical compound Cl.[O-][N+]1=CC=CC=C1Br FRYPQGMFDZBQEW-UHFFFAOYSA-N 0.000 description 2
- NPJOEZALOGQJPK-UHFFFAOYSA-N 2-methyl-2-[2-nitro-4-(trifluoromethyl)phenoxy]propanal Chemical compound O=CC(C)(C)OC1=CC=C(C(F)(F)F)C=C1[N+]([O-])=O NPJOEZALOGQJPK-UHFFFAOYSA-N 0.000 description 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 2
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- NRIGFAXKKZDHGU-UHFFFAOYSA-N 6-(benzenesulfonyl)-2,2-dimethyl-4h-1,4-benzoxazin-3-one Chemical compound C1=C2NC(=O)C(C)(C)OC2=CC=C1S(=O)(=O)C1=CC=CC=C1 NRIGFAXKKZDHGU-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 208000000884 Airway Obstruction Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 238000006859 Swern oxidation reaction Methods 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000003377 acid catalyst Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- OYTKINVCDFNREN-UHFFFAOYSA-N amifampridine Chemical compound NC1=CC=NC=C1N OYTKINVCDFNREN-UHFFFAOYSA-N 0.000 description 2
- 229960004012 amifampridine Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 210000001627 cerebral artery Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- UXTMROKLAAOEQO-UHFFFAOYSA-N chloroform;ethanol Chemical compound CCO.ClC(Cl)Cl UXTMROKLAAOEQO-UHFFFAOYSA-N 0.000 description 2
- DDKMFOUTRRODRE-UHFFFAOYSA-N chloromethanone Chemical compound Cl[C]=O DDKMFOUTRRODRE-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 2
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 2
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 2
- IOLQWGVDEFWYNP-UHFFFAOYSA-N ethyl 2-bromo-2-methylpropanoate Chemical compound CCOC(=O)C(C)(C)Br IOLQWGVDEFWYNP-UHFFFAOYSA-N 0.000 description 2
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 150000002367 halogens Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 125000005956 isoquinolyl group Chemical group 0.000 description 2
- 150000003951 lactams Chemical group 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 235000003270 potassium fluoride Nutrition 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 231100000816 toxic dose Toxicity 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 210000005090 tracheal smooth muscle Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- LPKSLSMKAZZMHM-UHFFFAOYSA-N (2,2-dimethyl-6-nitro-3h-1,4-benzoxazin-4-yl)-(furan-2-yl)methanone Chemical compound C12=CC([N+]([O-])=O)=CC=C2OC(C)(C)CN1C(=O)C1=CC=CO1 LPKSLSMKAZZMHM-UHFFFAOYSA-N 0.000 description 1
- CZPPZVSRLQLGMR-UHFFFAOYSA-N (2,2-dimethyl-6-nitro-3h-1,4-benzoxazin-4-yl)-pyridin-3-ylmethanone;hydrochloride Chemical compound Cl.C12=CC([N+]([O-])=O)=CC=C2OC(C)(C)CN1C(=O)C1=CC=CN=C1 CZPPZVSRLQLGMR-UHFFFAOYSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- DZKRDHLYQRTDBU-UPHRSURJSA-N (z)-but-2-enediperoxoic acid Chemical compound OOC(=O)\C=C/C(=O)OO DZKRDHLYQRTDBU-UPHRSURJSA-N 0.000 description 1
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- HTFVKMHFUBCIMH-UHFFFAOYSA-N 1,3,5-triiodo-1,3,5-triazinane-2,4,6-trione Chemical compound IN1C(=O)N(I)C(=O)N(I)C1=O HTFVKMHFUBCIMH-UHFFFAOYSA-N 0.000 description 1
- LJFZLFULOMXSFP-UHFFFAOYSA-N 1-(2,2-dimethyl-3h-1,4-benzoxazin-4-yl)pyrrolidin-2-one Chemical compound C12=CC=CC=C2OC(C)(C)CN1N1CCCC1=O LJFZLFULOMXSFP-UHFFFAOYSA-N 0.000 description 1
- BBLFUCHOQHNWJT-UHFFFAOYSA-N 1-(2,2-dimethyl-5,7-dinitro-3h-1,4-benzoxazin-4-yl)pyrrolidin-2-one Chemical compound C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1OC(C)(C)CN2N1CCCC1=O BBLFUCHOQHNWJT-UHFFFAOYSA-N 0.000 description 1
- PKYPPGYKZRJWJY-UHFFFAOYSA-N 1-(2,2-dimethyl-6-nitro-3h-1,4-benzoxazin-4-yl)propan-2-ol Chemical compound C1=C([N+]([O-])=O)C=C2N(CC(O)C)CC(C)(C)OC2=C1 PKYPPGYKZRJWJY-UHFFFAOYSA-N 0.000 description 1
- BKIUSMQQJHKXCL-UHFFFAOYSA-N 1-(2,2-dimethyl-6-nitro-3h-1,4-benzoxazin-4-yl)propan-2-one Chemical compound C1=C([N+]([O-])=O)C=C2N(CC(=O)C)CC(C)(C)OC2=C1 BKIUSMQQJHKXCL-UHFFFAOYSA-N 0.000 description 1
- SBEVXJVUGSXTGR-UHFFFAOYSA-N 1-(2,2-dimethyl-6-nitro-3h-1,4-benzoxazin-4-yl)pyrrolidin-2-one Chemical compound C12=CC([N+]([O-])=O)=CC=C2OC(C)(C)CN1N1CCCC1=O SBEVXJVUGSXTGR-UHFFFAOYSA-N 0.000 description 1
- HNEGJTWNOOWEMH-UHFFFAOYSA-N 1-fluoropropane Chemical group [CH2]CCF HNEGJTWNOOWEMH-UHFFFAOYSA-N 0.000 description 1
- DZJLJUXZISUCGU-UHFFFAOYSA-N 1-oxidopyridin-1-ium;hydrochloride Chemical compound Cl.[O-][N+]1=CC=CC=C1 DZJLJUXZISUCGU-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- XYPISWUKQGWYGX-UHFFFAOYSA-N 2,2,2-trifluoroethaneperoxoic acid Chemical compound OOC(=O)C(F)(F)F XYPISWUKQGWYGX-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- VANDPUANQKJCMP-UHFFFAOYSA-N 2,2-dimethyl-4-(1-oxidopyridin-1-ium-2-yl)-3h-1,4-benzoxazin-6-amine Chemical compound C12=CC(N)=CC=C2OC(C)(C)CN1C1=CC=CC=[N+]1[O-] VANDPUANQKJCMP-UHFFFAOYSA-N 0.000 description 1
- AUMQPZWBCBWRIK-UHFFFAOYSA-N 2,2-dimethyl-4-(2-oxocyclopentyl)-3h-1,4-benzoxazine-6-carbonitrile Chemical compound C12=CC(C#N)=CC=C2OC(C)(C)CN1C1CCCC1=O AUMQPZWBCBWRIK-UHFFFAOYSA-N 0.000 description 1
- IAFTYWKPEUUOJJ-UHFFFAOYSA-N 2,2-dimethyl-4-(2-oxooxolan-3-yl)-3h-1,4-benzoxazine-6-carbonitrile Chemical compound C12=CC(C#N)=CC=C2OC(C)(C)CN1C1CCOC1=O IAFTYWKPEUUOJJ-UHFFFAOYSA-N 0.000 description 1
- JZNTYADLPAJGIA-UHFFFAOYSA-N 2,2-dimethyl-4-(2-oxopyrrolidin-1-yl)-3h-1,4-benzoxazine-6-carbonitrile Chemical compound C12=CC(C#N)=CC=C2OC(C)(C)CN1N1CCCC1=O JZNTYADLPAJGIA-UHFFFAOYSA-N 0.000 description 1
- PUVYTYWUMAIGOY-UHFFFAOYSA-N 2,2-dimethyl-4-(3-oxocyclohexen-1-yl)-3h-1,4-benzoxazine-6-carbonitrile Chemical compound C12=CC(C#N)=CC=C2OC(C)(C)CN1C1=CC(=O)CCC1 PUVYTYWUMAIGOY-UHFFFAOYSA-N 0.000 description 1
- XMMYSLGODSFLMZ-UHFFFAOYSA-N 2,2-dimethyl-4-(3-oxocyclopenten-1-yl)-3h-1,4-benzoxazine-6-carbonitrile Chemical compound C12=CC(C#N)=CC=C2OC(C)(C)CN1C1=CC(=O)CC1 XMMYSLGODSFLMZ-UHFFFAOYSA-N 0.000 description 1
- HTLBYESPMRBFEE-UHFFFAOYSA-N 2,2-dimethyl-4-(4-methyl-5-oxocyclopenten-1-yl)-3h-1,4-benzoxazine-6-carbonitrile Chemical compound O=C1C(C)CC=C1N1C2=CC(C#N)=CC=C2OC(C)(C)C1 HTLBYESPMRBFEE-UHFFFAOYSA-N 0.000 description 1
- MIXJLFFNWSIQPY-UHFFFAOYSA-N 2,2-dimethyl-4-(5-oxocyclopenten-1-yl)-3h-1,4-benzoxazine-6-carbonitrile Chemical compound C12=CC(C#N)=CC=C2OC(C)(C)CN1C1=CCCC1=O MIXJLFFNWSIQPY-UHFFFAOYSA-N 0.000 description 1
- BZPHGFIDXLSLJQ-UHFFFAOYSA-N 2,2-dimethyl-4-(6-oxocyclohexen-1-yl)-3h-1,4-benzoxazine-6-carbonitrile Chemical compound C12=CC(C#N)=CC=C2OC(C)(C)CN1C1=CCCCC1=O BZPHGFIDXLSLJQ-UHFFFAOYSA-N 0.000 description 1
- CBXNIGCWMCUSHW-UHFFFAOYSA-N 2,2-dimethyl-4-(pyridin-3-ylmethyl)-3h-1,4-benzoxazine-6-carbonitrile Chemical compound C12=CC(C#N)=CC=C2OC(C)(C)CN1CC1=CC=CN=C1 CBXNIGCWMCUSHW-UHFFFAOYSA-N 0.000 description 1
- SKOINCOVXOORKR-UHFFFAOYSA-N 2,2-dimethyl-4-[(1-oxidopyridin-1-ium-3-yl)methyl]-3h-1,4-benzoxazine-6-carbonitrile Chemical compound C12=CC(C#N)=CC=C2OC(C)(C)CN1CC1=CC=C[N+]([O-])=C1 SKOINCOVXOORKR-UHFFFAOYSA-N 0.000 description 1
- CLSXPZNESPYELB-UHFFFAOYSA-N 2,2-dimethyl-6-(trifluoromethyl)-3,4-dihydro-1,4-benzoxazine Chemical compound FC(F)(F)C1=CC=C2OC(C)(C)CNC2=C1 CLSXPZNESPYELB-UHFFFAOYSA-N 0.000 description 1
- VHSXXSRMKIUOHO-UHFFFAOYSA-N 2,2-dimethyl-6-methylsulfonyl-3,4-dihydro-1,4-benzoxazine Chemical compound CS(=O)(=O)C1=CC=C2OC(C)(C)CNC2=C1 VHSXXSRMKIUOHO-UHFFFAOYSA-N 0.000 description 1
- MGIUXNYGZVKJBM-UHFFFAOYSA-N 2,2-dimethyl-6-methylsulfonyl-4-(1-oxidopyridin-1-ium-2-yl)-3h-1,4-benzoxazine Chemical compound C12=CC(S(C)(=O)=O)=CC=C2OC(C)(C)CN1C1=CC=CC=[N+]1[O-] MGIUXNYGZVKJBM-UHFFFAOYSA-N 0.000 description 1
- NBVAERFANIDDLX-UHFFFAOYSA-N 2,2-dimethyl-6-methylsulfonyl-4h-1,4-benzoxazin-3-one Chemical compound C1=C(S(C)(=O)=O)C=C2NC(=O)C(C)(C)OC2=C1 NBVAERFANIDDLX-UHFFFAOYSA-N 0.000 description 1
- MRRVFBGBRZDIHU-UHFFFAOYSA-N 2,2-dimethyl-6-nitro-4-(2-oxocyclopentyl)-1,4-benzoxazin-3-one Chemical compound O=C1C(C)(C)OC2=CC=C([N+]([O-])=O)C=C2N1C1CCCC1=O MRRVFBGBRZDIHU-UHFFFAOYSA-N 0.000 description 1
- WQNYNMFLDZOMQV-UHFFFAOYSA-N 2,2-dimethyl-6-nitro-4-(pyridin-3-ylmethyl)-3h-1,4-benzoxazine;hydrochloride Chemical compound Cl.C12=CC([N+]([O-])=O)=CC=C2OC(C)(C)CN1CC1=CC=CN=C1 WQNYNMFLDZOMQV-UHFFFAOYSA-N 0.000 description 1
- VCXZWPGYNNKEHR-UHFFFAOYSA-N 2,2-dimethyl-6-nitro-4-[(2-nitrophenyl)methyl]-3h-1,4-benzoxazine Chemical compound C12=CC([N+]([O-])=O)=CC=C2OC(C)(C)CN1CC1=CC=CC=C1[N+]([O-])=O VCXZWPGYNNKEHR-UHFFFAOYSA-N 0.000 description 1
- BWGCJQXYJXVYJQ-UHFFFAOYSA-N 2,2-dimethyl-6-nitro-4-[(3-nitrophenyl)methyl]-3h-1,4-benzoxazine Chemical compound C12=CC([N+]([O-])=O)=CC=C2OC(C)(C)CN1CC1=CC=CC([N+]([O-])=O)=C1 BWGCJQXYJXVYJQ-UHFFFAOYSA-N 0.000 description 1
- HVKHZXGGARKFKV-UHFFFAOYSA-N 2,2-dimethyl-6-nitro-4-[(4-nitrophenyl)methyl]-3h-1,4-benzoxazine Chemical compound C12=CC([N+]([O-])=O)=CC=C2OC(C)(C)CN1CC1=CC=C([N+]([O-])=O)C=C1 HVKHZXGGARKFKV-UHFFFAOYSA-N 0.000 description 1
- AEFTZHJMWLPNAQ-UHFFFAOYSA-N 2,2-dimethyl-6-nitro-4-phenacyl-1,4-benzoxazin-3-one Chemical compound O=C1C(C)(C)OC2=CC=C([N+]([O-])=O)C=C2N1CC(=O)C1=CC=CC=C1 AEFTZHJMWLPNAQ-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- CPUXOJVJEJZOSP-UHFFFAOYSA-N 2,4-difluoro-N-[2-methoxy-5-[4-methyl-8-[(3-methyloxetan-3-yl)methoxy]quinazolin-6-yl]pyridin-3-yl]benzenesulfonamide Chemical compound COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1cc(OCC2(C)COC2)c2ncnc(C)c2c1 CPUXOJVJEJZOSP-UHFFFAOYSA-N 0.000 description 1
- SKOVEBQVMZHDQB-UHFFFAOYSA-N 2-(2,2-dimethyl-6-nitro-3-oxo-1,4-benzoxazin-4-yl)-n-methylacetamide Chemical compound C1=C([N+]([O-])=O)C=C2N(CC(=O)NC)C(=O)C(C)(C)OC2=C1 SKOVEBQVMZHDQB-UHFFFAOYSA-N 0.000 description 1
- GGMUWLSNRXCPKK-UHFFFAOYSA-N 2-(2,2-dimethyl-6-nitro-3h-1,4-benzoxazin-4-yl)-1-phenylethanol Chemical compound C12=CC([N+]([O-])=O)=CC=C2OC(C)(C)CN1CC(O)C1=CC=CC=C1 GGMUWLSNRXCPKK-UHFFFAOYSA-N 0.000 description 1
- USYVAKRNAQYXPB-UHFFFAOYSA-N 2-(2,2-dimethyl-6-nitro-3h-1,4-benzoxazin-4-yl)-n,n-dimethylacetamide Chemical compound C1=C([N+]([O-])=O)C=C2N(CC(=O)N(C)C)CC(C)(C)OC2=C1 USYVAKRNAQYXPB-UHFFFAOYSA-N 0.000 description 1
- VHPJMOLJHJZAGT-UHFFFAOYSA-N 2-(2,2-dimethyl-6-nitro-3h-1,4-benzoxazin-4-yl)-n-(2-hydroxyethyl)acetamide Chemical compound [O-][N+](=O)C1=CC=C2OC(C)(C)CN(CC(=O)NCCO)C2=C1 VHPJMOLJHJZAGT-UHFFFAOYSA-N 0.000 description 1
- QGYLIJVGQKFVCN-UHFFFAOYSA-N 2-(2,2-dimethyl-6-nitro-3h-1,4-benzoxazin-4-yl)-n-ethylacetamide Chemical compound C1=C([N+]([O-])=O)C=C2N(CC(=O)NCC)CC(C)(C)OC2=C1 QGYLIJVGQKFVCN-UHFFFAOYSA-N 0.000 description 1
- FULTVMZGPYATGN-UHFFFAOYSA-N 2-(2,2-dimethyl-6-nitro-3h-1,4-benzoxazin-4-yl)-n-methyl-2-oxoacetamide Chemical compound C1=C([N+]([O-])=O)C=C2N(C(=O)C(=O)NC)CC(C)(C)OC2=C1 FULTVMZGPYATGN-UHFFFAOYSA-N 0.000 description 1
- ROVINHFKTPCVKN-UHFFFAOYSA-N 2-(2,2-dimethyl-6-nitro-3h-1,4-benzoxazin-4-yl)-n-methylpropanamide Chemical compound C1=C([N+]([O-])=O)C=C2N(C(C)C(=O)NC)CC(C)(C)OC2=C1 ROVINHFKTPCVKN-UHFFFAOYSA-N 0.000 description 1
- WPBXXTKEVOGCAV-UHFFFAOYSA-N 2-(2,2-dimethyl-6-nitro-3h-1,4-benzoxazin-4-yl)-n-phenylacetamide Chemical compound C12=CC([N+]([O-])=O)=CC=C2OC(C)(C)CN1CC(=O)NC1=CC=CC=C1 WPBXXTKEVOGCAV-UHFFFAOYSA-N 0.000 description 1
- ZSEKVOVEAKBIOO-UHFFFAOYSA-N 2-(2,2-dimethyl-6-nitro-3h-1,4-benzoxazin-4-yl)acetamide Chemical compound [O-][N+](=O)C1=CC=C2OC(C)(C)CN(CC(N)=O)C2=C1 ZSEKVOVEAKBIOO-UHFFFAOYSA-N 0.000 description 1
- RWFJSOCCOWJQDQ-UHFFFAOYSA-N 2-(2,2-dimethyl-6-nitro-3h-1,4-benzoxazin-4-yl)acetic acid Chemical compound [O-][N+](=O)C1=CC=C2OC(C)(C)CN(CC(O)=O)C2=C1 RWFJSOCCOWJQDQ-UHFFFAOYSA-N 0.000 description 1
- LCOCTOCFEIYGIC-UHFFFAOYSA-N 2-(2,2-dimethyl-6-nitro-3h-1,4-benzoxazin-4-yl)cyclopent-2-en-1-one Chemical compound C12=CC([N+]([O-])=O)=CC=C2OC(C)(C)CN1C1=CCCC1=O LCOCTOCFEIYGIC-UHFFFAOYSA-N 0.000 description 1
- WPRJIUBKSNDYJT-UHFFFAOYSA-N 2-(2,2-dimethyl-6-nitro-3h-1,4-benzoxazin-4-yl)cyclopentan-1-ol Chemical compound C12=CC([N+]([O-])=O)=CC=C2OC(C)(C)CN1C1CCCC1O WPRJIUBKSNDYJT-UHFFFAOYSA-N 0.000 description 1
- ARMKOVLEDRQFCX-UHFFFAOYSA-N 2-(2,2-dimethyl-6-nitro-3h-1,4-benzoxazin-4-yl)cyclopentan-1-one Chemical compound C12=CC([N+]([O-])=O)=CC=C2OC(C)(C)CN1C1CCCC1=O ARMKOVLEDRQFCX-UHFFFAOYSA-N 0.000 description 1
- MRPGQARUNHOVOV-UHFFFAOYSA-N 2-(2,2-dimethyl-7-nitro-3h-1,4-benzoxazin-4-yl)cyclopent-2-en-1-one Chemical compound C12=CC=C([N+]([O-])=O)C=C2OC(C)(C)CN1C1=CCCC1=O MRPGQARUNHOVOV-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- AVDSNKIYZURTBF-UHFFFAOYSA-N 2-(6-ethyl-2,2-dimethyl-3h-1,4-benzoxazin-4-yl)cyclopent-2-en-1-one Chemical compound C12=CC(CC)=CC=C2OC(C)(C)CN1C1=CCCC1=O AVDSNKIYZURTBF-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- LGFBEIIYUCYUKO-UHFFFAOYSA-N 2-amino-4-(benzenesulfonyl)phenol Chemical compound C1=C(O)C(N)=CC(S(=O)(=O)C=2C=CC=CC=2)=C1 LGFBEIIYUCYUKO-UHFFFAOYSA-N 0.000 description 1
- ZARYBZGMUVAJMK-UHFFFAOYSA-N 2-amino-4-chloro-5-nitrophenol Chemical compound NC1=CC(Cl)=C([N+]([O-])=O)C=C1O ZARYBZGMUVAJMK-UHFFFAOYSA-N 0.000 description 1
- KLTWFFAVGWWIKL-UHFFFAOYSA-N 2-bromo-2-methylpropanal Chemical compound CC(C)(Br)C=O KLTWFFAVGWWIKL-UHFFFAOYSA-N 0.000 description 1
- GLVYLTSKTCWWJR-UHFFFAOYSA-N 2-carbonoperoxoylbenzoic acid Chemical compound OOC(=O)C1=CC=CC=C1C(O)=O GLVYLTSKTCWWJR-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- JQPFYXFVUKHERX-UHFFFAOYSA-N 2-hydroxy-2-cyclohexen-1-one Natural products OC1=CCCCC1=O JQPFYXFVUKHERX-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- XZEDEVRSUANQEM-UHFFFAOYSA-N 2-nitro-4-(trifluoromethyl)phenol Chemical compound OC1=CC=C(C(F)(F)F)C=C1[N+]([O-])=O XZEDEVRSUANQEM-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000005131 2H-1,4-benzoxazines Chemical class 0.000 description 1
- BWIWAUYDSLJZCR-UHFFFAOYSA-N 3-(2,2-dimethyl-6-nitro-3h-1,4-benzoxazin-4-yl)-n,n-dimethylpyrazine-2-carboxamide Chemical compound CN(C)C(=O)C1=NC=CN=C1N1C2=CC([N+]([O-])=O)=CC=C2OC(C)(C)C1 BWIWAUYDSLJZCR-UHFFFAOYSA-N 0.000 description 1
- AYVNBJOPZPMPQN-UHFFFAOYSA-N 3-(2,2-dimethyl-6-nitro-3h-1,4-benzoxazine-4-carbonyl)-1h-pyridin-2-one Chemical compound C12=CC([N+]([O-])=O)=CC=C2OC(C)(C)CN1C(=O)C1=CC=CN=C1O AYVNBJOPZPMPQN-UHFFFAOYSA-N 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical compound NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- NYYSPVRERVXMLJ-UHFFFAOYSA-N 4,4-difluorocyclohexan-1-one Chemical compound FC1(F)CCC(=O)CC1 NYYSPVRERVXMLJ-UHFFFAOYSA-N 0.000 description 1
- LBOMJGCFUPJYHP-UHFFFAOYSA-N 4-(2,2-dimethyl-6-nitro-3h-1,4-benzoxazin-4-yl)-4-oxobut-2-enoic acid Chemical compound [O-][N+](=O)C1=CC=C2OC(C)(C)CN(C(=O)C=CC(O)=O)C2=C1 LBOMJGCFUPJYHP-UHFFFAOYSA-N 0.000 description 1
- JYGNMWNTYNTVJE-UHFFFAOYSA-N 4-(2,5-dimethylfuran-3-yl)-2,2-dimethyl-3h-1,4-benzoxazine-6-carbonitrile Chemical compound O1C(C)=CC(N2C3=CC(=CC=C3OC(C)(C)C2)C#N)=C1C JYGNMWNTYNTVJE-UHFFFAOYSA-N 0.000 description 1
- CZRLBPIWCPNYKW-UHFFFAOYSA-N 4-(2-ethenoxyethyl)-2,2-dimethyl-6-nitro-3h-1,4-benzoxazine Chemical compound [O-][N+](=O)C1=CC=C2OC(C)(C)CN(CCOC=C)C2=C1 CZRLBPIWCPNYKW-UHFFFAOYSA-N 0.000 description 1
- XSAMHQBZORHHLV-UHFFFAOYSA-N 4-(2-hydroxycyclopentyl)-2,2-dimethyl-3h-1,4-benzoxazine-6-carbonitrile Chemical compound C12=CC(C#N)=CC=C2OC(C)(C)CN1C1CCCC1O XSAMHQBZORHHLV-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- IDIBUDPQMWHFCS-UHFFFAOYSA-N 4-(5-methoxyiminocyclopenten-1-yl)-2,2-dimethyl-3h-1,4-benzoxazine-6-carbonitrile Chemical compound CON=C1CCC=C1N1C2=CC(C#N)=CC=C2OC(C)(C)C1 IDIBUDPQMWHFCS-UHFFFAOYSA-N 0.000 description 1
- KATRASQPUDIQOV-UHFFFAOYSA-N 4-(benzenesulfonyl)-2-nitrophenol Chemical compound C1=C([N+]([O-])=O)C(O)=CC=C1S(=O)(=O)C1=CC=CC=C1 KATRASQPUDIQOV-UHFFFAOYSA-N 0.000 description 1
- GCSGYBYGSXAQKY-UHFFFAOYSA-N 4-(furan-2-ylmethyl)-2,2-dimethyl-6-nitro-3h-1,4-benzoxazine Chemical compound C12=CC([N+]([O-])=O)=CC=C2OC(C)(C)CN1CC1=CC=CO1 GCSGYBYGSXAQKY-UHFFFAOYSA-N 0.000 description 1
- NHSORJKEBFJCJW-UHFFFAOYSA-N 4-[(1,3-dioxoisoindol-2-yl)methyl]-2,2-dimethyl-3h-1,4-benzoxazine-6-carbonitrile Chemical compound C12=CC(C#N)=CC=C2OC(C)(C)CN1CN1C(=O)C2=CC=CC=C2C1=O NHSORJKEBFJCJW-UHFFFAOYSA-N 0.000 description 1
- GRJDNSLQAMHXEC-UHFFFAOYSA-N 4-[(2-fluorophenyl)methyl]-2,2-dimethyl-6-nitro-3h-1,4-benzoxazine Chemical compound C12=CC([N+]([O-])=O)=CC=C2OC(C)(C)CN1CC1=CC=CC=C1F GRJDNSLQAMHXEC-UHFFFAOYSA-N 0.000 description 1
- UEPCMVSGCKTQCC-UHFFFAOYSA-N 4-[(3-fluorophenyl)methyl]-2,2-dimethyl-6-nitro-3h-1,4-benzoxazine Chemical compound C12=CC([N+]([O-])=O)=CC=C2OC(C)(C)CN1CC1=CC=CC(F)=C1 UEPCMVSGCKTQCC-UHFFFAOYSA-N 0.000 description 1
- ARZXXWMYVPWPJO-UHFFFAOYSA-N 4-benzyl-2,2-dimethyl-6-nitro-3h-1,4-benzoxazine Chemical compound C12=CC([N+]([O-])=O)=CC=C2OC(C)(C)CN1CC1=CC=CC=C1 ARZXXWMYVPWPJO-UHFFFAOYSA-N 0.000 description 1
- CDIIZULDSLKBKV-UHFFFAOYSA-N 4-chlorobutanoyl chloride Chemical compound ClCCCC(Cl)=O CDIIZULDSLKBKV-UHFFFAOYSA-N 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- HQQTZCPKNZVLFF-UHFFFAOYSA-N 4h-1,2-benzoxazin-3-one Chemical class C1=CC=C2ONC(=O)CC2=C1 HQQTZCPKNZVLFF-UHFFFAOYSA-N 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- IDQLPSUOUYUBIK-UHFFFAOYSA-N 6-(benzenesulfonyl)-2,2-dimethyl-4-(1-oxidopyridin-1-ium-2-yl)-3h-1,4-benzoxazine Chemical compound C=1C=C2OC(C)(C)CN(C=3[N+](=CC=CC=3)[O-])C2=CC=1S(=O)(=O)C1=CC=CC=C1 IDQLPSUOUYUBIK-UHFFFAOYSA-N 0.000 description 1
- WIQSBEQGGVTZRW-UHFFFAOYSA-N 6-bromo-2,2-dimethyl-3,4-dihydro-1,4-benzoxazine Chemical compound BrC1=CC=C2OC(C)(C)CNC2=C1 WIQSBEQGGVTZRW-UHFFFAOYSA-N 0.000 description 1
- HGKAGRURTSJWCI-UHFFFAOYSA-N 6-bromo-2,2-dimethyl-4-(1-oxidopyridin-1-ium-2-yl)-3h-1,4-benzoxazine Chemical compound C12=CC(Br)=CC=C2OC(C)(C)CN1C1=CC=CC=[N+]1[O-] HGKAGRURTSJWCI-UHFFFAOYSA-N 0.000 description 1
- HDEDYDGNMRMWMU-UHFFFAOYSA-N 6-chloro-2,2-dimethyl-7-nitro-3,4-dihydro-1,4-benzoxazine Chemical compound ClC1=C([N+]([O-])=O)C=C2OC(C)(C)CNC2=C1 HDEDYDGNMRMWMU-UHFFFAOYSA-N 0.000 description 1
- MWCQYGGJYLAAOQ-UHFFFAOYSA-N 6-chloro-2,2-dimethyl-7-nitro-4-(1-oxidopyridin-1-ium-2-yl)-3h-1,4-benzoxazine Chemical compound C12=CC(Cl)=C([N+]([O-])=O)C=C2OC(C)(C)CN1C1=CC=CC=[N+]1[O-] MWCQYGGJYLAAOQ-UHFFFAOYSA-N 0.000 description 1
- CMOPEBFPBQXXGS-UHFFFAOYSA-N 6-chloro-2,2-dimethyl-7-nitro-4h-1,4-benzoxazin-3-one Chemical compound [O-][N+](=O)C1=C(Cl)C=C2NC(=O)C(C)(C)OC2=C1 CMOPEBFPBQXXGS-UHFFFAOYSA-N 0.000 description 1
- MTWNMKFECPDGQV-UHFFFAOYSA-N 6-nitro-4-(1-oxidopyridin-1-ium-2-yl)-2,3-dihydro-1,4-benzoxazine Chemical compound C12=CC([N+](=O)[O-])=CC=C2OCCN1C1=CC=CC=[N+]1[O-] MTWNMKFECPDGQV-UHFFFAOYSA-N 0.000 description 1
- GJEZBVHHZQAEDB-UHFFFAOYSA-N 6-oxabicyclo[3.1.0]hexane Chemical compound C1CCC2OC21 GJEZBVHHZQAEDB-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- ZYUZLEUJKZZXNN-UHFFFAOYSA-N C1=CC(CC(N)C(O)=O)=CC=C1OS(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 Chemical group C1=CC(CC(N)C(O)=O)=CC=C1OS(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 ZYUZLEUJKZZXNN-UHFFFAOYSA-N 0.000 description 1
- SSUFDOMYCBCHML-UHFFFAOYSA-N CCCCC[S](=O)=O Chemical group CCCCC[S](=O)=O SSUFDOMYCBCHML-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100025597 Caspase-4 Human genes 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101100381997 Danio rerio tbc1d32 gene Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013554 Diverticulum Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 244000182067 Fraxinus ornus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000032041 Hearing impaired Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101100273284 Homo sapiens CASP4 gene Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 238000006809 Jones oxidation reaction Methods 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 101100381999 Mus musculus Tbc1d32 gene Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- GIIWGCBLYNDKBO-UHFFFAOYSA-N Quinoline 1-oxide Chemical compound C1=CC=C2[N+]([O-])=CC=CC2=C1 GIIWGCBLYNDKBO-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000026723 Urinary tract disease Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 description 1
- BHIIGRBMZRSDRI-UHFFFAOYSA-N [chloro(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(Cl)OC1=CC=CC=C1 BHIIGRBMZRSDRI-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000000676 alkoxyimino group Chemical group 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000002862 amidating effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- SLUNEGLMXGHOLY-UHFFFAOYSA-N benzene;hexane Chemical compound CCCCCC.C1=CC=CC=C1 SLUNEGLMXGHOLY-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- JFIOVJDNOJYLKP-UHFFFAOYSA-N bithionol Chemical compound OC1=C(Cl)C=C(Cl)C=C1SC1=CC(Cl)=CC(Cl)=C1O JFIOVJDNOJYLKP-UHFFFAOYSA-N 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910010277 boron hydride Inorganic materials 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 230000011128 cardiac conduction Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- QSKWJTXWJJOJFP-UHFFFAOYSA-N chloroform;ethoxyethane Chemical compound ClC(Cl)Cl.CCOCC QSKWJTXWJJOJFP-UHFFFAOYSA-N 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- OILAIQUEIWYQPH-UHFFFAOYSA-N cyclohexane-1,2-dione Chemical compound O=C1CCCCC1=O OILAIQUEIWYQPH-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
- WZEUDGJCAXJCCQ-UHFFFAOYSA-N diethyl 2-[1-(2,2-dimethyl-6-nitro-3h-1,4-benzoxazin-4-yl)ethoxymethyl]propanedioate Chemical compound C1=C([N+]([O-])=O)C=C2N(C(C)OCC(C(=O)OCC)C(=O)OCC)CC(C)(C)OC2=C1 WZEUDGJCAXJCCQ-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- VLNZUSMTOFYNPS-UHFFFAOYSA-N diethylphosphorylformonitrile Chemical compound CCP(=O)(CC)C#N VLNZUSMTOFYNPS-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- MYTMXVHNEWBFAL-UHFFFAOYSA-L dipotassium;carbonate;hydrate Chemical compound O.[K+].[K+].[O-]C([O-])=O MYTMXVHNEWBFAL-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- OHVWOGMFOADROY-BQYQJAHWSA-N ethyl (e)-4-(2,2-dimethyl-6-nitro-3h-1,4-benzoxazin-4-yl)-4-oxobut-2-enoate Chemical compound C1=C([N+]([O-])=O)C=C2N(C(=O)/C=C/C(=O)OCC)CC(C)(C)OC2=C1 OHVWOGMFOADROY-BQYQJAHWSA-N 0.000 description 1
- ONHHHMCFMGEPPJ-UHFFFAOYSA-N ethyl 2-(2,2-dimethyl-6-nitro-3-oxo-1,4-benzoxazin-4-yl)acetate Chemical compound C1=C([N+]([O-])=O)C=C2N(CC(=O)OCC)C(=O)C(C)(C)OC2=C1 ONHHHMCFMGEPPJ-UHFFFAOYSA-N 0.000 description 1
- HDWFOJRIBBKABZ-UHFFFAOYSA-N ethyl 2-(2,2-dimethyl-6-nitro-3h-1,4-benzoxazin-4-yl)cyclopentene-1-carboxylate Chemical compound C1CCC(C(=O)OCC)=C1N1C2=CC([N+]([O-])=O)=CC=C2OC(C)(C)C1 HDWFOJRIBBKABZ-UHFFFAOYSA-N 0.000 description 1
- MCUDKUGRHASFGH-UHFFFAOYSA-N ethyl 2-(2,2-dimethyl-6-nitro-3h-1,4-benzoxazin-4-yl)propanoate Chemical compound C1=C([N+]([O-])=O)C=C2N(C(C)C(=O)OCC)CC(C)(C)OC2=C1 MCUDKUGRHASFGH-UHFFFAOYSA-N 0.000 description 1
- RILYIRAJQNWCNZ-UHFFFAOYSA-N ethyl 2-(6-cyano-2,2-dimethyl-3h-1,4-benzoxazin-4-yl)acetate Chemical compound C1=C(C#N)C=C2N(CC(=O)OCC)CC(C)(C)OC2=C1 RILYIRAJQNWCNZ-UHFFFAOYSA-N 0.000 description 1
- LHUGZBZCOWNWGI-UHFFFAOYSA-N ethyl 2-(6-nitro-3-oxo-1,4-benzoxazin-4-yl)acetate Chemical compound C1=C([N+]([O-])=O)C=C2N(CC(=O)OCC)C(=O)COC2=C1 LHUGZBZCOWNWGI-UHFFFAOYSA-N 0.000 description 1
- OHVWOGMFOADROY-UHFFFAOYSA-N ethyl 4-(2,2-dimethyl-6-nitro-3h-1,4-benzoxazin-4-yl)-4-oxobut-2-enoate Chemical compound C1=C([N+]([O-])=O)C=C2N(C(=O)C=CC(=O)OCC)CC(C)(C)OC2=C1 OHVWOGMFOADROY-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- RBBOWEDMXHTEPA-UHFFFAOYSA-N hexane;toluene Chemical compound CCCCCC.CC1=CC=CC=C1 RBBOWEDMXHTEPA-UHFFFAOYSA-N 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 150000004966 inorganic peroxy acids Chemical class 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005932 isopentyloxycarbonyl group Chemical group 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- CEAJFNBWKBTRQE-UHFFFAOYSA-N methanamine;methanol Chemical compound NC.OC CEAJFNBWKBTRQE-UHFFFAOYSA-N 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- SSXOFWYPCZOGBM-UHFFFAOYSA-N methyl 3-chloropyrazine-2-carboxylate Chemical compound COC(=O)C1=NC=CN=C1Cl SSXOFWYPCZOGBM-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- CHULJAKADIAFFQ-UHFFFAOYSA-N n-(6-bromo-2,2-dimethyl-3h-1,4-benzoxazin-4-yl)acetamide Chemical compound C1=C(Br)C=C2N(NC(=O)C)CC(C)(C)OC2=C1 CHULJAKADIAFFQ-UHFFFAOYSA-N 0.000 description 1
- LGRLIUCWPBIVGK-UHFFFAOYSA-N n-[2,2-dimethyl-4-(1-oxidopyridin-1-ium-2-yl)-3h-1,4-benzoxazin-6-yl]acetamide Chemical compound C12=CC(NC(=O)C)=CC=C2OC(C)(C)CN1C1=CC=CC=[N+]1[O-] LGRLIUCWPBIVGK-UHFFFAOYSA-N 0.000 description 1
- HVHHQCZXBAOBPO-UHFFFAOYSA-N n-[2,2-dimethyl-4-(1-oxidopyridin-1-ium-2-yl)-3h-1,4-benzoxazin-6-yl]methanesulfonamide Chemical compound C12=CC(NS(C)(=O)=O)=CC=C2OC(C)(C)CN1C1=CC=CC=[N+]1[O-] HVHHQCZXBAOBPO-UHFFFAOYSA-N 0.000 description 1
- 229940037525 nasal preparations Drugs 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005933 neopentyloxycarbonyl group Chemical group 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000009935 nitrosation Effects 0.000 description 1
- 238000007034 nitrosation reaction Methods 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-O nitrosooxidanium Chemical compound [OH2+]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-O 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 150000004967 organic peroxy acids Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000005475 oxolanyl group Chemical group 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 150000004968 peroxymonosulfuric acids Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 239000004036 potassium channel stimulating agent Substances 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 231100000691 up-and-down procedure Toxicity 0.000 description 1
- JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
A novel benzoxazine derivative of the formula (I):
A novel benzoxazine derivative of the formula (I):
Description
~ J~'`3 NOVEL BENZO~ZINE DERI~TIVES AND PHAR~ACE~TICA~
COMPOSITIONS CONTAINING r~HE SAME
FIELD OF THE INVENTION
This invention relates to novel benzoxazine derivatives and pharmaceutically acceptable salts thereof, which are useful as drugs, in particular as potassium channel (K+ channel) activating agents, and pharmaceutical compositions containing the same as well as to intermediates for the production of these derivatives and salts.
The benzoxazine derivatives and salts thereof according to the present invention are compounds of a novel type which activate K+ channels and thereby exhibit antispasmodic activity, namely smooth muscle relaxant activity.
BACKGROUND OF THE INVENTION
As smooth muscle relaxants, those acting on the contractile process and those acting on the relaxing process are known. Among drugs in the former category are various excitatory chemical transmitter receptor blockers and calcium antagonLsts, while inhibitory chemical transmitter receptor stimulants and nitrates are representative of the latter type of drugs.
~ Recently, a drug which relaxes smooth muscles b~
activating the K+ channels has been reported as a new smooth muscle relaxant.
-- 1 ~
, In the thick arteries (particularl~ the coronary and cerebral arteries) and tracheal smooth muscles .in contrask with the general excitable tissues, the K+ channels function in such a manner that these tissues wi.ll not be excited to an unnecessary extent by premature and excessive activation (maintenance of lumen size) but if the physiological function of the K+ channels is impaired, an electric excitation takes place as intensely as in the general excitable tissues -to elicit intense local contractions, viz. spasms. It is acknowledged that spasms of the coronary or cerebral arteries and tracheal smooth muscles induce various diseases such as angina pectoris, cerebrovascular disorder and asthma. It is, therefore, believed that a Kt channel activating agent should be useful for the prevention and trea-tment of these diseases.
Among the compounds known to have K+ channel activating activity, there are ~-(2-oxo-1-pyrrolidinyl)-2H-benzo~b]pyran-3-ol derivatives as disclosed in EP 76075, for instance. The compounds according -to the present invention are novel 2H-1,4-benzoxazine derivatives differing in structure from such known compounds.
SUMMARY OF THE INVENTION
As a result of intensive investigations made in an attempt to find out potent K+ channel activating compounds, the present inventors found +~.hat novel benzoxazine derivatives of general formula (I) given below and salts thereof are potent K~ channel activators and that compounds ~13~
of general formula (II) or (III) shown be:Low are useful as intermediates for the production of said benzoxazine compounds and salts thereof. The present invention has been completed on the basis of such findings.
The present invention thus provides benzoxa~ine derivatives of general formula (I) R] ~ 0 1 R 5 R~
and pharmaceutically acceptable salts thereof, wherein, in the above formula, Rl, R2, R3 and R4, which may be the same or different, each independently represents a hydrogen or halogen atom or a lower alkyl, halo-substituted lower alkyl, lower alkoxy, cyano, nitro, amino, lower alkanoylamino, lower alkylsulfonylamino, lower alkylsulfonyl, or arylsulfonyl group;
R5 and R6, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group;
R7 represeIits a hydroxy-lower alkyl group, a carbocyclic group which may optionally be substituted, a heterocyclic group which may optionally be substituted, a group of the formula ~A1-R8 (in which A1 represents a lower alkylene or hydroxy-lower alkylene group and R3 represen~s an r~
aryl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, or a lower alkenyloxy group, when Al represents a non-substituted lower alkylene, R8 does not represent a phenyl group), a o group of the formula -A2-C-R9 (in which A2 represents a lower alkylene group and R9 represents a lower alkyl group, an aryl group which may optionally be substituted, a heterocyclic group which may optionally be substitu~ed, or a hydroxy, lower alkoxy, amino~ mono- or di-lower alk~lamino, hydroxy-lower alkylamino, aralkylamino or arylamino group), a O
group of the formula -C-A3-Rl0 (in which A3 represents a single bond, a lower alkylene group which may op-tionally be substituted, or a lower alkenylene group and Rl represents a :
heterocyclic group which may optionally be ~substituted, or a carboxyl, lower alkoxycarbonyl, carbamoyl, mono- or di-lower alkylaminocarbonyl, amino or mono- or di-lower alkylamino COOR
A4 ~
group) or a group of the formula \ COOR12 (in which A4 represents a lower alkylene group which may optionally be substituted by a hydroxy or lower alkoxy group, and Rll and Rl2, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group).
The compounds (I) accord:ing to the present invention are characterized, from the chemical structure ~iewpoint, in a~ _ ', : ' ~hat a spec --ic heterocycle, namely the 3,~-dihydro-2~
ber.~oxazine r~ng, is subs~ituted at a speci.lc posi~ion, namely ~he ~-~osi~ion o,~ ~he rins, by a specir-ic substituen~
r~presented by Rl.
Kno~-n i-. the ar. 2S similar 3,~-dihydro-2~-1,4-~enzoxa~i-.e de- va i~Jes are ~-acyl-3,4-dihy~ro--~benzoxazine de-ivatives [C. B. Chapleo et al., J. ~ed.
Chem., 32 (7), 1627-30 (1989)], and 4-benzyl-3,4-dihydro-2h-l, 4-benzoxazine derivatives LJP1034982 (Calll(ll):9725K), C.~.
Chspleo et al., ~. Med. Chem., 32(7), 1627-30 (1989)~ for instance. However, it has never been reported that such known compounds have K~ channel actlvating activity.
The valuable intermediates provided by the present inven_ion are compounds of general formula (II) or (III) given below.
Rl ' R 7 a 3 ~/~
R4 ~
In ~ormula (II), Rs and R6 are as defined above and R~, R2, R~ and R~ r which may be the same or differen~, each independently represents a hydrogen atom, a halogen atom, a cyano group, or a nitro group; R7~ represents a carbocyclic group which may optionally be substituted by an oYo group, ll or a 5-u? o^ ~he formula -A2-C-R9~ (in which ?~Z is as defined above and R~a represents a lower alkyl group, an ~J~
unsubstituted or halo- or nitro-substituted aryl group or a nitrogen-containing heterocyclic group which may optionally be substituted by at least one of an oxo group and a lower alkyl group, inclusive of the N-oxide form thereof, a hydroxy, a lower alkoxy, an amino, a mono- or di-lower alkylamino, hydroxy-lower alkylamino, aralkylamino or arylamino group).
Rl' Rl3 R3' R5 (III) R4' III formula (III), R~, R2, R3, R4, R5 and R6 are as defined above and R13 represents a nitroso or amino group.
The intermediates (II) according to the present invention are novel compounds that have not-been described in the literature and are useful in the manufacture of those compounds of general formula (I), including salts thereof, which have the group R7a as the group R7. The intermediates (III) are useful in the production of those compounds of general formula (I) in which a nitrogen-containing heterocyclic group (as R7) is bound, via the nitrogen atom thereof, to the 4-position nitrogen atom of the benzoxazine ring.
It is an object of the present invention to provide the above-mentioned compounds (I) and pharmaceutically acceptable salts thereof, which are useful as K+ channel activating agents.
Another object of the present invention is to provide pharmaceutical compositions comprising any of the above-mentioned compounds (I) and pharmaceutically acceptable salts thereof in admixture with a pharmaceutically acceptable carrier therefor.
A further object of the present invention is to provide the compounds (II) and compounds (III), inclusive of salts thereof, which are useful as intermediates for the production of the above-mentioned compounds (I) and salts thereof.
DETAI~ED DESCRIPTION OF THE INVENTION
The compounds of the present invention are described in more detail.
In the definitions given herein in relation to the general formulas shown hereinbefore and hereinlater, the term "lower" means, unless otherwise specified, that the relevant group includes a straight or branched carbon chain containing 1 to 6 carbon atoms.
Accordingly, the "lower alkyl group" includes, among others, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, l-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, l,l-dimethylbutyl, 1,2-dimethylbutyl, 2,2-.
dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, l-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl and l-ethyl-2-methylpropyl.
The "lower alkoxy group" includes, among others, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy (amyloxy), isopentyloxy, tert-pentyloxy, neopentyloxy, 2~methylbutoxy, 1,2-dimethylpropoxy, 1-ethylpropoxy and hexyloxy.
The "lower alkenyloxy group" contains 2 to 6 carbon atoms and may be straight or branched, more specifically including, among others, vinyloxy, allyloxy, 1-propenyloxy, isopropenyloxy, 1-butenyloxy, 2-butenyloxy, 3-butenyloxy, 2-methyl-1-propenyloxy, 2-methylallyloxy, 1-methyl-1-propenyloxy, 1-methylallyloxy, 1,1-dimethylvinyloxy, 1-pentenyloxy, 2-pentenyloxy, 3-pentenyloxy, 4-pentenyloxy, 3-methyl-1-butenyloxy, 1-hexenyloxy, 2-hexenyloxy, 3-hexenyloxy, 4-hexenyloxy and 5-hexenyloxy.
The "lower alkoxycarbonyl group", which is a group resulting from ester formation between a carobxy group and a straight or branched lower alcohol, includes, among others, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyL, isobutoxycarbonyl, sec-butoxycarbonylj tert-butoxycarbonyl, pentyloxycarbonyl, isopentyloxycarbonyl, neopentyloxycarbonyl, tert~
pentyloxycarbonyl and hexyloxycarbony:L.
.
, ~ . .
.
~ 4~ t_~
The lower alkanoyl group' includes, among o-thers, formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl and hexanoyl.
The "mono- or di-lower alkylamino group" means a group derived from an amino group by substitution of one or two hydrogen atoms thereof by the abo~e-mentioned "lower alkyl" group or groups and, more specifically, includes monoalkylamino groups in which the alkyl moiety is a straight or branched lower alkyl group, for example methylamino, ethylamino, propylamino, isopropylamino, butylamino, isobutylamino, pentylamino, isopentylamino and hexylamino;
symmetric dialkylamino groups in which the two alkyl moieties are the same and each is a straight or branched lower al~yl group, for example dimethylamino, diethylamino, dipropylamino, diisopropylamino, dibutylamino, dipentylamino and dihexylamino; and asymmetric dialkylami-no groups in which the alkyl moieties are different from each other and each is a straight or branched lower alkyl group, for example ethylmethylamino, methylpropylamino, ethylpropylamino, butylmethylamino, butylethylamino and butylpropylamino.
The "mono- or di-lower alkylaminocarbonyl group' is a group resulting from binding of a carbonyl group to the above-mentioned "mono- or di-lower alkylamino group" and more specifically, includes, among others, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, butylamlnocarbonyl, g ' . ~ , ' isobutylaminocarbonyl, sec-butylaminocarbonyl, tert-butylaminocarbonyl, pentylaminocarbonyl, isopentylaminocarbonyl, hexylaminocarbonyl, isohexylaminocarbonyl, dime-thylaminocarbonyl, diethylaminocarbonyl, dipropylaminocarbonyl, diisopropylaminocarbonyl, dibutylaminocarbonyl, dipentylaminocarbonyl, dihexylaminocarbonyl, methylethylaminocarbonyl, methylpropylaminocarbonyl, ethylpropylaminocarbonyl, methylbutylaminocarbonyl, ethylbutylaminocarbonyl and propylbutylaminocarbonyl.
The '~lower alkanoylamino group" may be straight or branched and includes, among others, formylamino, acetylamino, propionylamino, butyrylamino, isobutyryl amino, valerylamino, isovalerylamino, pivaloylamino and hexanoylamino.
The Illower alkylsulfonyl group" includes, among others, methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl, isobutylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl, pentylsulfonyl, isopentylsulfonyl, sec-pentylsulfonyl, neopentylsulfonyl, tert-pentylsulfonyl, hexylsulfonyl and isohexylsulfonyl.
The ~lower alkylsulfonylamino group~ is a group derived from an amino group by substitution of one hydrogen atom thereof by the "lower alkylsulfonyl group~ mentioned above and, more specifically, includes such straight or branched lower alkylsulfonylamino groups as ~ 10 , :, . . - , -~ .
' " . ,.' " ~ ' ' methylsulfonylamino, ethylsulfonylamino, propylsulfonylamino, isopropylsulfonylamino, butylsulfonylamino, isobutylsulfonylamino, sec-butylsulfonylamino/ tert-butylsulfonylamino, pentylsulfonylamino and hexylsulfonylamino.
The "lower alkylene group", which preferably contains 1 to 6 carbon atoms/ includes, among others, methylene, e-thylene, methylmethylene/ trimethylene, 2-methylethylene, 1-methylethylene, dimethylmethylene, tetramethylene, 1-methyltrimethylene, 2-methyltrimethylene, 3-methyltrimethylene, 1-ethylethylene, 2-ethylethylene, 2,2-dimethylethylene, 1,1-dimethylethylene, ethylmethylmethylene, pentamethylene, 1-methyltetramethylene, 2-methyltetramethylene, 3-methyltetramethylene, 4-methyltetramethylene, 1,1-dimethyltrimethylene, hexamethylene, 1-methylpentamethylene, 4-me-thylpentamethylene and 1,1-dimethyltetramethylene.
The "lower alkenylene group", which preferably contains 2 to 6 carbon atoms, includes, among others, vinylene, propenylene, 2-propenylene, 1-methylvinylene, 2-methylvinylene, butenylene, 2-butenylene, 3-butenylene, 1-methylpropenylene, 1-methyl-2-propenylene, pentenylene and 1-methyl-1-butenylene.
The "halogen atom" i.s not limited to any parti.cular species but includes fluorine, chlorine, bromi.ne and iodine.
. ' ' ' ' .
~J ''~ ~.J ~ .3.
The halo-substituted lower alkyl group" is a ~roup derived from the above-mentioned" lower alkyl group" by substitution of one or more hydrogen atoms thereof by the above-mentioned "halogen~ atom or atoms. When the halogen atom is fluorine, for instance, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, 3-fluoropropyl, 3,3,3-trifluoropropyl and 2-fluoro-1-methylethyl may be mentioned as typical examples.
The "hydroxy-lower alkyl group" menas a group derived from the above-mentioned 'llower alkyl group" by substitution of one hydrogen atom thereof by a hydroxy group and, more specifically, includes, among others, hydroxymethyl, 2-hydroxyethyl., 3-hydroxypropyl, 2-hydroxypropyl, 2-hydroxy-1-methylethyl, 4-hydroxybutyl, 3-hydroxybutyl, 2-hydroxybutyl, 3-hydroxy-2-methylpropyl, 5-hydroxypentyl and 6-hydroxyhexyl.
The "hydroxy-lower alkylene group" includes, among others, hydroxymethylene, 1-hydroxyethylene, 2-hydroxyethylene, hydroxymethylmethylene, l-hydroxytrimethylene, 2-hydroxytrimethylene, 3-hydroxytrimethylene, 2-hydroxytetramethylene, 2-hydroxypentamethylene and 2-hydroxyhexamethylene.
The "lower alkylene group which may optionally be substituted by a hydroxy or lower alkoxy group" includes lower alkylene groups such as those mentioned above, hydroxy-lower alkylene groups such as those mentioned above, and lower alkoxy-lower alkyl.ene groups s-lch as those mentioned : ' , . ' . .
above, and lower alkoxy-lower alkylene groups ~hich, when a methoxy group is taken as an example of the substituent lower alkoxy group, include, among others, methoxymethylene, 1-methoxyethylene, 2-methoxyethylene, methoxymethylmethylene, 1-methoxytrimethylene, 2-methoxytrimethylene, 3-methoxytrimethylene, 1-methoxytetramethylene, 4-methoxytetramethylene, 1-methoxypentamethylene, 5-methoxypentamethylene, 1-methoxyhexamethylene and 6-methoxyhexamethylene.
The "hydroxy-lower alkylamino group" means a group derived from an amino group by substitution of one hydrogen atom thereof by the above-mentioned "hydroxy-lower alkyl group'~ and, more specifically, includes, among others, hydroxymethylamino, 2-hydroxyethylamino, 3-hydroxypropylamino, 2-hydroxy-1-methylethylamino, 4-hydroxybutylamino, 5-hydroxypentylamino and- 6-hydroxyhexylamino.
The "lower alkylene group which may optionally be substituted~', when substituted, pre~erably has an amino or mono- or di-lower alkylamino group as the substi.tuent.
Typical examples of -the mono- or dl-lower alkylamino group have already been mentioned hereinabove.
The "carbocylic group" means a nonaromatic carbocyclic group, cycloalkyl or cycloalkenyl group, which in itself is not an aromatic carboc~rcllc ri.ng but may preferably be condensed with a benzene ring, and, more speci.fically, :
, ~J~ 3~
includes, among others, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl and indenyl.
The carbocyclic group may have one or more substituents preferably selected from among lower alkyl groups such as those mentioned above, a hydroxy'group, an oxo group, lower alkoxycarbonyl groups such as those mentioned above, a hydroxyimino group and lower alkoxyimino groups such as methoxyimino, ethoxyimino, propoxyimino, isopropoxyimino, butoxyimino, pentyloxyimino and hexyloxyimino.
The "aryl group" means an aromatic hydrocarbon group and includes, as preferred species r phenyl and naphthyl. The aryl group may have one or more substituents each independently selected from among halogen atoms such as those mentioned hereinabove, a nitro group, etc.
The "aralkyl group" means a group d rived from the above-mentioned "lower alkyl group" by substitution of at .
least one hydrogen atom thereof by the above-mentioned "aryl group~. More specifically, when a phenyl group is taken as an example of said aryl group, said aralkyl group includes, among others, benzyl, phenethyl, 3-phenylpropyl, 2-phenylpropyl, 2-phenyl-1-methylpropyl, 4-phenylbutyl, 3-phenylbutyl, 3-phenyl-2-methyl propyl, 5-phenylpentyl, 6-phenylpentyl, benzhydryl and trityl.
The aralkyl group may have one or more substituen-ts, for example a halogen atom or atoms such as those mentioned - 14 ~
hereinabove and/or a nitro group or groups on the aryl ring and/or a hydroxy group on the alkyl chain.
The aryl moiety of the '~arylamino group" and of the "arylsulfonyl group includes phenyl and naphthyl as preferred species, as in the case of the above-mentioned "aryl group". Preferred examples of the arylamino group and arylsulfonyl group are thus phenylamino, l-naphthylamino, 2-naphthylamino, phenylsulfonyl, 1-naphthylsulfonyl and 2-naphthylsulfonyl.
The "aralkylamino group" is a group derived from an amino group by substitution of one hydrogen atom thereof by the above-mentioned ~aralkyl group'. Benzylamino may be mentioned as a typical example when a benzyl group is taken as an example of the aralkyl group.
The "heterocyclic group" includes, among others, 5-or 6-membered heterocyclic groups which may optionally be condensed with a benzene ring, for example furyl, thienyl, pyrrolyl, pyrrolidinyl, pyranyl, pyridyl, oxazolyl, isoxazolyl, thiazolyl r isothiazolyl, thiazolinyl, imidazolyl, imidazolinyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyrimidyl, pyrazinyl, pyridazinyl, thiazinyl, benzofuranyl, isobenzofuranyl, benzothienyl, indolyl, isoindolyl, chromenyl, quinolyl, isoquinolyl, phthalazinyl and quinoxalinyl.
Preferred among them are those nitrogen-containing monocyclic or bicyclic heteroaromatic groups which can be ': '" -~JJJ 3 ~
converted to the N-oxide form, for example pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinolyl, isoquinolyl, phthalazinyl and quinoxalinyl, those nitrogen-containing nonaromatic monocyclic or bicyclic heterocyclic groups which are available for bonding through the nitrogen atom thereof and can be substituted by an oxo group to form a lactam ring, for example pyrrolidinyl, piperidinyl, indolyl and isoindolyl, such nitrogen-containing heterocyclic groups as benzimidazolyl and such oxygen-containing heterocyclic groups as furyl, oxolanyl and pyranyl.
These heterocyclic groups may have one or more substituents each indepen~ently selected from among halogen atoms, lower alkyl groups, a hydroxy group, lower alkoxy groups, an oxo group, a carbamoyl group, mono- or di-lower alkylaminocarbonyl groups, etc. Nitrogen-containing heteroaromatic groups may further have an N-oxide forming oxygen as a substituent thereon. Typical examples o these substituents are as mentioned hereinabove.
Particularly preferred among the compounds (I) according to the invention are those compounds in which one of R2 and R3 is a nitro or cyano group or a halogen atom and the other is a hydrogen atom or a nitro group, those compounds in which R7 is a nitrogen-containing heterocyclic group which may optionally be in -the N-oxide for~ and/or substituted by a lower alkyl group or groups, for example 1-oxo-2-pyridil group or 6-meth-yl-l-oxo-2-pyridil group, an ~ i;J ~
oxo-substituted nitrogen-containing heterocyclic group, such as 2-oxo-1-pyrrolidinyl, an oxo-substituted carbocyclic group, such as 2-oxocyclopentyl or 5-oxo-l-cyclopenten-l-yl/
a group of the formula -A1-R8 (Al and R8 being as defined above), for example (1-oxo-2-pyridil)methyl, or a group O
of the formula -A2-C-R9 (A2 and R9 being as defined above), for example acetonyl, phenacyl, carbamoylmethyl, N-methylaminocarbonylmethyl or N,N-dimethylaminocarbonylmethyl.
The compounds (I) according to the present invention may form salts with acids, as the case may be. They may form salts with bases depending on the substituent or substituents. Such salts include addition salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid and phosphoric acid, and with organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, malic acid, tartaric acid, methanesulfonic acid and ethanesulfonic acid, addition salts with acidic amino acids such as aspartic acid and glutamic acid, salts with inorganic bases such as sodium, potassium, magnesium, calcium and aluminum, with organic bases such as methylamine, ethylamine and ethanolamine, and with basic amino acids such as lysine and ornithine, and the ammonium salt.
, :
The compounds according to the present invention may have a double bond and/or an asymmetric carbon atom or atoms depending on the substituent or substituents. Accordingly, the compounds according to the present invention include within the scope thereof the resulting various isomers, for example geometric isomers, tautomers and optical isomers, either in an each individual isolated isomer form or in a mixture form.
The compounds (I) according to the present invention can be produced by applying various synthetic methods taking advantage of the characteristics of the skeletal structure and/or various substituents. Typical examples of applicable production processes are given below.
Process l Rl Rl I
R3 ~N 1 R7C-y 1 ( V ) ~o~-R5R 6 (IV) (Ic) ~ 18 -.
. ' . '
COMPOSITIONS CONTAINING r~HE SAME
FIELD OF THE INVENTION
This invention relates to novel benzoxazine derivatives and pharmaceutically acceptable salts thereof, which are useful as drugs, in particular as potassium channel (K+ channel) activating agents, and pharmaceutical compositions containing the same as well as to intermediates for the production of these derivatives and salts.
The benzoxazine derivatives and salts thereof according to the present invention are compounds of a novel type which activate K+ channels and thereby exhibit antispasmodic activity, namely smooth muscle relaxant activity.
BACKGROUND OF THE INVENTION
As smooth muscle relaxants, those acting on the contractile process and those acting on the relaxing process are known. Among drugs in the former category are various excitatory chemical transmitter receptor blockers and calcium antagonLsts, while inhibitory chemical transmitter receptor stimulants and nitrates are representative of the latter type of drugs.
~ Recently, a drug which relaxes smooth muscles b~
activating the K+ channels has been reported as a new smooth muscle relaxant.
-- 1 ~
, In the thick arteries (particularl~ the coronary and cerebral arteries) and tracheal smooth muscles .in contrask with the general excitable tissues, the K+ channels function in such a manner that these tissues wi.ll not be excited to an unnecessary extent by premature and excessive activation (maintenance of lumen size) but if the physiological function of the K+ channels is impaired, an electric excitation takes place as intensely as in the general excitable tissues -to elicit intense local contractions, viz. spasms. It is acknowledged that spasms of the coronary or cerebral arteries and tracheal smooth muscles induce various diseases such as angina pectoris, cerebrovascular disorder and asthma. It is, therefore, believed that a Kt channel activating agent should be useful for the prevention and trea-tment of these diseases.
Among the compounds known to have K+ channel activating activity, there are ~-(2-oxo-1-pyrrolidinyl)-2H-benzo~b]pyran-3-ol derivatives as disclosed in EP 76075, for instance. The compounds according -to the present invention are novel 2H-1,4-benzoxazine derivatives differing in structure from such known compounds.
SUMMARY OF THE INVENTION
As a result of intensive investigations made in an attempt to find out potent K+ channel activating compounds, the present inventors found +~.hat novel benzoxazine derivatives of general formula (I) given below and salts thereof are potent K~ channel activators and that compounds ~13~
of general formula (II) or (III) shown be:Low are useful as intermediates for the production of said benzoxazine compounds and salts thereof. The present invention has been completed on the basis of such findings.
The present invention thus provides benzoxa~ine derivatives of general formula (I) R] ~ 0 1 R 5 R~
and pharmaceutically acceptable salts thereof, wherein, in the above formula, Rl, R2, R3 and R4, which may be the same or different, each independently represents a hydrogen or halogen atom or a lower alkyl, halo-substituted lower alkyl, lower alkoxy, cyano, nitro, amino, lower alkanoylamino, lower alkylsulfonylamino, lower alkylsulfonyl, or arylsulfonyl group;
R5 and R6, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group;
R7 represeIits a hydroxy-lower alkyl group, a carbocyclic group which may optionally be substituted, a heterocyclic group which may optionally be substituted, a group of the formula ~A1-R8 (in which A1 represents a lower alkylene or hydroxy-lower alkylene group and R3 represen~s an r~
aryl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, or a lower alkenyloxy group, when Al represents a non-substituted lower alkylene, R8 does not represent a phenyl group), a o group of the formula -A2-C-R9 (in which A2 represents a lower alkylene group and R9 represents a lower alkyl group, an aryl group which may optionally be substituted, a heterocyclic group which may optionally be substitu~ed, or a hydroxy, lower alkoxy, amino~ mono- or di-lower alk~lamino, hydroxy-lower alkylamino, aralkylamino or arylamino group), a O
group of the formula -C-A3-Rl0 (in which A3 represents a single bond, a lower alkylene group which may op-tionally be substituted, or a lower alkenylene group and Rl represents a :
heterocyclic group which may optionally be ~substituted, or a carboxyl, lower alkoxycarbonyl, carbamoyl, mono- or di-lower alkylaminocarbonyl, amino or mono- or di-lower alkylamino COOR
A4 ~
group) or a group of the formula \ COOR12 (in which A4 represents a lower alkylene group which may optionally be substituted by a hydroxy or lower alkoxy group, and Rll and Rl2, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group).
The compounds (I) accord:ing to the present invention are characterized, from the chemical structure ~iewpoint, in a~ _ ', : ' ~hat a spec --ic heterocycle, namely the 3,~-dihydro-2~
ber.~oxazine r~ng, is subs~ituted at a speci.lc posi~ion, namely ~he ~-~osi~ion o,~ ~he rins, by a specir-ic substituen~
r~presented by Rl.
Kno~-n i-. the ar. 2S similar 3,~-dihydro-2~-1,4-~enzoxa~i-.e de- va i~Jes are ~-acyl-3,4-dihy~ro--~benzoxazine de-ivatives [C. B. Chapleo et al., J. ~ed.
Chem., 32 (7), 1627-30 (1989)], and 4-benzyl-3,4-dihydro-2h-l, 4-benzoxazine derivatives LJP1034982 (Calll(ll):9725K), C.~.
Chspleo et al., ~. Med. Chem., 32(7), 1627-30 (1989)~ for instance. However, it has never been reported that such known compounds have K~ channel actlvating activity.
The valuable intermediates provided by the present inven_ion are compounds of general formula (II) or (III) given below.
Rl ' R 7 a 3 ~/~
R4 ~
In ~ormula (II), Rs and R6 are as defined above and R~, R2, R~ and R~ r which may be the same or differen~, each independently represents a hydrogen atom, a halogen atom, a cyano group, or a nitro group; R7~ represents a carbocyclic group which may optionally be substituted by an oYo group, ll or a 5-u? o^ ~he formula -A2-C-R9~ (in which ?~Z is as defined above and R~a represents a lower alkyl group, an ~J~
unsubstituted or halo- or nitro-substituted aryl group or a nitrogen-containing heterocyclic group which may optionally be substituted by at least one of an oxo group and a lower alkyl group, inclusive of the N-oxide form thereof, a hydroxy, a lower alkoxy, an amino, a mono- or di-lower alkylamino, hydroxy-lower alkylamino, aralkylamino or arylamino group).
Rl' Rl3 R3' R5 (III) R4' III formula (III), R~, R2, R3, R4, R5 and R6 are as defined above and R13 represents a nitroso or amino group.
The intermediates (II) according to the present invention are novel compounds that have not-been described in the literature and are useful in the manufacture of those compounds of general formula (I), including salts thereof, which have the group R7a as the group R7. The intermediates (III) are useful in the production of those compounds of general formula (I) in which a nitrogen-containing heterocyclic group (as R7) is bound, via the nitrogen atom thereof, to the 4-position nitrogen atom of the benzoxazine ring.
It is an object of the present invention to provide the above-mentioned compounds (I) and pharmaceutically acceptable salts thereof, which are useful as K+ channel activating agents.
Another object of the present invention is to provide pharmaceutical compositions comprising any of the above-mentioned compounds (I) and pharmaceutically acceptable salts thereof in admixture with a pharmaceutically acceptable carrier therefor.
A further object of the present invention is to provide the compounds (II) and compounds (III), inclusive of salts thereof, which are useful as intermediates for the production of the above-mentioned compounds (I) and salts thereof.
DETAI~ED DESCRIPTION OF THE INVENTION
The compounds of the present invention are described in more detail.
In the definitions given herein in relation to the general formulas shown hereinbefore and hereinlater, the term "lower" means, unless otherwise specified, that the relevant group includes a straight or branched carbon chain containing 1 to 6 carbon atoms.
Accordingly, the "lower alkyl group" includes, among others, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, l-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, l,l-dimethylbutyl, 1,2-dimethylbutyl, 2,2-.
dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, l-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl and l-ethyl-2-methylpropyl.
The "lower alkoxy group" includes, among others, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy (amyloxy), isopentyloxy, tert-pentyloxy, neopentyloxy, 2~methylbutoxy, 1,2-dimethylpropoxy, 1-ethylpropoxy and hexyloxy.
The "lower alkenyloxy group" contains 2 to 6 carbon atoms and may be straight or branched, more specifically including, among others, vinyloxy, allyloxy, 1-propenyloxy, isopropenyloxy, 1-butenyloxy, 2-butenyloxy, 3-butenyloxy, 2-methyl-1-propenyloxy, 2-methylallyloxy, 1-methyl-1-propenyloxy, 1-methylallyloxy, 1,1-dimethylvinyloxy, 1-pentenyloxy, 2-pentenyloxy, 3-pentenyloxy, 4-pentenyloxy, 3-methyl-1-butenyloxy, 1-hexenyloxy, 2-hexenyloxy, 3-hexenyloxy, 4-hexenyloxy and 5-hexenyloxy.
The "lower alkoxycarbonyl group", which is a group resulting from ester formation between a carobxy group and a straight or branched lower alcohol, includes, among others, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyL, isobutoxycarbonyl, sec-butoxycarbonylj tert-butoxycarbonyl, pentyloxycarbonyl, isopentyloxycarbonyl, neopentyloxycarbonyl, tert~
pentyloxycarbonyl and hexyloxycarbony:L.
.
, ~ . .
.
~ 4~ t_~
The lower alkanoyl group' includes, among o-thers, formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl and hexanoyl.
The "mono- or di-lower alkylamino group" means a group derived from an amino group by substitution of one or two hydrogen atoms thereof by the abo~e-mentioned "lower alkyl" group or groups and, more specifically, includes monoalkylamino groups in which the alkyl moiety is a straight or branched lower alkyl group, for example methylamino, ethylamino, propylamino, isopropylamino, butylamino, isobutylamino, pentylamino, isopentylamino and hexylamino;
symmetric dialkylamino groups in which the two alkyl moieties are the same and each is a straight or branched lower al~yl group, for example dimethylamino, diethylamino, dipropylamino, diisopropylamino, dibutylamino, dipentylamino and dihexylamino; and asymmetric dialkylami-no groups in which the alkyl moieties are different from each other and each is a straight or branched lower alkyl group, for example ethylmethylamino, methylpropylamino, ethylpropylamino, butylmethylamino, butylethylamino and butylpropylamino.
The "mono- or di-lower alkylaminocarbonyl group' is a group resulting from binding of a carbonyl group to the above-mentioned "mono- or di-lower alkylamino group" and more specifically, includes, among others, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, butylamlnocarbonyl, g ' . ~ , ' isobutylaminocarbonyl, sec-butylaminocarbonyl, tert-butylaminocarbonyl, pentylaminocarbonyl, isopentylaminocarbonyl, hexylaminocarbonyl, isohexylaminocarbonyl, dime-thylaminocarbonyl, diethylaminocarbonyl, dipropylaminocarbonyl, diisopropylaminocarbonyl, dibutylaminocarbonyl, dipentylaminocarbonyl, dihexylaminocarbonyl, methylethylaminocarbonyl, methylpropylaminocarbonyl, ethylpropylaminocarbonyl, methylbutylaminocarbonyl, ethylbutylaminocarbonyl and propylbutylaminocarbonyl.
The '~lower alkanoylamino group" may be straight or branched and includes, among others, formylamino, acetylamino, propionylamino, butyrylamino, isobutyryl amino, valerylamino, isovalerylamino, pivaloylamino and hexanoylamino.
The Illower alkylsulfonyl group" includes, among others, methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl, isobutylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl, pentylsulfonyl, isopentylsulfonyl, sec-pentylsulfonyl, neopentylsulfonyl, tert-pentylsulfonyl, hexylsulfonyl and isohexylsulfonyl.
The ~lower alkylsulfonylamino group~ is a group derived from an amino group by substitution of one hydrogen atom thereof by the "lower alkylsulfonyl group~ mentioned above and, more specifically, includes such straight or branched lower alkylsulfonylamino groups as ~ 10 , :, . . - , -~ .
' " . ,.' " ~ ' ' methylsulfonylamino, ethylsulfonylamino, propylsulfonylamino, isopropylsulfonylamino, butylsulfonylamino, isobutylsulfonylamino, sec-butylsulfonylamino/ tert-butylsulfonylamino, pentylsulfonylamino and hexylsulfonylamino.
The "lower alkylene group", which preferably contains 1 to 6 carbon atoms/ includes, among others, methylene, e-thylene, methylmethylene/ trimethylene, 2-methylethylene, 1-methylethylene, dimethylmethylene, tetramethylene, 1-methyltrimethylene, 2-methyltrimethylene, 3-methyltrimethylene, 1-ethylethylene, 2-ethylethylene, 2,2-dimethylethylene, 1,1-dimethylethylene, ethylmethylmethylene, pentamethylene, 1-methyltetramethylene, 2-methyltetramethylene, 3-methyltetramethylene, 4-methyltetramethylene, 1,1-dimethyltrimethylene, hexamethylene, 1-methylpentamethylene, 4-me-thylpentamethylene and 1,1-dimethyltetramethylene.
The "lower alkenylene group", which preferably contains 2 to 6 carbon atoms, includes, among others, vinylene, propenylene, 2-propenylene, 1-methylvinylene, 2-methylvinylene, butenylene, 2-butenylene, 3-butenylene, 1-methylpropenylene, 1-methyl-2-propenylene, pentenylene and 1-methyl-1-butenylene.
The "halogen atom" i.s not limited to any parti.cular species but includes fluorine, chlorine, bromi.ne and iodine.
. ' ' ' ' .
~J ''~ ~.J ~ .3.
The halo-substituted lower alkyl group" is a ~roup derived from the above-mentioned" lower alkyl group" by substitution of one or more hydrogen atoms thereof by the above-mentioned "halogen~ atom or atoms. When the halogen atom is fluorine, for instance, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, 3-fluoropropyl, 3,3,3-trifluoropropyl and 2-fluoro-1-methylethyl may be mentioned as typical examples.
The "hydroxy-lower alkyl group" menas a group derived from the above-mentioned 'llower alkyl group" by substitution of one hydrogen atom thereof by a hydroxy group and, more specifically, includes, among others, hydroxymethyl, 2-hydroxyethyl., 3-hydroxypropyl, 2-hydroxypropyl, 2-hydroxy-1-methylethyl, 4-hydroxybutyl, 3-hydroxybutyl, 2-hydroxybutyl, 3-hydroxy-2-methylpropyl, 5-hydroxypentyl and 6-hydroxyhexyl.
The "hydroxy-lower alkylene group" includes, among others, hydroxymethylene, 1-hydroxyethylene, 2-hydroxyethylene, hydroxymethylmethylene, l-hydroxytrimethylene, 2-hydroxytrimethylene, 3-hydroxytrimethylene, 2-hydroxytetramethylene, 2-hydroxypentamethylene and 2-hydroxyhexamethylene.
The "lower alkylene group which may optionally be substituted by a hydroxy or lower alkoxy group" includes lower alkylene groups such as those mentioned above, hydroxy-lower alkylene groups such as those mentioned above, and lower alkoxy-lower alkyl.ene groups s-lch as those mentioned : ' , . ' . .
above, and lower alkoxy-lower alkylene groups ~hich, when a methoxy group is taken as an example of the substituent lower alkoxy group, include, among others, methoxymethylene, 1-methoxyethylene, 2-methoxyethylene, methoxymethylmethylene, 1-methoxytrimethylene, 2-methoxytrimethylene, 3-methoxytrimethylene, 1-methoxytetramethylene, 4-methoxytetramethylene, 1-methoxypentamethylene, 5-methoxypentamethylene, 1-methoxyhexamethylene and 6-methoxyhexamethylene.
The "hydroxy-lower alkylamino group" means a group derived from an amino group by substitution of one hydrogen atom thereof by the above-mentioned "hydroxy-lower alkyl group'~ and, more specifically, includes, among others, hydroxymethylamino, 2-hydroxyethylamino, 3-hydroxypropylamino, 2-hydroxy-1-methylethylamino, 4-hydroxybutylamino, 5-hydroxypentylamino and- 6-hydroxyhexylamino.
The "lower alkylene group which may optionally be substituted~', when substituted, pre~erably has an amino or mono- or di-lower alkylamino group as the substi.tuent.
Typical examples of -the mono- or dl-lower alkylamino group have already been mentioned hereinabove.
The "carbocylic group" means a nonaromatic carbocyclic group, cycloalkyl or cycloalkenyl group, which in itself is not an aromatic carboc~rcllc ri.ng but may preferably be condensed with a benzene ring, and, more speci.fically, :
, ~J~ 3~
includes, among others, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl and indenyl.
The carbocyclic group may have one or more substituents preferably selected from among lower alkyl groups such as those mentioned above, a hydroxy'group, an oxo group, lower alkoxycarbonyl groups such as those mentioned above, a hydroxyimino group and lower alkoxyimino groups such as methoxyimino, ethoxyimino, propoxyimino, isopropoxyimino, butoxyimino, pentyloxyimino and hexyloxyimino.
The "aryl group" means an aromatic hydrocarbon group and includes, as preferred species r phenyl and naphthyl. The aryl group may have one or more substituents each independently selected from among halogen atoms such as those mentioned hereinabove, a nitro group, etc.
The "aralkyl group" means a group d rived from the above-mentioned "lower alkyl group" by substitution of at .
least one hydrogen atom thereof by the above-mentioned "aryl group~. More specifically, when a phenyl group is taken as an example of said aryl group, said aralkyl group includes, among others, benzyl, phenethyl, 3-phenylpropyl, 2-phenylpropyl, 2-phenyl-1-methylpropyl, 4-phenylbutyl, 3-phenylbutyl, 3-phenyl-2-methyl propyl, 5-phenylpentyl, 6-phenylpentyl, benzhydryl and trityl.
The aralkyl group may have one or more substituen-ts, for example a halogen atom or atoms such as those mentioned - 14 ~
hereinabove and/or a nitro group or groups on the aryl ring and/or a hydroxy group on the alkyl chain.
The aryl moiety of the '~arylamino group" and of the "arylsulfonyl group includes phenyl and naphthyl as preferred species, as in the case of the above-mentioned "aryl group". Preferred examples of the arylamino group and arylsulfonyl group are thus phenylamino, l-naphthylamino, 2-naphthylamino, phenylsulfonyl, 1-naphthylsulfonyl and 2-naphthylsulfonyl.
The "aralkylamino group" is a group derived from an amino group by substitution of one hydrogen atom thereof by the above-mentioned ~aralkyl group'. Benzylamino may be mentioned as a typical example when a benzyl group is taken as an example of the aralkyl group.
The "heterocyclic group" includes, among others, 5-or 6-membered heterocyclic groups which may optionally be condensed with a benzene ring, for example furyl, thienyl, pyrrolyl, pyrrolidinyl, pyranyl, pyridyl, oxazolyl, isoxazolyl, thiazolyl r isothiazolyl, thiazolinyl, imidazolyl, imidazolinyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyrimidyl, pyrazinyl, pyridazinyl, thiazinyl, benzofuranyl, isobenzofuranyl, benzothienyl, indolyl, isoindolyl, chromenyl, quinolyl, isoquinolyl, phthalazinyl and quinoxalinyl.
Preferred among them are those nitrogen-containing monocyclic or bicyclic heteroaromatic groups which can be ': '" -~JJJ 3 ~
converted to the N-oxide form, for example pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinolyl, isoquinolyl, phthalazinyl and quinoxalinyl, those nitrogen-containing nonaromatic monocyclic or bicyclic heterocyclic groups which are available for bonding through the nitrogen atom thereof and can be substituted by an oxo group to form a lactam ring, for example pyrrolidinyl, piperidinyl, indolyl and isoindolyl, such nitrogen-containing heterocyclic groups as benzimidazolyl and such oxygen-containing heterocyclic groups as furyl, oxolanyl and pyranyl.
These heterocyclic groups may have one or more substituents each indepen~ently selected from among halogen atoms, lower alkyl groups, a hydroxy group, lower alkoxy groups, an oxo group, a carbamoyl group, mono- or di-lower alkylaminocarbonyl groups, etc. Nitrogen-containing heteroaromatic groups may further have an N-oxide forming oxygen as a substituent thereon. Typical examples o these substituents are as mentioned hereinabove.
Particularly preferred among the compounds (I) according to the invention are those compounds in which one of R2 and R3 is a nitro or cyano group or a halogen atom and the other is a hydrogen atom or a nitro group, those compounds in which R7 is a nitrogen-containing heterocyclic group which may optionally be in -the N-oxide for~ and/or substituted by a lower alkyl group or groups, for example 1-oxo-2-pyridil group or 6-meth-yl-l-oxo-2-pyridil group, an ~ i;J ~
oxo-substituted nitrogen-containing heterocyclic group, such as 2-oxo-1-pyrrolidinyl, an oxo-substituted carbocyclic group, such as 2-oxocyclopentyl or 5-oxo-l-cyclopenten-l-yl/
a group of the formula -A1-R8 (Al and R8 being as defined above), for example (1-oxo-2-pyridil)methyl, or a group O
of the formula -A2-C-R9 (A2 and R9 being as defined above), for example acetonyl, phenacyl, carbamoylmethyl, N-methylaminocarbonylmethyl or N,N-dimethylaminocarbonylmethyl.
The compounds (I) according to the present invention may form salts with acids, as the case may be. They may form salts with bases depending on the substituent or substituents. Such salts include addition salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid and phosphoric acid, and with organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, malic acid, tartaric acid, methanesulfonic acid and ethanesulfonic acid, addition salts with acidic amino acids such as aspartic acid and glutamic acid, salts with inorganic bases such as sodium, potassium, magnesium, calcium and aluminum, with organic bases such as methylamine, ethylamine and ethanolamine, and with basic amino acids such as lysine and ornithine, and the ammonium salt.
, :
The compounds according to the present invention may have a double bond and/or an asymmetric carbon atom or atoms depending on the substituent or substituents. Accordingly, the compounds according to the present invention include within the scope thereof the resulting various isomers, for example geometric isomers, tautomers and optical isomers, either in an each individual isolated isomer form or in a mixture form.
The compounds (I) according to the present invention can be produced by applying various synthetic methods taking advantage of the characteristics of the skeletal structure and/or various substituents. Typical examples of applicable production processes are given below.
Process l Rl Rl I
R3 ~N 1 R7C-y 1 ( V ) ~o~-R5R 6 (IV) (Ic) ~ 18 -.
. ' . '
2 ~ ~ ~ 3 ~ 9 Process 2 R7a-1 Rl Rl R2~N R7a-1-Yl(v-a) R2~N O
R3 ~\ R5 R3 ~\ ~RR5 6 (VI) (IIa-l) OH
R e d u c t i o n ~ , Ox i d a t i o n R3 ~Jl~ O ~
( I d ) O
Rl I
R3~ R5 R4 ~ :
(Ie) :
.. ..
Process 3 NO
Rl Rl R6 -- ~ 1 R6 (IV) (VII) Rl NH2 Rl8COOH (IX) or a Reduction R2 ~ N thereof R3 ~
(VIII) ~6 ~
NHCo-R18 Cycllzation ~ N ' Rl I when R18 is a R2 I N halo-substituted R2 ~ N
propyl or butyl (X) (If) ; - 20 ~
. . ~ ~' " '' .: . '' ~
~ 3 Process 4 Rl9 ~ Rl9 A7-COOH < R20 R I R20 R (XI) ~ ~
(Ig) (Ih) or a reactive derivative thereof Process 5 l As - ~ N ¦
R3 ~ h ~ Oxida~ion R2 ~ l RR6 (Ii) (Ij) Process 6 Rl5 Rl6 y4 1 ¦ ,Rl4 Rl4 ~ o R3 r h Y \\ / < Rls ~1 R4 -~ R4 (IV) (Ik) -- 21 ~
, 7J.i2~3 In the above formulas, Rl, R2, R3, R'', Rl , R2 , R3 , 4' R5 R6 R7 Al R8 A2 R9 A3 Rl, A.4, Rll and Rl2 are as defined above and the other symbols are defined as follows:
R7c repxesents a heterocycli~ group which is available for bonding through a ring-forming carbon atom (no-t a hetero atom) and may optionally have a substituent or substituents, a group of the formula -AlC-R3c (in which AlC is a lower alkylene group and R8C is an aryl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, or a lower alkenyloxy group, when AlC represents a non-substituted lower alkylene, R3 does not represent a phenyl group), a group of the formula O
-A2-C-R9 (in which A2 and R9 are as defined abo~e), a group of O ..
the formula -C-A3C-Rl0 (in which Rl are as defined above and A3c is a single bond or a lower alkylene or lower alkenylene R
CH <
- CH < Rl5 group) or a group of the formula z1-R16 (in which Rl'' is a hydrogen atom or a lower alkyl or lower alkoxycarbonyl group, Rl5 and Rl6, whlch may be the same or different, each independently is a lower alk-yl group or combinedly represent a lower alkylene, o-phenylene or carbonyl group -to form a ring, and zl is a carbonyl, methylene or carbinol group;
'- ' ~:J ~
yl represents a halogen atom or an alkyl or aryl sulfonylo~y group or ester residue;
R7a-1 represents a group of the formula -A2-C-R9 and R9 being as defined above) or a group of the < CH <
formula C-R16 (Rl4, Rl5 and Rl6 being as defined o above);
A5 represents a group represented by A2 or a group of Rl~
> < Rls (Rl' and being as defined above);
Rl7 is a group represented by R9 or Rl6 (each being as defined above);
R13 represents a halo-substituted propyl or halo-substituted butyl;
A6 represents a trimethylene or tetramethylene group;
A7 represents a lower alkylene group or a group of O
the formula -C-A3- (A3 being as defined above);
Rl9 and R20 are the same or different and each independently is a hydrogen atom or a lower alkyl yroup or combinedly, together with the adjacent nitrogen atom, form a ~ 23 - :
~$S'.'J'~3~
heterocyclic group which may have a substituent or substituents;
A8 represents a single bond. A group represented by Al or A2 or a group of the formula -C-A3- (A3 being as defined above);
/~
- ~ N represents a nitrogen-containing monocyclic or bicyclic heteroaromatic group which may optionally be substituted;
y2 represen-ts a halogen atom or, when taken together with Y3, represents a carbonyl oxygen atom;
Y3 represents a halogen atom or, when ta~en together with y2, represents a carbonyl oxygen atom, or a hydrogen atom when Y4 iS a halogen atom; and Y4 represents a hydrogen atom when y2 and Y3 are both halogen atoms or combinedly represent a carbonyl oxygen atom, or represents a halogen atom when y2 iS a halogen atom and Y3 is a hydrogen atom.
The halogen atom represented by y~, y2 ~ y3 or Y4 or in RIB is preferably an iodine, bromine or chlorine atom while an alkyl or aryl sulfonyloxy group represented by yl is preferably methanesulfonyloxy, benzenesulfonyloxy or toulenesulfonyloxy (in particular p-toluenesu].fonyloxy). The ester residue represented by Y~ is, for example, a lower - 2~ -alkoxy group, such as methoxy or ethoxy, or the residue of an active ester with N-hydroxybenzotriazole, N~
hydroxysuccinimide or the like.
In the following, the above processes are described in further detail.
Process 1 Among the compounds according to the invention, the compounds of general formula (Ic) can be synthesized by the so-called N-alkylation or N-acylation which comprises reacting a benzoxazine derivative of the formula (IV), which has a free nitrogen atom, with a halide, sulfonate or ester of the formula (V).
This reaction is carried out generally in an organic solvent inert to the reaction, for example N,N-dimethylformamide, dimethyl sulfoxide, hexamethylphosphoramide, ether, dioxane, tetrahydrofuran, methylene chloride, dichloroethane, chloroform, benzene, toluene or xylene, although the reaction may proceed in the absence of a solvent.
In carrying out the reaction, it is advantageous to use a base, such as trimethylamine, triethylamine, sodium hydride, potassium hydride, an alkali metal alcoholate (e.g.
potassium tert-butoxide) or potassium carbonate, or a copper catalyst, such as copper, copper iodide or copper sulfate.
The reaction temperature is not cr;.tical but may suitably be selected depending on the reactan-ts. Thus the ~J 'i ~- ~ ,',J ~
reaction is carried out with cooling, at room temperature, or under heating.
Process 2 Those benzoxazine derivatives of the formula (Id) which have a hydroxyalkyl group can be produced by the so-called N-alkylation or N-acylation which comprises reacting an 3-oxobenzoxazine derivative of the formula (VI) with a halide, sulfonate or ester of the formula (V-a), followed by reduction of the resulting 3-oxo-4-substituted carbonylalkylbenzoxazine derivative of the formula (IIa-1).
Those compounds of the formula (Ie) which have a carbonyl group can be produced by oxidizing the compounds (Id) obtained in the above manner.
The N-alkylation or N-acylation in the first step can be conducted in the same manner as in Process 1.
The second-step reduction is advantageously effected by adding a compound (IIa-1) or the reacti.on mixture from the first step to a reducing agent, such as borane, preferably borane-tetrahydrofuran complex (which is commercially available), followed by heating or by heating under refluxing.
The third step oxidation is advantageously carried out in the manner of Swern oxidation or Jones oxidation although any other method for oxidizing a carbinol group to a carbonyl group can be employed. In the case of Swern oxidation, for instance, the reaction is carri.ed out ln an ,:
, .
~J r~ J
organic solvent inert to the reaction, such as methylene chloride, preferably in an inert gas atmosphere and with cooling (about -60 C). Under such conditions, the intermediate (Id) is treated with activated DMSO (which is prepared from oxalyl chloride and dimethyl sulfoxide), and then with triethylamine.
Process 3 Among the compounds according to the present invention, those compounds of the formula (If) which have a lactam ring bound, via the nitrogen atom thereof, to the benzoxazine ring at the 4-position thereof can be produced by subjecting the corresponding halobutyrylamino or halovalerylamino compounds (X) to cycli~ation.
The cyclization (ring formation) reaction is carried out under substantially the same conditions as used in the N-alkylation in Process 1 using an acid halide. An alkali metal alcoholate, such as potassium tert-butoxide, is advantageously used as the base.
The intermediates (X) can be prepared by nitrosating a compound (I~), reducing the resulting nitroso compound (VII) and reacting the resulting amino compound (VIII) with a carboxylic acid of the formula (I~) or a reactive derivati.ve thereo~.
For the nitrosation, the compound (IV) is reacted with a nitrosating agent, such as sodi.um nitrite, nitrous acid or a nitrite ester, in an inert solvent, such as an , . - 27 -!
' ~ ' ' ~ ' ~' '' ' ~ s~-~
alcohol (e.g. methanol, ethanol, isopropanol) or acetic acid-water, under acidic conditions with cooling to maintain a temperature not higher than 20C, preferably not higher than 10C, and then, a~ter heat generation has subsided, at room temperature.
The reduction is generally carried out in an organic solvent inert to the reaction, for example an alcohol such as methanol, ethanol or isopropanol, in the presence of a base, such as sodium hydroxide, with cooling or at room temperature, using an appropriate reducing agent, for example formamidinesulfinic acid or a boron hydride compound such as diborane or sodium borohydride. In some instances, the reduction may be performed in the manner of catalytic hydrogenation using Raney nickel, palladium-carbon, platinum black or palladium as the catalyst or in the manner of chemical reduction using iron, tin or zinc in combination with an acid such as hydrochloric acid, sulfuric acid or acetic acid.
The amidation is carried out in a conventional manner. As the reactive derivative of the compound (IX), there may be mentioned an ester, such as methyl ester or ethyl ester, an acid chloride, such as acid chloride Qr acid bromide, an acid azide, an active ester, such as N-hydroxybenzotriazole ester or N-hydroxysuccinimide ester, the symmetric acid anhydr:ide and a mixed acid anhydride with an alkylcarbonic acidj p~toluenesulfonic acid, - 2~ --:
diphenylphosphoryl chloride or the like. When the compound (IX) is subjected to amidation in its -free forrn, a condensing agent, such as dicyclohexylcarbodiimide, 1,1'-carbonyldiimidazole, diphenylphosphoryl azide or diethylphosphoryl cyanide. The reaction is carried out in an organic solvent inert to the reaction, for example an alcohol such as methanol, ethanol or isopropanol, N,N-dimethylformamide, pyridine, tetrahydrofuran, dioxane, ether, benzene, toluene, xylene, methylene chloride, dichloroethane, chloroform, ethyl acetate or acetonitrile, generally at room temperature or wi.th warming or, for certain reactive derivatives, with cooling, in the presence of a base, for example an organic base, such as pyridine, picoline, lutidine, dimethylaniline or N-methylmorpholine, or an inorganie base, such as potassium earbonate, sodium carbonate, sodium hydrogen earbonate, sodium hydroxide or potassium hydroxide, using the compound (IX) or a reactive derivative thereof in an equimolar or exeessive amount relative to eompound (VIII).
Proeess 4 Among the compounds according to the invention, the eompounds of the formula (Ih) can be produced by reaeting (amidating) a earboxylic acid of the formula (Ig) or a reaetive derivative thereof with an amine of the formula (IX) or a salt -thereof.
_ 29 -,, -: ' . : ' . -: . -.
, The amidation reaction can be conducted in the same manner and under the same reaction conditions as in the amidation for preparing intermediates (X) in Process 3 mentioned above.
When an ester compound corresponding to compound (Ig) is available, the ester compound may be subjected to hydrolysis and the resul-ting compound (Ig) to the above-mentioned amidation. The hydrolysis is preferably carried out in a conventional manner in the presence of an acid, such as trifluoroacetic acid, or a base, such as sodium hydroxide or potassium hydroxide.
Process 5 The ~-oxide compounds of the formula (Ij) can be produced by oxidizing the corresponding nitrogen-containing heterocyclic compounds (Ii).
The oxidation can be carried out in an organic solvent inert to the reaction, for example methylene chloride, dichloroethane, chloroform, carbon tetrachloride, an alcohol such as me-thanol, or ether, at room temperature or with warming, using an oxidiz;ng agent, for example hydrogen peroxide, an inorganic peracid, such as perphosphoric acid, chromic anhydride, persulfuric acid or potassium persulfate, or an organic peracid, such as perbenzoic acid, m-chloroperbenzoic acid, performic acid, trifluoroperacetic acid, perphthalic acid, permaleic acid or peracetic acid.
, : ' ' '. ~
;J~ ~ t. ~ ~ ~
Process 6 Among the compounds according to the present invention, the compounds of the formula (Ik) can be produced by reacting a compound (IV) with a dihalide or diketone of the formula (VIII).
The dihalide compound can be prepared by reacting the corresponding carbonyl compound having active hydrogen in the position alpha to carbonyl with a halogenating agent, such ~s a halogen gas, N-bromosuccinimide, sulfuryl chloride or copper chloride, in an inert organic solvent, such as dichloromethane, dichloroethane, chloroform, carbon tetrachloride, N,N-dimethylformamide, ether, dioxane, benzene or acetic acid, in the presence of an acid catalyst or radical initiator, such as benzoyl peroxide, azobisisobutyronitrile or a hydrogen halide, at room temperature or under heating, as illustrated by the reaction formula shown below.
l ¦ Halogenating Rl~-CH C=O
Rl4-CH C=O agent C
CH2 / \
ys ys and/or R14-C C=O
/ \
~5 CH
.- 31~5 .. . . .. . ..
: ~ . . : . :. ,, . , -. -. ~ ~ . , , :
. . : .
- . , ~ 3~ ~
(In the above reaction formula, Rl4, Rl5 and Rl6 are as defined above and Y5 represents a halogen atom.) The reaction of the compound (IV) with the dihalide or diketone is advantageously carried out in an organic solvent inert to the reaction, such as methylene chloride, dichloroethane, chloroform, carbon tetrachloride, ether, dioxane, tetrahydrofuran, benzene, toluene or xylene, in the presence of an acid catalyst, for example an organic acid such as p-toluenesulfonic acid or methanesulfonic acid or a Lewis acid such as titanium tetrachloride, when the compound (IV) is reacted with the diketone, or in the presence of a base such as trimethylamine, triethylamine, pyridine, picoline, lutidine, N,N-dimethylaniline or N-methylmorpholine when the compound (IV) is reacted with the dihalide, with heating, preferably with heating under refluxing, using the compound (XII) in an equimolar or excessive- amount relative to the compound (IV).
The intermediates (II), which differ from the compounds according to the present invention in tha-t they have an oxo group at the 3-position of the benzoxazine skeleton, can be produced by essentially the same methods as those mentioned above for the compounds according to the present invention unless the carbonyl group is reduced as in Process 2.
Thus, for instance, those compounds of formula (II) in which R7a is a nitro~en~containin~ heterocyclic group ~ 32 ~
, . ' ~ , ' - , ' ~ ~ ' which may optionally be substituted by at least one of an oxo group and a lower alkyl group and may be in the form of an N-oxide can be produced by applying the above-mentioned Process 1, 3 or 5. Those compounds of formula (II) in which R7a is a carbocylic group which may optionally be substituted by an oxo group can be produced by applying Process 6. Those compounds of formula (II) which have a group represented by the formula -Al-R8a can be produced by Process 1 or 5 and those compounds of formula (II) which have a group of the O
formula -A2-C-R9~ can be produced by Process 1 or 4.
To give the final products, namely the compounds (I~
according to the invention, the intermediates (II) are subjected to Process 2 when their 4-position substituent contains a carbonyl group readily reducible with such a reducing agent as borane. When the 4-position substituent is an unreducible one, the intermediates (II) can directly be reduced with borane to give the corresponding compounds (I).
The intermediates (III) can be produced by applying the methods (step 1 and step 2) involved in Process 3 and the compounds according to the invention can be derived therefrom by applying ~he subsequent steps of Process 3.
The reaction period to be employed in each reaction step in the processes mentioned above should suitably be .
determined depending on various reaction conditions.
. ~ ,. . . ..
- .
. ' `
f~ 3 ~3~ ~
The product given by each reaction can be easily isolated and purified.
For instance, after completion of the reaction, the reaction mixture is poured into an excessive amount of water or ice water, the organic matter is extracted with an appropriate organic solvent, such as methylene chloride, chloroform, benzene, diethyl e-ther or ethyl acetate, the extract layer is then dried, the solvent is evaporated, and the residue is purified by recrystalliza-tion or silica gel column chromatography on silicagel to give the desired intermediate or product in a purified form. The solvent for recrystallization and/or column chromatography may suitably be selected from among hexane, benzene, methylene chloride, chloroform, ethyl acetate, acetone, ethanol, methanol, etc., and mixtures of these.
In some instances, the reaction product may precipitate out as crystals with the progress of the reaction. In such cases, the product can be more readily isolated and purified by collecting the crystalline precipitate by filtration and recrystallizing the same from an appropriate organic solvent.
As mentioned above, the compounds according to the invention may include various types of stereoisomers.
Geometric isomers and tautomers can be separated into individual isomers and each isomer can be purified by taking , , - : , ~ 3 advantage of a difference or differences in physical properties between the isomers, for instance.
Optical isomers can be produced by using appropriate starting compounds or obtained in a purified form by a technique generally used for optical resolution of racemic mixtures, for example the technique of optical resolution which comprises the formation of diastereomer salts with an optically active acid (in particular tartaric acid) in general use for the above purpose.
The compounds provided by the present invention have K+ channel activating activity and are useful for the prevention and treatment of ischemic heart diseases such as angina pectoris and myocardial infarction as well as cardiovascular diseases such as hypertension and related diseases (arteriosclerosis, obesity, hyperlipemia, etc.), congestive heart failure, arrhythmia and peripheral vascular disorders (alopecia etc.), among others.
Furthermore, the compounds according to the present invention are useful as therapeutic agents ior various disorders associated with smooth muscle contraction, such as cerebrovascular disorders (cerebrovascular spasms, migraine, diz~iness, etc.), respiratory disorders (reversible airway obstruction, hypersensitive airway obstruction, asthma, etc.), gastrointestinal disorders (ulcer, nervous gastrointestinal disease, irrltable colon syndrome, diverticulosis, biliary obstructiorl, e-tc.), visual and -- 35 ~
' auditory disorders (disorders of inner ear, disorders of auditory organs, glaucoma, dysopia, ocular hypertension, etc.), urinary tract disorders (renal failure, disorders associated with passage of renal stones, pollakiuria, dysuria, incontinence, etc.), genital organ disorders (premature labor, dysmenorrhea, etc.) and the like. In addition, the compounds of the present invention are of value as therapeutic agents for disorders due to abnormal blood sugar level (hypoglycemia, diabetes, etc.) and to abnormality of the cardiac conduction system (arrhythmia etc.).
These pharmacological actions of the compounds according to the present invention can be demonstrated using the test methods mentioned below. Thus, the K+ channel activating action of the compounds was demonstrated in the concentration range from 10-9 to 10-4 M in isolated tissue.
The compounds, when given intravenously, reduced the blood pressure and increased the coronary blood flow in the dose range of 1 to 1,000 ~g/kg and, when administered in-to the coronary artery, they dilated the coronary artery in the dose range of 0.3 to 100 ~g. Furthermore, hypotensive and coronaryvasodilating activities of the some compounds according to the present invention were found -to be effective for a long period of time.
The test methods or supporting the pharmacological effects of several typical compounds among the compounds according to the present invention are described below.
~ 36 -Test methods:
(1) Effects on 3,4-diaminopyridine-induced rhythmic contractions The method of Uchida and Sugimoto (Myakkangaku, 24, 133-143, 1984) was used. Mongrel dogs of either sex were anesthetized with pentobarbital (30 mg/kg i.v.) and bled to death and, then, the heart was excised from each animal. In the Krebs-Henseleit solution, the left coronary circumflex branch or the anterior descending branch was isolated and cut into rings, about 2 mm in width. The ring segment was fixed to a stainless steel hook and suspended in a Krebs-Henseleit bath (37C) aerated with 95%02-5%CO2 gas mixture under a tension load of 1~0 g, and isometric contractions were recorded.
After the specimen was stabilized for 30 minutes, rhythmic contractions were induced by additlon of 3,4-diaminopyridine (10 mM). When the amplitude and frequency of rhythmic conkractions became substantiall~ steady, cumulative addition of the test compound to the organ bath was started.
The concentration-response curves for the amplitude and frequency of contractions were constructed and the efficacy was evaluated.
The inhibitory effect on the frequenc~ of contractions is shown in Column (1) in Table 1.
J ~ J ~
(2) Effects on the cardiovascular system Mongrel dogs of either sex were anesthetized with pentobarbital, 30 mg/kg i.v. and, after tracheal intubation, the experiment was performed under artificial respiration.
After thoracotomy, heart rate, blood pressure, left ventricular pressure, max d~VP/dt, pulmonary arterial pressure, central venous pressure, cardiac output and coronary blood flow were measured. The test eompound was administered through a cannula indwelt in the femoral vein and the efficacy was evaluated.
Column (2) in Table 1 shows the mean blood pressure (MBP)-lowering effect in terms of the percent reduc-tion (~%).
R3 ~\ R5 R3 ~\ ~RR5 6 (VI) (IIa-l) OH
R e d u c t i o n ~ , Ox i d a t i o n R3 ~Jl~ O ~
( I d ) O
Rl I
R3~ R5 R4 ~ :
(Ie) :
.. ..
Process 3 NO
Rl Rl R6 -- ~ 1 R6 (IV) (VII) Rl NH2 Rl8COOH (IX) or a Reduction R2 ~ N thereof R3 ~
(VIII) ~6 ~
NHCo-R18 Cycllzation ~ N ' Rl I when R18 is a R2 I N halo-substituted R2 ~ N
propyl or butyl (X) (If) ; - 20 ~
. . ~ ~' " '' .: . '' ~
~ 3 Process 4 Rl9 ~ Rl9 A7-COOH < R20 R I R20 R (XI) ~ ~
(Ig) (Ih) or a reactive derivative thereof Process 5 l As - ~ N ¦
R3 ~ h ~ Oxida~ion R2 ~ l RR6 (Ii) (Ij) Process 6 Rl5 Rl6 y4 1 ¦ ,Rl4 Rl4 ~ o R3 r h Y \\ / < Rls ~1 R4 -~ R4 (IV) (Ik) -- 21 ~
, 7J.i2~3 In the above formulas, Rl, R2, R3, R'', Rl , R2 , R3 , 4' R5 R6 R7 Al R8 A2 R9 A3 Rl, A.4, Rll and Rl2 are as defined above and the other symbols are defined as follows:
R7c repxesents a heterocycli~ group which is available for bonding through a ring-forming carbon atom (no-t a hetero atom) and may optionally have a substituent or substituents, a group of the formula -AlC-R3c (in which AlC is a lower alkylene group and R8C is an aryl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, or a lower alkenyloxy group, when AlC represents a non-substituted lower alkylene, R3 does not represent a phenyl group), a group of the formula O
-A2-C-R9 (in which A2 and R9 are as defined abo~e), a group of O ..
the formula -C-A3C-Rl0 (in which Rl are as defined above and A3c is a single bond or a lower alkylene or lower alkenylene R
CH <
- CH < Rl5 group) or a group of the formula z1-R16 (in which Rl'' is a hydrogen atom or a lower alkyl or lower alkoxycarbonyl group, Rl5 and Rl6, whlch may be the same or different, each independently is a lower alk-yl group or combinedly represent a lower alkylene, o-phenylene or carbonyl group -to form a ring, and zl is a carbonyl, methylene or carbinol group;
'- ' ~:J ~
yl represents a halogen atom or an alkyl or aryl sulfonylo~y group or ester residue;
R7a-1 represents a group of the formula -A2-C-R9 and R9 being as defined above) or a group of the < CH <
formula C-R16 (Rl4, Rl5 and Rl6 being as defined o above);
A5 represents a group represented by A2 or a group of Rl~
> < Rls (Rl' and being as defined above);
Rl7 is a group represented by R9 or Rl6 (each being as defined above);
R13 represents a halo-substituted propyl or halo-substituted butyl;
A6 represents a trimethylene or tetramethylene group;
A7 represents a lower alkylene group or a group of O
the formula -C-A3- (A3 being as defined above);
Rl9 and R20 are the same or different and each independently is a hydrogen atom or a lower alkyl yroup or combinedly, together with the adjacent nitrogen atom, form a ~ 23 - :
~$S'.'J'~3~
heterocyclic group which may have a substituent or substituents;
A8 represents a single bond. A group represented by Al or A2 or a group of the formula -C-A3- (A3 being as defined above);
/~
- ~ N represents a nitrogen-containing monocyclic or bicyclic heteroaromatic group which may optionally be substituted;
y2 represen-ts a halogen atom or, when taken together with Y3, represents a carbonyl oxygen atom;
Y3 represents a halogen atom or, when ta~en together with y2, represents a carbonyl oxygen atom, or a hydrogen atom when Y4 iS a halogen atom; and Y4 represents a hydrogen atom when y2 and Y3 are both halogen atoms or combinedly represent a carbonyl oxygen atom, or represents a halogen atom when y2 iS a halogen atom and Y3 is a hydrogen atom.
The halogen atom represented by y~, y2 ~ y3 or Y4 or in RIB is preferably an iodine, bromine or chlorine atom while an alkyl or aryl sulfonyloxy group represented by yl is preferably methanesulfonyloxy, benzenesulfonyloxy or toulenesulfonyloxy (in particular p-toluenesu].fonyloxy). The ester residue represented by Y~ is, for example, a lower - 2~ -alkoxy group, such as methoxy or ethoxy, or the residue of an active ester with N-hydroxybenzotriazole, N~
hydroxysuccinimide or the like.
In the following, the above processes are described in further detail.
Process 1 Among the compounds according to the invention, the compounds of general formula (Ic) can be synthesized by the so-called N-alkylation or N-acylation which comprises reacting a benzoxazine derivative of the formula (IV), which has a free nitrogen atom, with a halide, sulfonate or ester of the formula (V).
This reaction is carried out generally in an organic solvent inert to the reaction, for example N,N-dimethylformamide, dimethyl sulfoxide, hexamethylphosphoramide, ether, dioxane, tetrahydrofuran, methylene chloride, dichloroethane, chloroform, benzene, toluene or xylene, although the reaction may proceed in the absence of a solvent.
In carrying out the reaction, it is advantageous to use a base, such as trimethylamine, triethylamine, sodium hydride, potassium hydride, an alkali metal alcoholate (e.g.
potassium tert-butoxide) or potassium carbonate, or a copper catalyst, such as copper, copper iodide or copper sulfate.
The reaction temperature is not cr;.tical but may suitably be selected depending on the reactan-ts. Thus the ~J 'i ~- ~ ,',J ~
reaction is carried out with cooling, at room temperature, or under heating.
Process 2 Those benzoxazine derivatives of the formula (Id) which have a hydroxyalkyl group can be produced by the so-called N-alkylation or N-acylation which comprises reacting an 3-oxobenzoxazine derivative of the formula (VI) with a halide, sulfonate or ester of the formula (V-a), followed by reduction of the resulting 3-oxo-4-substituted carbonylalkylbenzoxazine derivative of the formula (IIa-1).
Those compounds of the formula (Ie) which have a carbonyl group can be produced by oxidizing the compounds (Id) obtained in the above manner.
The N-alkylation or N-acylation in the first step can be conducted in the same manner as in Process 1.
The second-step reduction is advantageously effected by adding a compound (IIa-1) or the reacti.on mixture from the first step to a reducing agent, such as borane, preferably borane-tetrahydrofuran complex (which is commercially available), followed by heating or by heating under refluxing.
The third step oxidation is advantageously carried out in the manner of Swern oxidation or Jones oxidation although any other method for oxidizing a carbinol group to a carbonyl group can be employed. In the case of Swern oxidation, for instance, the reaction is carri.ed out ln an ,:
, .
~J r~ J
organic solvent inert to the reaction, such as methylene chloride, preferably in an inert gas atmosphere and with cooling (about -60 C). Under such conditions, the intermediate (Id) is treated with activated DMSO (which is prepared from oxalyl chloride and dimethyl sulfoxide), and then with triethylamine.
Process 3 Among the compounds according to the present invention, those compounds of the formula (If) which have a lactam ring bound, via the nitrogen atom thereof, to the benzoxazine ring at the 4-position thereof can be produced by subjecting the corresponding halobutyrylamino or halovalerylamino compounds (X) to cycli~ation.
The cyclization (ring formation) reaction is carried out under substantially the same conditions as used in the N-alkylation in Process 1 using an acid halide. An alkali metal alcoholate, such as potassium tert-butoxide, is advantageously used as the base.
The intermediates (X) can be prepared by nitrosating a compound (I~), reducing the resulting nitroso compound (VII) and reacting the resulting amino compound (VIII) with a carboxylic acid of the formula (I~) or a reactive derivati.ve thereo~.
For the nitrosation, the compound (IV) is reacted with a nitrosating agent, such as sodi.um nitrite, nitrous acid or a nitrite ester, in an inert solvent, such as an , . - 27 -!
' ~ ' ' ~ ' ~' '' ' ~ s~-~
alcohol (e.g. methanol, ethanol, isopropanol) or acetic acid-water, under acidic conditions with cooling to maintain a temperature not higher than 20C, preferably not higher than 10C, and then, a~ter heat generation has subsided, at room temperature.
The reduction is generally carried out in an organic solvent inert to the reaction, for example an alcohol such as methanol, ethanol or isopropanol, in the presence of a base, such as sodium hydroxide, with cooling or at room temperature, using an appropriate reducing agent, for example formamidinesulfinic acid or a boron hydride compound such as diborane or sodium borohydride. In some instances, the reduction may be performed in the manner of catalytic hydrogenation using Raney nickel, palladium-carbon, platinum black or palladium as the catalyst or in the manner of chemical reduction using iron, tin or zinc in combination with an acid such as hydrochloric acid, sulfuric acid or acetic acid.
The amidation is carried out in a conventional manner. As the reactive derivative of the compound (IX), there may be mentioned an ester, such as methyl ester or ethyl ester, an acid chloride, such as acid chloride Qr acid bromide, an acid azide, an active ester, such as N-hydroxybenzotriazole ester or N-hydroxysuccinimide ester, the symmetric acid anhydr:ide and a mixed acid anhydride with an alkylcarbonic acidj p~toluenesulfonic acid, - 2~ --:
diphenylphosphoryl chloride or the like. When the compound (IX) is subjected to amidation in its -free forrn, a condensing agent, such as dicyclohexylcarbodiimide, 1,1'-carbonyldiimidazole, diphenylphosphoryl azide or diethylphosphoryl cyanide. The reaction is carried out in an organic solvent inert to the reaction, for example an alcohol such as methanol, ethanol or isopropanol, N,N-dimethylformamide, pyridine, tetrahydrofuran, dioxane, ether, benzene, toluene, xylene, methylene chloride, dichloroethane, chloroform, ethyl acetate or acetonitrile, generally at room temperature or wi.th warming or, for certain reactive derivatives, with cooling, in the presence of a base, for example an organic base, such as pyridine, picoline, lutidine, dimethylaniline or N-methylmorpholine, or an inorganie base, such as potassium earbonate, sodium carbonate, sodium hydrogen earbonate, sodium hydroxide or potassium hydroxide, using the compound (IX) or a reactive derivative thereof in an equimolar or exeessive amount relative to eompound (VIII).
Proeess 4 Among the compounds according to the invention, the eompounds of the formula (Ih) can be produced by reaeting (amidating) a earboxylic acid of the formula (Ig) or a reaetive derivative thereof with an amine of the formula (IX) or a salt -thereof.
_ 29 -,, -: ' . : ' . -: . -.
, The amidation reaction can be conducted in the same manner and under the same reaction conditions as in the amidation for preparing intermediates (X) in Process 3 mentioned above.
When an ester compound corresponding to compound (Ig) is available, the ester compound may be subjected to hydrolysis and the resul-ting compound (Ig) to the above-mentioned amidation. The hydrolysis is preferably carried out in a conventional manner in the presence of an acid, such as trifluoroacetic acid, or a base, such as sodium hydroxide or potassium hydroxide.
Process 5 The ~-oxide compounds of the formula (Ij) can be produced by oxidizing the corresponding nitrogen-containing heterocyclic compounds (Ii).
The oxidation can be carried out in an organic solvent inert to the reaction, for example methylene chloride, dichloroethane, chloroform, carbon tetrachloride, an alcohol such as me-thanol, or ether, at room temperature or with warming, using an oxidiz;ng agent, for example hydrogen peroxide, an inorganic peracid, such as perphosphoric acid, chromic anhydride, persulfuric acid or potassium persulfate, or an organic peracid, such as perbenzoic acid, m-chloroperbenzoic acid, performic acid, trifluoroperacetic acid, perphthalic acid, permaleic acid or peracetic acid.
, : ' ' '. ~
;J~ ~ t. ~ ~ ~
Process 6 Among the compounds according to the present invention, the compounds of the formula (Ik) can be produced by reacting a compound (IV) with a dihalide or diketone of the formula (VIII).
The dihalide compound can be prepared by reacting the corresponding carbonyl compound having active hydrogen in the position alpha to carbonyl with a halogenating agent, such ~s a halogen gas, N-bromosuccinimide, sulfuryl chloride or copper chloride, in an inert organic solvent, such as dichloromethane, dichloroethane, chloroform, carbon tetrachloride, N,N-dimethylformamide, ether, dioxane, benzene or acetic acid, in the presence of an acid catalyst or radical initiator, such as benzoyl peroxide, azobisisobutyronitrile or a hydrogen halide, at room temperature or under heating, as illustrated by the reaction formula shown below.
l ¦ Halogenating Rl~-CH C=O
Rl4-CH C=O agent C
CH2 / \
ys ys and/or R14-C C=O
/ \
~5 CH
.- 31~5 .. . . .. . ..
: ~ . . : . :. ,, . , -. -. ~ ~ . , , :
. . : .
- . , ~ 3~ ~
(In the above reaction formula, Rl4, Rl5 and Rl6 are as defined above and Y5 represents a halogen atom.) The reaction of the compound (IV) with the dihalide or diketone is advantageously carried out in an organic solvent inert to the reaction, such as methylene chloride, dichloroethane, chloroform, carbon tetrachloride, ether, dioxane, tetrahydrofuran, benzene, toluene or xylene, in the presence of an acid catalyst, for example an organic acid such as p-toluenesulfonic acid or methanesulfonic acid or a Lewis acid such as titanium tetrachloride, when the compound (IV) is reacted with the diketone, or in the presence of a base such as trimethylamine, triethylamine, pyridine, picoline, lutidine, N,N-dimethylaniline or N-methylmorpholine when the compound (IV) is reacted with the dihalide, with heating, preferably with heating under refluxing, using the compound (XII) in an equimolar or excessive- amount relative to the compound (IV).
The intermediates (II), which differ from the compounds according to the present invention in tha-t they have an oxo group at the 3-position of the benzoxazine skeleton, can be produced by essentially the same methods as those mentioned above for the compounds according to the present invention unless the carbonyl group is reduced as in Process 2.
Thus, for instance, those compounds of formula (II) in which R7a is a nitro~en~containin~ heterocyclic group ~ 32 ~
, . ' ~ , ' - , ' ~ ~ ' which may optionally be substituted by at least one of an oxo group and a lower alkyl group and may be in the form of an N-oxide can be produced by applying the above-mentioned Process 1, 3 or 5. Those compounds of formula (II) in which R7a is a carbocylic group which may optionally be substituted by an oxo group can be produced by applying Process 6. Those compounds of formula (II) which have a group represented by the formula -Al-R8a can be produced by Process 1 or 5 and those compounds of formula (II) which have a group of the O
formula -A2-C-R9~ can be produced by Process 1 or 4.
To give the final products, namely the compounds (I~
according to the invention, the intermediates (II) are subjected to Process 2 when their 4-position substituent contains a carbonyl group readily reducible with such a reducing agent as borane. When the 4-position substituent is an unreducible one, the intermediates (II) can directly be reduced with borane to give the corresponding compounds (I).
The intermediates (III) can be produced by applying the methods (step 1 and step 2) involved in Process 3 and the compounds according to the invention can be derived therefrom by applying ~he subsequent steps of Process 3.
The reaction period to be employed in each reaction step in the processes mentioned above should suitably be .
determined depending on various reaction conditions.
. ~ ,. . . ..
- .
. ' `
f~ 3 ~3~ ~
The product given by each reaction can be easily isolated and purified.
For instance, after completion of the reaction, the reaction mixture is poured into an excessive amount of water or ice water, the organic matter is extracted with an appropriate organic solvent, such as methylene chloride, chloroform, benzene, diethyl e-ther or ethyl acetate, the extract layer is then dried, the solvent is evaporated, and the residue is purified by recrystalliza-tion or silica gel column chromatography on silicagel to give the desired intermediate or product in a purified form. The solvent for recrystallization and/or column chromatography may suitably be selected from among hexane, benzene, methylene chloride, chloroform, ethyl acetate, acetone, ethanol, methanol, etc., and mixtures of these.
In some instances, the reaction product may precipitate out as crystals with the progress of the reaction. In such cases, the product can be more readily isolated and purified by collecting the crystalline precipitate by filtration and recrystallizing the same from an appropriate organic solvent.
As mentioned above, the compounds according to the invention may include various types of stereoisomers.
Geometric isomers and tautomers can be separated into individual isomers and each isomer can be purified by taking , , - : , ~ 3 advantage of a difference or differences in physical properties between the isomers, for instance.
Optical isomers can be produced by using appropriate starting compounds or obtained in a purified form by a technique generally used for optical resolution of racemic mixtures, for example the technique of optical resolution which comprises the formation of diastereomer salts with an optically active acid (in particular tartaric acid) in general use for the above purpose.
The compounds provided by the present invention have K+ channel activating activity and are useful for the prevention and treatment of ischemic heart diseases such as angina pectoris and myocardial infarction as well as cardiovascular diseases such as hypertension and related diseases (arteriosclerosis, obesity, hyperlipemia, etc.), congestive heart failure, arrhythmia and peripheral vascular disorders (alopecia etc.), among others.
Furthermore, the compounds according to the present invention are useful as therapeutic agents ior various disorders associated with smooth muscle contraction, such as cerebrovascular disorders (cerebrovascular spasms, migraine, diz~iness, etc.), respiratory disorders (reversible airway obstruction, hypersensitive airway obstruction, asthma, etc.), gastrointestinal disorders (ulcer, nervous gastrointestinal disease, irrltable colon syndrome, diverticulosis, biliary obstructiorl, e-tc.), visual and -- 35 ~
' auditory disorders (disorders of inner ear, disorders of auditory organs, glaucoma, dysopia, ocular hypertension, etc.), urinary tract disorders (renal failure, disorders associated with passage of renal stones, pollakiuria, dysuria, incontinence, etc.), genital organ disorders (premature labor, dysmenorrhea, etc.) and the like. In addition, the compounds of the present invention are of value as therapeutic agents for disorders due to abnormal blood sugar level (hypoglycemia, diabetes, etc.) and to abnormality of the cardiac conduction system (arrhythmia etc.).
These pharmacological actions of the compounds according to the present invention can be demonstrated using the test methods mentioned below. Thus, the K+ channel activating action of the compounds was demonstrated in the concentration range from 10-9 to 10-4 M in isolated tissue.
The compounds, when given intravenously, reduced the blood pressure and increased the coronary blood flow in the dose range of 1 to 1,000 ~g/kg and, when administered in-to the coronary artery, they dilated the coronary artery in the dose range of 0.3 to 100 ~g. Furthermore, hypotensive and coronaryvasodilating activities of the some compounds according to the present invention were found -to be effective for a long period of time.
The test methods or supporting the pharmacological effects of several typical compounds among the compounds according to the present invention are described below.
~ 36 -Test methods:
(1) Effects on 3,4-diaminopyridine-induced rhythmic contractions The method of Uchida and Sugimoto (Myakkangaku, 24, 133-143, 1984) was used. Mongrel dogs of either sex were anesthetized with pentobarbital (30 mg/kg i.v.) and bled to death and, then, the heart was excised from each animal. In the Krebs-Henseleit solution, the left coronary circumflex branch or the anterior descending branch was isolated and cut into rings, about 2 mm in width. The ring segment was fixed to a stainless steel hook and suspended in a Krebs-Henseleit bath (37C) aerated with 95%02-5%CO2 gas mixture under a tension load of 1~0 g, and isometric contractions were recorded.
After the specimen was stabilized for 30 minutes, rhythmic contractions were induced by additlon of 3,4-diaminopyridine (10 mM). When the amplitude and frequency of rhythmic conkractions became substantiall~ steady, cumulative addition of the test compound to the organ bath was started.
The concentration-response curves for the amplitude and frequency of contractions were constructed and the efficacy was evaluated.
The inhibitory effect on the frequenc~ of contractions is shown in Column (1) in Table 1.
J ~ J ~
(2) Effects on the cardiovascular system Mongrel dogs of either sex were anesthetized with pentobarbital, 30 mg/kg i.v. and, after tracheal intubation, the experiment was performed under artificial respiration.
After thoracotomy, heart rate, blood pressure, left ventricular pressure, max d~VP/dt, pulmonary arterial pressure, central venous pressure, cardiac output and coronary blood flow were measured. The test eompound was administered through a cannula indwelt in the femoral vein and the efficacy was evaluated.
Column (2) in Table 1 shows the mean blood pressure (MBP)-lowering effect in terms of the percent reduc-tion (~%).
(3) Coronary vasodilating effect Mongrel dogs of either sex were anes-thetized with pentobarbital, 30 mg/kg i.v. and subjected to the experiment under artificial respiration wi-th tracheal intubation. After thoracotomy, the left eoronary circumflex branch was perfused with the autologous blood derived from the common carotid artery at a constant pressure through an extracorporeal circuit. Coronary blood flow was measured with an electromagnetic flow probe installed in the extracorporeal circuit. The test compound was administered directly into the coronary artery through the extracorporeal circuit and the coronary vasodilating effect was assessed.
As the indicator of the coronary vasodilative effect of the test compound, the percentage of ~he response was - 3~ -determined with the response to coronary arterial administration of 300 ~g of papaverine being taken as 100%
and the dose sufficient to produce a blood flow increase of 100% (EDIoo pap) was calculated.
Test results:
Table 1 (l) (2) . .
Example - _ No. IC50 MBP
(~M)[~g/kg i.v. (~)]
1 0.01 3 (-16) 2 0.24 10 (-20) 38 0.07 10 (-23) 41(4) 0.05 3 (-20) 56 0.02 3 (-11) 0.01 10 ( -9) Cromakalim 0.39 10 (-28) Then, in connection with Examples 1 and 2, the hypotensive effect of the test compound given orally in conscious spontaneously hypertensive rats (SHR) and the intravenous acute toxicity in mice were determined.
.
~ J ~
Test method:
(1) Hypotensive effect Spontaneously hypertensive rats (SHR) of Okamoto-Aoki strain were anesthetized with pentobarbital, 60 mg/kg i.p.
Then, a cannula for blood pressure measurement was indwelt in the left common carotid artery and the other end of the cannula was led out extracorporeally from the posterior neck.
After a stabilization period of 4-5 postoperative days, the blood pressure and heart rate were measured without restraint under no anesthesia. The test compound was suspended in 0.5 methylcellulose solution and the suspension was orally administered in a volume of 5 ml/kg and the efficacy was evaluated.
Table 2 shows the mean blood pressure (MBP)-lowering effect in terms of ~%.
(2) Acute toxic effect The acute toxic dose (LD50) of -the test compound administered into the caudal vein was determined by the up and down method in male mice.
Table 3 shows acute toxic doses (LDso).
-- ~0 --~, . , ' . : :
Test results:
Table 2 Example Dose No. (~g/kg p.o.) MBP (~%
Cromakalim 300 -35 .
Table 3 .
Example No. LD50 (mg/kg i.v.) 1 50.4 . .
2 ~60 Cromakalim 49.7 The compounds (I) according to the present invention or salts thereof can be used as potassium channel activators in the form of conventional pharmaceutical preparations containing one or more of said compounds or salts thereof as active ingredients, together with the usual carrier, excipient and/or other additlves, and suited for oral or nonoral administration, for example in the form of tablets, ~
- ' , . :
., . :
.
' ' '' ' ~ ' ~
buccal tablets, powders, fine granules, granules, capsules, pills, liquid preparations for oral administration (inclusive of syrups), in~ections, inhalants, suppositories, liquid preparations for percutaneous administration, ointments, transdermal therapeutic systems or transmucosal therapeutic systems (e.g. for intraoral use), liquid preparations for permucosal administration (e.g. liquid nasal preparations) and so on.
The carriers or excipients for use in said various preparations are pharmaceutically acceptable and nontoxic solid or liquid substances, fox example lactose, magnesium stearate, starch, talc, gelatin, agar, pectin, gum arabic, olive oil, sesame oil, cacao butter, ethylene glycol and other substances in common pharmaceutical use. -The clinical dose of the compounds according to thepresent invention should suitably be decided depending on the disease to be treated, symptom, patient's body weight, age and sex, route of administration and other factors.
Generally, however, the daily dose for human adults lies within the range of 0.1 to 300 mg per adult in the case of oral administration and 0.06 to 100 mg per adult in the case of intravenous administration. Such dose is administered in a single dose or in two to four divided doses.
The following examples and dosage form examples are further illustrative of the present invention. The starting compounds include some novel compounds. Typical processes for - ~2 -.
.
., :~. ' ' .
$
preparing such novel compounds from known compounds are described in the reference examples which follow. Unless otherwise indicated, the ratios used hereinafter are by volume.
- ~3 ~
, .
.
r~
Reference Example 1 Br~ ~ CuC21 ~C~ )~
A mixture of 480 mg of 6-bromo-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazine, 206 mg of cuprous cyanide and 5 ml of N,N-dimethylformamide was stirred at 130C for 4 hours and further at 150C for ~ hours. This reaction mixture was diluted with 0.5 ml of ethylenediamine and 10 ml of water and extracted with benzene. The organic layer was washed with water and dried over anhydrous magnesium sulfate and the solvent was distilled off. The residue was chromatographed on a silica gel column and elution was carried out with ethyl acetate-hexane (10:1). The crude crystals from the eluate were washed with hexane and dried to give 160 mg of 6-cyano-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazine. This compound has the following physicochemlcal properties.
i) Melting point: l02-103.5C
ii) NMR spectrom (CDC 13 ) (ppm): 1.37 (6H, s), 1.5-2.5 (lH, s), 3.12 (2H, s), 6.77 (lH, d), 6.86 (lH, d), 6-97 (lH, dd) :
_ ~4 -" : ' C~J ~3 ~J ~
Reference ~xample 2 PhsO2 ~ No2 2)(CH3)2CBrCO2Et, KF hS02 ~ N ~ O
In 120 ml of dehydrated ethanol was suspended 11.05 g of 2-nitro-4-phenylsulfonylphenol followed by addition of a catalytic amount of Raney nickel for reduction in a hydrogen stream at atmospheric temperature and pressure. After completion of the reduction reaction, the catalyst was filtered off and the solvent was distilled off. The residue was dried under reduced pressure to give 9.73 g of crude 2-amino-4-phenylsulfonylphenol. This product was dissolved in 19 ml of N,N-dimethylformamide and the solution was added dropwise to a mixture of 5.89 g of potassium fluoride, 7.61 g of ethyl 2-bromoisobutyrate and 11 ml of N,N~
dimethylformamide. The mixture was then stirred at 60C
overnight. The reaction mlxture was poured in ice-water and extracted with ethyl acetate. The organic layer was washed with water and dried over anhydrous magnesium sulfate and the solvent was distilled off. The resldue was chromatographed on a silica gel~column and elution was carried out with hexane-ethyl acetate (2:1). The crude crystals from the eluate were recrystallized from 15 ml of ethanol to recover ~ ~5 -~ ;3~
As the indicator of the coronary vasodilative effect of the test compound, the percentage of ~he response was - 3~ -determined with the response to coronary arterial administration of 300 ~g of papaverine being taken as 100%
and the dose sufficient to produce a blood flow increase of 100% (EDIoo pap) was calculated.
Test results:
Table 1 (l) (2) . .
Example - _ No. IC50 MBP
(~M)[~g/kg i.v. (~)]
1 0.01 3 (-16) 2 0.24 10 (-20) 38 0.07 10 (-23) 41(4) 0.05 3 (-20) 56 0.02 3 (-11) 0.01 10 ( -9) Cromakalim 0.39 10 (-28) Then, in connection with Examples 1 and 2, the hypotensive effect of the test compound given orally in conscious spontaneously hypertensive rats (SHR) and the intravenous acute toxicity in mice were determined.
.
~ J ~
Test method:
(1) Hypotensive effect Spontaneously hypertensive rats (SHR) of Okamoto-Aoki strain were anesthetized with pentobarbital, 60 mg/kg i.p.
Then, a cannula for blood pressure measurement was indwelt in the left common carotid artery and the other end of the cannula was led out extracorporeally from the posterior neck.
After a stabilization period of 4-5 postoperative days, the blood pressure and heart rate were measured without restraint under no anesthesia. The test compound was suspended in 0.5 methylcellulose solution and the suspension was orally administered in a volume of 5 ml/kg and the efficacy was evaluated.
Table 2 shows the mean blood pressure (MBP)-lowering effect in terms of ~%.
(2) Acute toxic effect The acute toxic dose (LD50) of -the test compound administered into the caudal vein was determined by the up and down method in male mice.
Table 3 shows acute toxic doses (LDso).
-- ~0 --~, . , ' . : :
Test results:
Table 2 Example Dose No. (~g/kg p.o.) MBP (~%
Cromakalim 300 -35 .
Table 3 .
Example No. LD50 (mg/kg i.v.) 1 50.4 . .
2 ~60 Cromakalim 49.7 The compounds (I) according to the present invention or salts thereof can be used as potassium channel activators in the form of conventional pharmaceutical preparations containing one or more of said compounds or salts thereof as active ingredients, together with the usual carrier, excipient and/or other additlves, and suited for oral or nonoral administration, for example in the form of tablets, ~
- ' , . :
., . :
.
' ' '' ' ~ ' ~
buccal tablets, powders, fine granules, granules, capsules, pills, liquid preparations for oral administration (inclusive of syrups), in~ections, inhalants, suppositories, liquid preparations for percutaneous administration, ointments, transdermal therapeutic systems or transmucosal therapeutic systems (e.g. for intraoral use), liquid preparations for permucosal administration (e.g. liquid nasal preparations) and so on.
The carriers or excipients for use in said various preparations are pharmaceutically acceptable and nontoxic solid or liquid substances, fox example lactose, magnesium stearate, starch, talc, gelatin, agar, pectin, gum arabic, olive oil, sesame oil, cacao butter, ethylene glycol and other substances in common pharmaceutical use. -The clinical dose of the compounds according to thepresent invention should suitably be decided depending on the disease to be treated, symptom, patient's body weight, age and sex, route of administration and other factors.
Generally, however, the daily dose for human adults lies within the range of 0.1 to 300 mg per adult in the case of oral administration and 0.06 to 100 mg per adult in the case of intravenous administration. Such dose is administered in a single dose or in two to four divided doses.
The following examples and dosage form examples are further illustrative of the present invention. The starting compounds include some novel compounds. Typical processes for - ~2 -.
.
., :~. ' ' .
$
preparing such novel compounds from known compounds are described in the reference examples which follow. Unless otherwise indicated, the ratios used hereinafter are by volume.
- ~3 ~
, .
.
r~
Reference Example 1 Br~ ~ CuC21 ~C~ )~
A mixture of 480 mg of 6-bromo-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazine, 206 mg of cuprous cyanide and 5 ml of N,N-dimethylformamide was stirred at 130C for 4 hours and further at 150C for ~ hours. This reaction mixture was diluted with 0.5 ml of ethylenediamine and 10 ml of water and extracted with benzene. The organic layer was washed with water and dried over anhydrous magnesium sulfate and the solvent was distilled off. The residue was chromatographed on a silica gel column and elution was carried out with ethyl acetate-hexane (10:1). The crude crystals from the eluate were washed with hexane and dried to give 160 mg of 6-cyano-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazine. This compound has the following physicochemlcal properties.
i) Melting point: l02-103.5C
ii) NMR spectrom (CDC 13 ) (ppm): 1.37 (6H, s), 1.5-2.5 (lH, s), 3.12 (2H, s), 6.77 (lH, d), 6.86 (lH, d), 6-97 (lH, dd) :
_ ~4 -" : ' C~J ~3 ~J ~
Reference ~xample 2 PhsO2 ~ No2 2)(CH3)2CBrCO2Et, KF hS02 ~ N ~ O
In 120 ml of dehydrated ethanol was suspended 11.05 g of 2-nitro-4-phenylsulfonylphenol followed by addition of a catalytic amount of Raney nickel for reduction in a hydrogen stream at atmospheric temperature and pressure. After completion of the reduction reaction, the catalyst was filtered off and the solvent was distilled off. The residue was dried under reduced pressure to give 9.73 g of crude 2-amino-4-phenylsulfonylphenol. This product was dissolved in 19 ml of N,N-dimethylformamide and the solution was added dropwise to a mixture of 5.89 g of potassium fluoride, 7.61 g of ethyl 2-bromoisobutyrate and 11 ml of N,N~
dimethylformamide. The mixture was then stirred at 60C
overnight. The reaction mlxture was poured in ice-water and extracted with ethyl acetate. The organic layer was washed with water and dried over anhydrous magnesium sulfate and the solvent was distilled off. The resldue was chromatographed on a silica gel~column and elution was carried out with hexane-ethyl acetate (2:1). The crude crystals from the eluate were recrystallized from 15 ml of ethanol to recover ~ ~5 -~ ;3~
4.706 g of 3,4-dihydro-2,2-dimethyl-3-oxo-6-phenylsulfonyl-2H-1,4-benzoxazine.
This compound has the following physicochemical properties.
i) Melting point: 153-157C
ii) Elemental analysis (for Cl6Hl5NO4S) C (%) H (%) N (%) S (%) Calcd.: 60.55 4.76 4.41 lO.lO
Found : 60.62 4.79 4.25 10.13 iii) NMR spectrum (CDCl3) (ppm): 1.52 (6H, s), 6.99 (lH, d), 7.3-7.6 (5H, m), 7.8-8.0 (2H, m), 9.27 (lH, s) Reference Example 3 The following compound was synthesized generally in the same manner as Reference Example 2.
3,4-Dihydro-2,2-dimethyl-6-methylsulfonyl-3-oxo-2H-1,4-benzoxazine Physicochemical properties:
i) Melting point: 241-243C
ii) Elemental analysis (for C1lH13NO4S) C (%) H (%) N (%) S (%) Calcd.: 51.75 5.13 5.49 12.56 Found : 51.74 5.13 5.43 12.56 iii) NMR spectrum (DMSO-d6) ` ~ (ppm): 1.43 (6H, s), 3.15 (3H, s), 7.15 (lH, d), 7.3-7.6 (2H, m), 10.54 (lH, s) , :
';
~ ~2~ ~ 9 Reference Example 4 C~ ~ NH2 (CH3)2CBrCO2Et ce O~o To a mixture of 40 g of potassium fluoride, 40 ml of ethyl 2-bromoisobutyrate and 200 ml of N,N-dimethylformamide was added 49.1 g of 2-amino-4-chloro-5-nitrophenol and the whole mixture was stirred at 60 for 4 days. The reaction mixture was then poured in ice-water and the resulting solid was recrystallized from 800 ml of isopropyl alcohol to give 37.03 g of 6-chloro-3,4-dihydro-2,2-dimethyl-7-nitro-3-oxo-2H-1,4-benzoxazine. A 0.51 g portion of the above product was recrystallized from 14 ml of ethanol to give 0.31 g of a sample for elemental analysis.
This compound has the following physicochemical properties.
i) Melting point: 243-245C
ii) Elemental analysis (for CloH9ClN2O4) C (%) H (%) N (%) Cl (%) Calcd.: 46. ao 3.53 10.92 13.81 Found : 46.84 3.46 10.90 13.91 _ 47 -.
2 ~ 2 ~
iii) NMR spectrum (DMSO-d6) (ppm): 1.43 (6H, s), 7.04 (lH, s), 7.68 (lH, s), 11.23 (lH, s) Reference Example 5 PhSO~ N ~ O BH3-0 3 PhSO~ ol To 35 ml of a solution of borane-tetrahydrofuran complex in tetrahydrofuran (lM) was added 4.625 g of 3,4-dihydro-2,2-dimethyl-3-oxo-6-phenylsulfonyl-2H-1,4-benzoxazine with ice-cooling and the mixture was refluxed under heating with constant stirring for 2 hours. This reaction mixture was diluted with 4.3 ml of methanol and further refluxed for 45 minutes. Then, 3.6 ml of concentrated hydrochloric acid was added and the mixture was further refluxed for 45 minutes. The reaction mixture was then concentrated and the resulting solid was pulverized in ether and filtered. The pulverizate was suspended in a dilute aqueous solution of sodium hydroxide and extracted with ethyl acetate. The organlc layer was washed with water and drled over anhydrous magnesium sulfate and the solvent was distilled off. The residue was recrystallized from 15 ml of ethanol to recover 3.76 g of 3,4-dihydro-2,2-dimethyl-6~
phenylsulfonyl-2H-1,4-benzoxazine.
, :
:' ~ ~ ' '' ~ ' '' This compound has the following physicochemical properties.
i) Melting point: 138-140.5C
ii) Elemental analysis (for C16HI7NO3S) C (%) ~ (%) N (%) S (%) Calcd.: 63.34 5.65 4.62 10.57 Found : 63.36 5.65 4.54 10.65 iii) NMR spectrum (CDC13) (ppm): 1.28 (6H, s), 3.04 (3H, s), 3.2-4.2 (lH), 6.76 (lH, dd), 7.1-7.3 (2H, m), 7.3-7.6 (3H, m), 7.8-8.0 (2H, m) Reference Example 6-8 The following compound was synthesized in the same manner as Reference Example 5.
Reference Example 6 3,4-Dihydro-2,2-dimethyl-6-methylsulfonyl-2H-1,4-benzoxazine Physicochemical properties:
i) Melting point: 137-142C
ii) Elemental analysis (for CllHl5NO3S) C (%) H (%) N (%) S (%) Calcd.: 54.75 6.27 5.80 13.29 Found : 54.86 6.29 5.78 13.30 iii) NMR spectrum (CDCl3) (ppm): 1.32 (6H, s), 3.50 (3H, s), 3.09 (2H, d), 4.33 (1~1, s), 6.80 (lH, dd), 7.1~7.3 (2H, m) 2 ~.~ 2 ~
Reference Example 7 6-Chloro-3,4-dihydro-2,2-dimethyl-7-nitro-2H-1,4-benzoxazine Physicochemical properties:
i) Melting point: 139-140.5C
ii) Elemental analysis (for CloHllclN2o3) C (%) H (%) N (%) Cl (%) Calcd.: 49.50 4.57 11.54 14.61 Found : 49~45 4.53 11.52 14.57 iii) NMR spectrum (CDCl3) (ppm): 1.32 (6H, s), 3.18 (2H, d), 4.72 (lH, s), 6.57 (lH, s), 7.54 (lH, s) Reference ExamPle 8 3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine Physicochemical properties:
i) Melting point: 151-153C
ii) Elemental analysis (for CloHl2N23) C (%) ~ (%) N (%) Calcd.: 57.69 5.81 13.45 Found : 57.59 5.88 13.48 iii) NMR spectrum (CDCl3) (ppm): 1.37 (6H, s), 3.15 (2H, d), 6.78 (lH, d), 7.50 (lH, d), 7.59 (lH, dd) ',, , ,' , ,; ` , . . . . .
" ~
. . . ~ ~ ' ' .
~J 5'I'j ;~J ~ $3 ~
Reference Examp_e 9 CF3 No2 l)(CH3)2CB~CHO CF3 ~ K 2C 03 ~ N
(l) To a mixture of 10 g of 2-nitro-4-trifluoromethylphenol, 8.0 g of anhydrous calcium carbonate and 30 ml of N,N-dimethylformamide was added dropwise a solution of 8.8 g of 2-bromoisobutyraldehyde in 23 ml of N,N-dimethylformamide and the mixture was stirred at room temperature for 4 days. The reaction mixture was then poured in ice-water and extracted with toluene. The organic layer was washed with 0.5 N aqueous sodium hydroxide solution and water ln that order and dried over anhydrous magnesium sulfate and the solvent was distilled off. The residue was chromatographed on a silica gel column and elution was carried out with hexane-eth~l acetate (3:1). The ,rys-tals from the eluate were recrystallized from 15 ml of hexane twice to give 4.428 g of 2-(2-nitro-4-trifluoromethylphenoxy)isobutyraldehyde.
(2) In 40 ml of ethanol was dissolved 4.408 g of -the above aldehyde and after addition of a catalytic amount of Raney nickel, reduction was carried out in a hydrogen stream at a-tmospheric temperature and pressure. The catalys-t was .
' .
, ' ' . , '.~
.: :
': . . ,,, ' i ' ~
, ç~ ~
then filtered off and the solvent was distilled off. The residue was chromatographed on a silica gel column and elution was carried out with hexane-benzene (3:2) to recover 2.294 g of 3,4-dihydro-2,2-dimethyl-6-trifluoromethyl-2H-1,4-benzoxazine. A 1 g portion of this product was recrystallized from 2 ml of hexane to give 908 mg of a sample for elemental analysis.
This compound has the following physicochemical properties.
i) Melting point: 81-82C
ii) Elemental analysis (for C,lH12F3NO) C (%) H (%) N (%) F (%) Calcd.: 57.14 5.23 6.06 24.65 Found : 57.10 5.31 6.00 24.62 iii) NMR spectrum (CDC13) (ppm): 1.35 (6H, s), 3.10 (2H, s)-, 3.3-4.4 (lH, broad s), 6.7-7.1 (3H, m) Example 1 1) NaH
02N ~ H ~ ' ~ 07N N
In 10 ml of N,N-dimethylformamide was dissolved 2.66 g of 3,4-dihydro-2,2-dimethyl-6-ni-tro-2H-1,4-benzoxazine ,, . , :
. ' '.'' ~, .
, . . : .
. . :
S;~J~
followed by addition of 1.02 g of sodium hydride (60~ in oil) and the mixture was stirred at room temperature for 30 minutes. Then, 2.77 g of 2-bromopyridine N-oxide hydrochloride was added with ice-cooling and, after the evolution of heat had subsided, the mixture was stirred at room temperature for 2 hours. The reaction mixture was then poured in water and extracted with ethyl acetate. The organic layer was separated and dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and the residue was chromatographed on a silica gel column using chloroform as the eluent to give crude 2-(3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)pyridine N-oxide.
Recrystallization from chloroform-ethanol gave 2.0 g of the object compound.
Physicochemical properties: -i) Melting point: 224-226C
ii) Elemental analysis (for Cl5HIsN3O4) C (%) H (%) N(%) Calcd.: 59.80 5.02 13.95 Found : 59.73 5.20 13.80 iii) NMR spectrum (CDC13) (ppm): 1.42 (6H, s), 3.69 (2H, s), 6.94 (lH, d), 7.05-7.41 (3H, m), 7.49 (lH, d), 7.77 (lH, dd), 8.31 (lH, ddd) -' : ' .
-. .~ '' J~ , Example 2 1) NaH
Il 2) ~N~ NC,~N~
In 10 ml of N,N-dimethylformamide was dissolved 1.5 g of 6-cyano-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxa~ine and, then, 0.96 g of sodium hydride (60% in oil) was gradually added. After 10 minutes, 3.36 g of 2-bromop-yridine N-oxide hydrochloride was added in several portions and after the evolution of heat had subsided, the mixture was stirred at room temperature for 3 hours. The reaction mixture was ~ , diluted with water and extracted with ethyl acetate. The organic layer was separated, dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and the residue was chromatographed on a silica gel column using ethyl acetate-methanol (5:1) as the eluent to give crude 2-(6-cyano-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-4-yljpyridine N-oxide. Crystalliza-tion from ethyl acetate gave 0.78 g of crude crystals. Finally the crystals were recrystallized from e-thanol to recover 0.6 g of the object compound.
.
_ 54 -.- : . .. . , ~ .
. ' - ' . ' ,, ' ' ,' ~
- : ,, . . ; , , ~ ~ 2 ~
This compound has the following physicochemical properties.
i) Melting point: 175-177C .
ii) Elemental analysis (for Cl6HI5N3O2) C (%) H (%) N (%) Calcd.: 68.31 5.37 14.94 Found : 68.20 5.38 14.88 iii) NMR spectrum (CDCl3) (ppm): 1-40 (6H, s), 3.67 (2H, s), 6.86-7.33 (6H, m), 8.26-8.33 (lH, m) Example 3 throu~h 32 The compounds listed in the following table were synthesized by Process 1 as in Examples 1 and 2. It should be understood that where the reaction did not proceed well at room temperature, the reaction was conducted at elevated temperature. As the base, not only sodium ~hydride but also triethylamine or potassium carbonate was used. That is, in Examples 13 through 27, and 32, the reactions were conducted at 100 C to 120 C, or with heating under refluxing. As the base, triethylamine was used in Examples 13, 14l 17 through 21, and 28 through 31, and anhydrous potassium carbonate was used in Example 15, 16 and 22.
.
` ' :
r:
~ " N
Example Starting No. R2 R3 R5 R6 R7 Salt Compound (V) 3PhS02 H CH3 CH3 ~ ~ 0 free ~ N .HCl . Br 4N02 H H H \~N~o free ~ N .HCl Br 5Br H CH3 C~3 ~ free ~ N ~ H
Br 6N02 H CN3 CH3 ~ free ~ .HC , Cl 7MeS02 H CH3 CF13 ~ free ~ .HCl Br . . . . . - . . . ~ , .
f 3` o~ R6 Example Starting No. R2 R3 R5 R6 R~ Salt Compound (V) 8 Cl N02 CH3 CH3 ~ free ~ O
9 CF3 H CH3 CH3~ ~ salt ~ .HCl Br No2 H CH3 CH3/ ~ ~ I HCl O O
N ~ N
ll N02 H CH3~ CH3 Me2NOC ~ Me2NOC
12 N02 H IH3 CH3 ; ~ ' free C.l ~
~ C1 ._ '' , ~ , ~ ;
~J ~'.3s~
¦ R 6 Example Starting No. R2 R3 R5 R6 R7 Salt Compound (V) 13 CN H CH3 CH3CH2 ~ N Cl-CH2 ~ .HCl 14 N02 H CH3 CH3 H ~ Cl-CH2 ~ .HCl N02 H CH3 CH3 ~ free Hr-CH2 16 N02 H CH3 CH3 -CH2 < ~ free ClCH2 ~/
H H
17 N02 U CH3 CH3 CH2 ~ free Br-CH
This compound has the following physicochemical properties.
i) Melting point: 153-157C
ii) Elemental analysis (for Cl6Hl5NO4S) C (%) H (%) N (%) S (%) Calcd.: 60.55 4.76 4.41 lO.lO
Found : 60.62 4.79 4.25 10.13 iii) NMR spectrum (CDCl3) (ppm): 1.52 (6H, s), 6.99 (lH, d), 7.3-7.6 (5H, m), 7.8-8.0 (2H, m), 9.27 (lH, s) Reference Example 3 The following compound was synthesized generally in the same manner as Reference Example 2.
3,4-Dihydro-2,2-dimethyl-6-methylsulfonyl-3-oxo-2H-1,4-benzoxazine Physicochemical properties:
i) Melting point: 241-243C
ii) Elemental analysis (for C1lH13NO4S) C (%) H (%) N (%) S (%) Calcd.: 51.75 5.13 5.49 12.56 Found : 51.74 5.13 5.43 12.56 iii) NMR spectrum (DMSO-d6) ` ~ (ppm): 1.43 (6H, s), 3.15 (3H, s), 7.15 (lH, d), 7.3-7.6 (2H, m), 10.54 (lH, s) , :
';
~ ~2~ ~ 9 Reference Example 4 C~ ~ NH2 (CH3)2CBrCO2Et ce O~o To a mixture of 40 g of potassium fluoride, 40 ml of ethyl 2-bromoisobutyrate and 200 ml of N,N-dimethylformamide was added 49.1 g of 2-amino-4-chloro-5-nitrophenol and the whole mixture was stirred at 60 for 4 days. The reaction mixture was then poured in ice-water and the resulting solid was recrystallized from 800 ml of isopropyl alcohol to give 37.03 g of 6-chloro-3,4-dihydro-2,2-dimethyl-7-nitro-3-oxo-2H-1,4-benzoxazine. A 0.51 g portion of the above product was recrystallized from 14 ml of ethanol to give 0.31 g of a sample for elemental analysis.
This compound has the following physicochemical properties.
i) Melting point: 243-245C
ii) Elemental analysis (for CloH9ClN2O4) C (%) H (%) N (%) Cl (%) Calcd.: 46. ao 3.53 10.92 13.81 Found : 46.84 3.46 10.90 13.91 _ 47 -.
2 ~ 2 ~
iii) NMR spectrum (DMSO-d6) (ppm): 1.43 (6H, s), 7.04 (lH, s), 7.68 (lH, s), 11.23 (lH, s) Reference Example 5 PhSO~ N ~ O BH3-0 3 PhSO~ ol To 35 ml of a solution of borane-tetrahydrofuran complex in tetrahydrofuran (lM) was added 4.625 g of 3,4-dihydro-2,2-dimethyl-3-oxo-6-phenylsulfonyl-2H-1,4-benzoxazine with ice-cooling and the mixture was refluxed under heating with constant stirring for 2 hours. This reaction mixture was diluted with 4.3 ml of methanol and further refluxed for 45 minutes. Then, 3.6 ml of concentrated hydrochloric acid was added and the mixture was further refluxed for 45 minutes. The reaction mixture was then concentrated and the resulting solid was pulverized in ether and filtered. The pulverizate was suspended in a dilute aqueous solution of sodium hydroxide and extracted with ethyl acetate. The organlc layer was washed with water and drled over anhydrous magnesium sulfate and the solvent was distilled off. The residue was recrystallized from 15 ml of ethanol to recover 3.76 g of 3,4-dihydro-2,2-dimethyl-6~
phenylsulfonyl-2H-1,4-benzoxazine.
, :
:' ~ ~ ' '' ~ ' '' This compound has the following physicochemical properties.
i) Melting point: 138-140.5C
ii) Elemental analysis (for C16HI7NO3S) C (%) ~ (%) N (%) S (%) Calcd.: 63.34 5.65 4.62 10.57 Found : 63.36 5.65 4.54 10.65 iii) NMR spectrum (CDC13) (ppm): 1.28 (6H, s), 3.04 (3H, s), 3.2-4.2 (lH), 6.76 (lH, dd), 7.1-7.3 (2H, m), 7.3-7.6 (3H, m), 7.8-8.0 (2H, m) Reference Example 6-8 The following compound was synthesized in the same manner as Reference Example 5.
Reference Example 6 3,4-Dihydro-2,2-dimethyl-6-methylsulfonyl-2H-1,4-benzoxazine Physicochemical properties:
i) Melting point: 137-142C
ii) Elemental analysis (for CllHl5NO3S) C (%) H (%) N (%) S (%) Calcd.: 54.75 6.27 5.80 13.29 Found : 54.86 6.29 5.78 13.30 iii) NMR spectrum (CDCl3) (ppm): 1.32 (6H, s), 3.50 (3H, s), 3.09 (2H, d), 4.33 (1~1, s), 6.80 (lH, dd), 7.1~7.3 (2H, m) 2 ~.~ 2 ~
Reference Example 7 6-Chloro-3,4-dihydro-2,2-dimethyl-7-nitro-2H-1,4-benzoxazine Physicochemical properties:
i) Melting point: 139-140.5C
ii) Elemental analysis (for CloHllclN2o3) C (%) H (%) N (%) Cl (%) Calcd.: 49.50 4.57 11.54 14.61 Found : 49~45 4.53 11.52 14.57 iii) NMR spectrum (CDCl3) (ppm): 1.32 (6H, s), 3.18 (2H, d), 4.72 (lH, s), 6.57 (lH, s), 7.54 (lH, s) Reference ExamPle 8 3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine Physicochemical properties:
i) Melting point: 151-153C
ii) Elemental analysis (for CloHl2N23) C (%) ~ (%) N (%) Calcd.: 57.69 5.81 13.45 Found : 57.59 5.88 13.48 iii) NMR spectrum (CDCl3) (ppm): 1.37 (6H, s), 3.15 (2H, d), 6.78 (lH, d), 7.50 (lH, d), 7.59 (lH, dd) ',, , ,' , ,; ` , . . . . .
" ~
. . . ~ ~ ' ' .
~J 5'I'j ;~J ~ $3 ~
Reference Examp_e 9 CF3 No2 l)(CH3)2CB~CHO CF3 ~ K 2C 03 ~ N
(l) To a mixture of 10 g of 2-nitro-4-trifluoromethylphenol, 8.0 g of anhydrous calcium carbonate and 30 ml of N,N-dimethylformamide was added dropwise a solution of 8.8 g of 2-bromoisobutyraldehyde in 23 ml of N,N-dimethylformamide and the mixture was stirred at room temperature for 4 days. The reaction mixture was then poured in ice-water and extracted with toluene. The organic layer was washed with 0.5 N aqueous sodium hydroxide solution and water ln that order and dried over anhydrous magnesium sulfate and the solvent was distilled off. The residue was chromatographed on a silica gel column and elution was carried out with hexane-eth~l acetate (3:1). The ,rys-tals from the eluate were recrystallized from 15 ml of hexane twice to give 4.428 g of 2-(2-nitro-4-trifluoromethylphenoxy)isobutyraldehyde.
(2) In 40 ml of ethanol was dissolved 4.408 g of -the above aldehyde and after addition of a catalytic amount of Raney nickel, reduction was carried out in a hydrogen stream at a-tmospheric temperature and pressure. The catalys-t was .
' .
, ' ' . , '.~
.: :
': . . ,,, ' i ' ~
, ç~ ~
then filtered off and the solvent was distilled off. The residue was chromatographed on a silica gel column and elution was carried out with hexane-benzene (3:2) to recover 2.294 g of 3,4-dihydro-2,2-dimethyl-6-trifluoromethyl-2H-1,4-benzoxazine. A 1 g portion of this product was recrystallized from 2 ml of hexane to give 908 mg of a sample for elemental analysis.
This compound has the following physicochemical properties.
i) Melting point: 81-82C
ii) Elemental analysis (for C,lH12F3NO) C (%) H (%) N (%) F (%) Calcd.: 57.14 5.23 6.06 24.65 Found : 57.10 5.31 6.00 24.62 iii) NMR spectrum (CDC13) (ppm): 1.35 (6H, s), 3.10 (2H, s)-, 3.3-4.4 (lH, broad s), 6.7-7.1 (3H, m) Example 1 1) NaH
02N ~ H ~ ' ~ 07N N
In 10 ml of N,N-dimethylformamide was dissolved 2.66 g of 3,4-dihydro-2,2-dimethyl-6-ni-tro-2H-1,4-benzoxazine ,, . , :
. ' '.'' ~, .
, . . : .
. . :
S;~J~
followed by addition of 1.02 g of sodium hydride (60~ in oil) and the mixture was stirred at room temperature for 30 minutes. Then, 2.77 g of 2-bromopyridine N-oxide hydrochloride was added with ice-cooling and, after the evolution of heat had subsided, the mixture was stirred at room temperature for 2 hours. The reaction mixture was then poured in water and extracted with ethyl acetate. The organic layer was separated and dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and the residue was chromatographed on a silica gel column using chloroform as the eluent to give crude 2-(3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)pyridine N-oxide.
Recrystallization from chloroform-ethanol gave 2.0 g of the object compound.
Physicochemical properties: -i) Melting point: 224-226C
ii) Elemental analysis (for Cl5HIsN3O4) C (%) H (%) N(%) Calcd.: 59.80 5.02 13.95 Found : 59.73 5.20 13.80 iii) NMR spectrum (CDC13) (ppm): 1.42 (6H, s), 3.69 (2H, s), 6.94 (lH, d), 7.05-7.41 (3H, m), 7.49 (lH, d), 7.77 (lH, dd), 8.31 (lH, ddd) -' : ' .
-. .~ '' J~ , Example 2 1) NaH
Il 2) ~N~ NC,~N~
In 10 ml of N,N-dimethylformamide was dissolved 1.5 g of 6-cyano-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxa~ine and, then, 0.96 g of sodium hydride (60% in oil) was gradually added. After 10 minutes, 3.36 g of 2-bromop-yridine N-oxide hydrochloride was added in several portions and after the evolution of heat had subsided, the mixture was stirred at room temperature for 3 hours. The reaction mixture was ~ , diluted with water and extracted with ethyl acetate. The organic layer was separated, dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and the residue was chromatographed on a silica gel column using ethyl acetate-methanol (5:1) as the eluent to give crude 2-(6-cyano-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-4-yljpyridine N-oxide. Crystalliza-tion from ethyl acetate gave 0.78 g of crude crystals. Finally the crystals were recrystallized from e-thanol to recover 0.6 g of the object compound.
.
_ 54 -.- : . .. . , ~ .
. ' - ' . ' ,, ' ' ,' ~
- : ,, . . ; , , ~ ~ 2 ~
This compound has the following physicochemical properties.
i) Melting point: 175-177C .
ii) Elemental analysis (for Cl6HI5N3O2) C (%) H (%) N (%) Calcd.: 68.31 5.37 14.94 Found : 68.20 5.38 14.88 iii) NMR spectrum (CDCl3) (ppm): 1-40 (6H, s), 3.67 (2H, s), 6.86-7.33 (6H, m), 8.26-8.33 (lH, m) Example 3 throu~h 32 The compounds listed in the following table were synthesized by Process 1 as in Examples 1 and 2. It should be understood that where the reaction did not proceed well at room temperature, the reaction was conducted at elevated temperature. As the base, not only sodium ~hydride but also triethylamine or potassium carbonate was used. That is, in Examples 13 through 27, and 32, the reactions were conducted at 100 C to 120 C, or with heating under refluxing. As the base, triethylamine was used in Examples 13, 14l 17 through 21, and 28 through 31, and anhydrous potassium carbonate was used in Example 15, 16 and 22.
.
` ' :
r:
~ " N
Example Starting No. R2 R3 R5 R6 R7 Salt Compound (V) 3PhS02 H CH3 CH3 ~ ~ 0 free ~ N .HCl . Br 4N02 H H H \~N~o free ~ N .HCl Br 5Br H CH3 C~3 ~ free ~ N ~ H
Br 6N02 H CN3 CH3 ~ free ~ .HC , Cl 7MeS02 H CH3 CF13 ~ free ~ .HCl Br . . . . . - . . . ~ , .
f 3` o~ R6 Example Starting No. R2 R3 R5 R6 R~ Salt Compound (V) 8 Cl N02 CH3 CH3 ~ free ~ O
9 CF3 H CH3 CH3~ ~ salt ~ .HCl Br No2 H CH3 CH3/ ~ ~ I HCl O O
N ~ N
ll N02 H CH3~ CH3 Me2NOC ~ Me2NOC
12 N02 H IH3 CH3 ; ~ ' free C.l ~
~ C1 ._ '' , ~ , ~ ;
~J ~'.3s~
¦ R 6 Example Starting No. R2 R3 R5 R6 R7 Salt Compound (V) 13 CN H CH3 CH3CH2 ~ N Cl-CH2 ~ .HCl 14 N02 H CH3 CH3 H ~ Cl-CH2 ~ .HCl N02 H CH3 CH3 ~ free Hr-CH2 16 N02 H CH3 CH3 -CH2 < ~ free ClCH2 ~/
H H
17 N02 U CH3 CH3 CH2 ~ free Br-CH
- 5~ -,, .. .
2~3,~
H l7 3, ~ X ~/ ~ R
Example Starting No. R2 R3 R5 R6 R7_ SaltCompound (V) 18 NO2 H CH3 CH3 ~ free ~
-cH2 NO2 Br~CH2 N02 19 N02 H CH3 CH3 CH2 ~ salt ~ .HC1 N02 H CH3 CH3 ~ Cl-CH ~
21 N02 H CH3 CH3 ~ free~ NO2 -CH2 Br-CH2 22 N02 H CH3 CH3 ~ free -CE12 Br-CH2 F F
.
_ 59 _ .
2 ~
H
~r~ ~ ~
Example Starting No. R2 R3 R5 R6 R7 Salt Compound (V) O O
23 CN H CH3 CH3 -CH2-N ~ free Br-CH2-O O
24 N2 H CH3 CH3 -CH2COOC2H5 free BrCH2COOC2H5 CN H CH3 CH3 -CH2COOC2H5 free .BrCH2cOoc2H5 :
fH3 C~3 26 N2 H CH3 CH3 -CHCOOC2H5 free Br-CHCOOC2H5 27 N2 H CH3 CH3 -CH2CH2OCH=CH2 free srcH2cH2ocH=cH2 :
` - 60 -.3 ~3 ~7 ,J ~ ~ h e~
R3 ~ O
H
Example Starting No. R2 R3 R5 R6 R7 Salt Compound (V) 28 No2 H CH3 CH3 ~N SHaCllt ~N .HCl -CO ClCO
29 N02 H CH3 CH3 ~ ~ free -CO ClCO
N02 H CH3 CH3 -COCH=CHCOOC2Hs free ClCOCH=CHCOOC2H5 : *trans .
31 N02 H CH3 CH3 -COCOOC2H5 free ClCOCOOC2H5 32 CN H CH3 CH3 ~ ~ free Br :
: - 6l -. . :
:" .
.' . : . . . ~:
,''' . , , - , , ~,~2~9~
Physicochemical propexties of these compounds are as follows.
Example 3 2-(3,4-Dihydro-2,2-dimethyl-6-phenylsulfonyl-2H-1,4-benzoxazin-4-yl)pyridine N-oxide Physicochemical properties:
i) Melting point: 123-124C
ii) Elemental analysis (for C2lH20N2O~,S) C (%) H (%) N (%) S (%) Calcd.: 63.62 5.08 7.07 8.09 Found : 63.42 5.09 7.05 8.09 iii) NMR spectrum (CDCl3) (ppm): 1.35 (6H, s), 3.69 (2H, t),
2~3,~
H l7 3, ~ X ~/ ~ R
Example Starting No. R2 R3 R5 R6 R7_ SaltCompound (V) 18 NO2 H CH3 CH3 ~ free ~
-cH2 NO2 Br~CH2 N02 19 N02 H CH3 CH3 CH2 ~ salt ~ .HC1 N02 H CH3 CH3 ~ Cl-CH ~
21 N02 H CH3 CH3 ~ free~ NO2 -CH2 Br-CH2 22 N02 H CH3 CH3 ~ free -CE12 Br-CH2 F F
.
_ 59 _ .
2 ~
H
~r~ ~ ~
Example Starting No. R2 R3 R5 R6 R7 Salt Compound (V) O O
23 CN H CH3 CH3 -CH2-N ~ free Br-CH2-O O
24 N2 H CH3 CH3 -CH2COOC2H5 free BrCH2COOC2H5 CN H CH3 CH3 -CH2COOC2H5 free .BrCH2cOoc2H5 :
fH3 C~3 26 N2 H CH3 CH3 -CHCOOC2H5 free Br-CHCOOC2H5 27 N2 H CH3 CH3 -CH2CH2OCH=CH2 free srcH2cH2ocH=cH2 :
` - 60 -.3 ~3 ~7 ,J ~ ~ h e~
R3 ~ O
H
Example Starting No. R2 R3 R5 R6 R7 Salt Compound (V) 28 No2 H CH3 CH3 ~N SHaCllt ~N .HCl -CO ClCO
29 N02 H CH3 CH3 ~ ~ free -CO ClCO
N02 H CH3 CH3 -COCH=CHCOOC2Hs free ClCOCH=CHCOOC2H5 : *trans .
31 N02 H CH3 CH3 -COCOOC2H5 free ClCOCOOC2H5 32 CN H CH3 CH3 ~ ~ free Br :
: - 6l -. . :
:" .
.' . : . . . ~:
,''' . , , - , , ~,~2~9~
Physicochemical propexties of these compounds are as follows.
Example 3 2-(3,4-Dihydro-2,2-dimethyl-6-phenylsulfonyl-2H-1,4-benzoxazin-4-yl)pyridine N-oxide Physicochemical properties:
i) Melting point: 123-124C
ii) Elemental analysis (for C2lH20N2O~,S) C (%) H (%) N (%) S (%) Calcd.: 63.62 5.08 7.07 8.09 Found : 63.42 5.09 7.05 8.09 iii) NMR spectrum (CDCl3) (ppm): 1.35 (6H, s), 3.69 (2H, t),
6.9-7.6 (9H, m), 7.8-7.9 (2H, m), 8.2-8.4 (lH, m) Example 4 2-(3,4-Dihydro-6-nitro-2H-1,4-benzoxazin-4-yl)pyridine N-oxide Physicochemical properties:
i) Melting point: 139-141C
ii) Elemental analysis (for Cl3HIlN3O,~ O.lH2O) C (%) H (%) N (%) Calcd.: 56.77 4.10 15.28 Found : 56.74 4.10 15.17 :
:
iii) NMR spectrum (CDCl3) (ppm): 3.96 (2H, t), 4.44 (2H, t), 7.02 (lH, d),
i) Melting point: 139-141C
ii) Elemental analysis (for Cl3HIlN3O,~ O.lH2O) C (%) H (%) N (%) Calcd.: 56.77 4.10 15.28 Found : 56.74 4.10 15.17 :
:
iii) NMR spectrum (CDCl3) (ppm): 3.96 (2H, t), 4.44 (2H, t), 7.02 (lH, d),
7.2~7.4 (3H, m), 7.52 (lH, d), 7.78 (lH, dd), 8.36 (lH, d) Example 5 2-(6-Bromo-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-4-yl)pyridine N-oxide Physicochemical properties:
i) Melting point: 149-151C
ii) Elemental analysis (for Cl5Hl5N2O2Br) C (%) H (%) N (%) Br (%) Calcd.: 53.75 4.51 8.36 23.84 Found : 53.74 4.49 8.39 23.83 iii) NMR spectrum (CDCl3) (ppm): 1.34 (6H, s), 3.65 (2H, s), 6.68-7.40 (6H, m), 3.19-8.-28 (lH, m) Example 6 2-(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)-6-methylpyridine N-oxide Physicochemical properties:
i) Melting point: 161-163C
ii) Elemental analysis (for Cl6HI7N3O4) C (~) H (~) N (%) Calcd.: 60.94 5.43 13.33 Found : 60.97 5.43 13.21 .. . . . . .
.
.: , - - : . ' ' . ' ' ,: : .. , :
iii) NMR spectrum (CDCl3) (ppm): 1.43 (6H, s), 2.57 (3H, s), 3.65 (2H, s), 6.89 (lH, d), 7.13-7.28 (3H, m), 7.40 (lH, d), 7.70 (lH, dd) Ex~mple 7 2-(3,4-Dihydro-2,2-dimethyl-6-methylsulfonyl-2H-1,4-benzoxazin-4-yl)pyridine N-oxide Physicochemical properties:
i) Melting point; 220-222C
ii) Elemental analysis (for Cl6Hl8N2O4S) C (%) H (%) N (%) S (%) Calcd.: 57.47 5.43 8.38 9.59 Found : 57.51 5.49 8.30 9.59 iii) NMR spectrum (CDCl3) (ppm): 1.38 (6H, s), 2.86 (3H, s)-, 3.65 (2H, s), 6.9-7.5 (6H, m), 8.2-8.3 (lH, m) Example 8 2-(6-Chloro-3,4-dihydro-2,2-dimethyl-7-nitro-2H-1,4-benzoxazin-4-yl)pyridine N-oxide Physicochemical properties:
i) Melting point: 179-180.5C
ii) Elemental analysis (for Cl5H~4N3O,,Cl) C (%) H (%) N (%) Cl (%) Calcd.: ~53.66 4.20 12.52 10.56 Found : 53.58 4.25 12.39 10.61 - 6~ -~: :
.
iii) NMR spectrum (CDCl3) (ppm): 1.40 (6H, s), 3.60 (2H, broad s), 6.46 (lH, s), 7.1-7.5 (3H, m), 7.60 (]H, s), 8.2~8.4 (lH, m) Example 9 2-(3,4-Dihydxo-2,2-dimethyl-6-trifluoromethyl-2H-1,4-benzoxazin-4-yl)pyridine N-oxide hydrochloride Physicochemical properties:
i) Melting point: 144-166C
ii) Elemental analysis (for Cl6H15N2O2F3-HCl) C (%) H (~) N (%) Cl (%) F (%) Calcd.: 53.27 4.47 7.77 9.83 15.80 Found : 53.08 4.38 7.68 9.86 15.67 iii) NMR spectrum (CDCl3) (ppm): 1.37 (6H, s)l 3.97 (2H, s)-, 7.03 (lH, d), 7.2-7.5 (3H, m), 7.64 (lH, dd), 7.8-8.1 (lH, m), 8.76 (lH, dd), 11.85 (lH, broad s) Example 10 2-(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1~4-benzoxazin-4-yl)quinoline 1-oxide Physicochemical properties:
i) Melting point: 183-184C
~ .
~' ' ' ' ' ~ ' ' ' '~. ' ' ii) Elemental analysis (for Cl9HI7N3O4) C (%) H (%) N (%) Calcd.: 64.95 4.88 11.96 Found : 64.92 4.90 11.92 iii) NMR spectrum (CDCl3) (ppm): 1.43 (6H, s), 3.84 (2H, s), 6.94 (lH, d), 7.24-7.90 (7H, m), 8.71 (lH, d of t) Example 11 3-(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)-N,N-dimethylpyrazine-2-carboxamide Physicochemical properties:
i) Melting point: 134-135C (ethanol) ii) Elemental analysis (for Cl7Hl9N5O4) C (%) H (%) N (%) Calcd.: 57.14 5.36 19.60 Found : 57.19 5.47 19.52 iii) NMR spectrum (CDCl3) (ppm): 1.48 (6H, s), 2.82 (3H, s), 3.19 (3H, s), 3.80 (2H, s), 6.95 (lH, d), 7.66 (lH, d), 7.84 (lH, dd), 8.26 (lH, d), 8.37 (lH, d) Example 12 3,4-Dihydro-2,2-dimethyl-6-nitro-4-(3,4,5,6~
tetrachloro-2-pyridyl)-2EI-1,4-ben~oxazine Physicochemical properties:
i) Melting point: 117-119C
- 66 -~
~)?~
ii) Elemental analysis (Eor C15HIlN3O3Cl4) C (%) H (%) N (%) Cl (%) Calcd.: 42.58 2.62 9.93 33.52 Found : 42.14 2.56 9.76 33.40 iii) NMR spectrum (CDCl3) (ppm): 1.51 (6H, s), 3.49 (2H, s), 6.92-7.04 (2H, m), 7.77 (lH, dd) Example 13 3-(6-Cyano-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-4-yl)methylpyridine Physicochemical properties:
i) Melting point: 107-108C (ethanol-hexane) ii) Elemental analysis (for C17HI7N3O) C (%) H (%) N (%) Calcd.: 73.10 6.13 15.04 Found : 73.01 6.19 15.02 iii) NMR spectrum (CDCl3) (ppm): 1.35 (6H, s), 3.07 (2H, s), 4.46 (2H, s), 6.74-7.04 (3H, m), 7.20-7.33 (lH, m), 7.51-7.65 (lH, m), 8.50-8.58 (2H, m) Example 14 3,4-Dihydro-2,2-dimethyl-6-nitro-4-(2-pyridylmethyl)-2H-1,4-benzoxa~ine hydrochlorlde Physicochemical properties:
i) Melting point: 174-178C (ethanol) .
, - , ~
. .
, ~. .. . .
, , ::
.
ii) Elemental analysis (for Cl6H~7N3O3-HCl) C (%) H (%) N (%) Cl (%) Calcd.: 57.23 5.40 12.51 10.56 Found : 57.36 5.39 12.59 10.77 iii) NMR spectrum (DMSO-d6) (ppm) 1-34 (6H~ s), 3-37 (2H, s), 5.04 (2H, s), 6.84-6.96 (lH, m), 7.48-7.61 (2H, m), 7.72-7.91 (2H, m), 8.37 (lH, d of t),
i) Melting point: 149-151C
ii) Elemental analysis (for Cl5Hl5N2O2Br) C (%) H (%) N (%) Br (%) Calcd.: 53.75 4.51 8.36 23.84 Found : 53.74 4.49 8.39 23.83 iii) NMR spectrum (CDCl3) (ppm): 1.34 (6H, s), 3.65 (2H, s), 6.68-7.40 (6H, m), 3.19-8.-28 (lH, m) Example 6 2-(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)-6-methylpyridine N-oxide Physicochemical properties:
i) Melting point: 161-163C
ii) Elemental analysis (for Cl6HI7N3O4) C (~) H (~) N (%) Calcd.: 60.94 5.43 13.33 Found : 60.97 5.43 13.21 .. . . . . .
.
.: , - - : . ' ' . ' ' ,: : .. , :
iii) NMR spectrum (CDCl3) (ppm): 1.43 (6H, s), 2.57 (3H, s), 3.65 (2H, s), 6.89 (lH, d), 7.13-7.28 (3H, m), 7.40 (lH, d), 7.70 (lH, dd) Ex~mple 7 2-(3,4-Dihydro-2,2-dimethyl-6-methylsulfonyl-2H-1,4-benzoxazin-4-yl)pyridine N-oxide Physicochemical properties:
i) Melting point; 220-222C
ii) Elemental analysis (for Cl6Hl8N2O4S) C (%) H (%) N (%) S (%) Calcd.: 57.47 5.43 8.38 9.59 Found : 57.51 5.49 8.30 9.59 iii) NMR spectrum (CDCl3) (ppm): 1.38 (6H, s), 2.86 (3H, s)-, 3.65 (2H, s), 6.9-7.5 (6H, m), 8.2-8.3 (lH, m) Example 8 2-(6-Chloro-3,4-dihydro-2,2-dimethyl-7-nitro-2H-1,4-benzoxazin-4-yl)pyridine N-oxide Physicochemical properties:
i) Melting point: 179-180.5C
ii) Elemental analysis (for Cl5H~4N3O,,Cl) C (%) H (%) N (%) Cl (%) Calcd.: ~53.66 4.20 12.52 10.56 Found : 53.58 4.25 12.39 10.61 - 6~ -~: :
.
iii) NMR spectrum (CDCl3) (ppm): 1.40 (6H, s), 3.60 (2H, broad s), 6.46 (lH, s), 7.1-7.5 (3H, m), 7.60 (]H, s), 8.2~8.4 (lH, m) Example 9 2-(3,4-Dihydxo-2,2-dimethyl-6-trifluoromethyl-2H-1,4-benzoxazin-4-yl)pyridine N-oxide hydrochloride Physicochemical properties:
i) Melting point: 144-166C
ii) Elemental analysis (for Cl6H15N2O2F3-HCl) C (%) H (~) N (%) Cl (%) F (%) Calcd.: 53.27 4.47 7.77 9.83 15.80 Found : 53.08 4.38 7.68 9.86 15.67 iii) NMR spectrum (CDCl3) (ppm): 1.37 (6H, s)l 3.97 (2H, s)-, 7.03 (lH, d), 7.2-7.5 (3H, m), 7.64 (lH, dd), 7.8-8.1 (lH, m), 8.76 (lH, dd), 11.85 (lH, broad s) Example 10 2-(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1~4-benzoxazin-4-yl)quinoline 1-oxide Physicochemical properties:
i) Melting point: 183-184C
~ .
~' ' ' ' ' ~ ' ' ' '~. ' ' ii) Elemental analysis (for Cl9HI7N3O4) C (%) H (%) N (%) Calcd.: 64.95 4.88 11.96 Found : 64.92 4.90 11.92 iii) NMR spectrum (CDCl3) (ppm): 1.43 (6H, s), 3.84 (2H, s), 6.94 (lH, d), 7.24-7.90 (7H, m), 8.71 (lH, d of t) Example 11 3-(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)-N,N-dimethylpyrazine-2-carboxamide Physicochemical properties:
i) Melting point: 134-135C (ethanol) ii) Elemental analysis (for Cl7Hl9N5O4) C (%) H (%) N (%) Calcd.: 57.14 5.36 19.60 Found : 57.19 5.47 19.52 iii) NMR spectrum (CDCl3) (ppm): 1.48 (6H, s), 2.82 (3H, s), 3.19 (3H, s), 3.80 (2H, s), 6.95 (lH, d), 7.66 (lH, d), 7.84 (lH, dd), 8.26 (lH, d), 8.37 (lH, d) Example 12 3,4-Dihydro-2,2-dimethyl-6-nitro-4-(3,4,5,6~
tetrachloro-2-pyridyl)-2EI-1,4-ben~oxazine Physicochemical properties:
i) Melting point: 117-119C
- 66 -~
~)?~
ii) Elemental analysis (Eor C15HIlN3O3Cl4) C (%) H (%) N (%) Cl (%) Calcd.: 42.58 2.62 9.93 33.52 Found : 42.14 2.56 9.76 33.40 iii) NMR spectrum (CDCl3) (ppm): 1.51 (6H, s), 3.49 (2H, s), 6.92-7.04 (2H, m), 7.77 (lH, dd) Example 13 3-(6-Cyano-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-4-yl)methylpyridine Physicochemical properties:
i) Melting point: 107-108C (ethanol-hexane) ii) Elemental analysis (for C17HI7N3O) C (%) H (%) N (%) Calcd.: 73.10 6.13 15.04 Found : 73.01 6.19 15.02 iii) NMR spectrum (CDCl3) (ppm): 1.35 (6H, s), 3.07 (2H, s), 4.46 (2H, s), 6.74-7.04 (3H, m), 7.20-7.33 (lH, m), 7.51-7.65 (lH, m), 8.50-8.58 (2H, m) Example 14 3,4-Dihydro-2,2-dimethyl-6-nitro-4-(2-pyridylmethyl)-2H-1,4-benzoxa~ine hydrochlorlde Physicochemical properties:
i) Melting point: 174-178C (ethanol) .
, - , ~
. .
, ~. .. . .
, , ::
.
ii) Elemental analysis (for Cl6H~7N3O3-HCl) C (%) H (%) N (%) Cl (%) Calcd.: 57.23 5.40 12.51 10.56 Found : 57.36 5.39 12.59 10.77 iii) NMR spectrum (DMSO-d6) (ppm) 1-34 (6H~ s), 3-37 (2H, s), 5.04 (2H, s), 6.84-6.96 (lH, m), 7.48-7.61 (2H, m), 7.72-7.91 (2H, m), 8.37 (lH, d of t),
8.80-8.90 (lH, m) Example 15 4-(3-Fluorobenzyl)-3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine Physicochemical properties:
i) Melting point: 68-69C (ethanol) ii) Elemental analysis (for Cl7H~7N2O3F) C (%) H (%) N (%) F -(%) Calcd.: 64.55 5.42 8.86 6.01 Found : 64.68 5.43 8.78 6.08 iii) NMR spectrum (CDCl3) (ppm): 1.38 (6H, s), 3.11 (2H, s), 4.52 (2H, s), 6.7-7.7 (7H, m) Example 16 4-(2-Benzimidazolylmethyl ? -3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine Physicochemical properties~:
i) Melting pOillt: 213-214C
ii) Elemental analysis (for Cl8H~8NI,O3) C (%) H (%) N (%) Calcd.: 63.89 5.36 16.56 Found : 63.87 5.39 16.55 iii) Mass spectrum (EI) : m/z 338 (M+) Example 17 3,4-Dihydro-2,2-dimethyl-6-nitro-4-(2-nitrobenzyl)-2H-1,4-benzoxazine Physicochemical properties:
i) Melting point: 116-118C
ii) Elemental analysis (for Cl7H~7N3O5) C (%) H (%) N (%) Calcd.: 59.47 4.99 12.24 Found : 59.31 4.98 12.26 iii) NMR spectrum (CDCl3) (ppm): 1.39 (6H, s), 3.18 (2H, s)-, 4.93 (2H, s), 6.90 (lH, d), 7.4-7.7 (5H, m), 8.1-8.2 (lH, m) Example 18 3,4-Dihydro-2,2-dimethyl-6-nitro-4-(3-nitrobenzyl)-2H-1,4-benzoxazine Physicochemical properties:
i) Melting point: 125-1~7C
, , : . : , , : . : .
:: :
- ! . : ~ ' ';''' '' . ~ ' s~
ii) Elemental analysis (for Cl7HI7N3OsoO.lH~O) C (%) H (%) N (%) Calcd.: 59.16 5.02 12.17 Found : 59.04 4.93 12.10 iii) NMR spectrum (CDCl3) (ppm): 1.20 (6H, s), 3.12 (2H, s), 4.60 (2H, s), 6.81 (lH, d), 7.4-7.7 (4H, m), 8.0-8.2 (2H, m) Example 19 3-(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)methylpyridine hydrochloride Physicochemical properties:
i) Melting point: 186~189C
ii) Elemental analysis (for Cl6Hl8N3O3Cl) C (%) H (%) N (%) Cl (%) Calcd.: 57.23 5.40 12.51 10.56 Found : 57.21 5.26 12.70 10.78 iii) NMR spectrum (DMSO-d6) (ppm): 1.33 (6H, s), 3.29 (2H, s3, 4.84 (2H, s), 6.84-6.93 (lH, m), 7.48-7.59 (2H, m), 7.91-8.06 (lH, m), 8.36-8.50 (lH, m), 8.77-8.89 (2H, m) Example 20 4-Benzyl-3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine -- , . - . .
Physicochemical properties:
i) Melting point: 92-93C
ii) Elemental analysis (for Cl~7HlaN2o3) C (%) H (%) N (%) Calcd.: 68.44 6.08 9.39 Found : 68.57 6.13 9.30 iii) NMR spectrum (CDC13) (ppm): 1.36 (6H, s), 3.06 (2H, s), 4.28 (2H, s), 6.78 (lH, d), 7.2-7.4 (5H, m), 7.5_7.7 (2H, m) - ExamPle 21 3,4-Dihydro-2,2-dimethyl-6-nitro-4-(4-nitrobenzyl)-2H-1,4-benzoxazine Physicochemical properties:
i) Melting point: 118-119C
ii) Elemental analysis (for Cl7Hl7N30s) C (%) H (%) N (%) Calcd.: 59.47 4.99 12.24 Found : 59.47 4.90 12.32 iii) NMR spectrum (CDCl3) tppm): 1.39 (6H, s), 3.13 (2H, s), 4.61 (2H, s), 6.82 (lH, d), 7.40-7.67 (4H, m), 8.13-8.28 ~2H, m) .
. . . .
., .. , : . .
.. .
s~
Example 22 4-(2-Fluorobenzyl)-3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine Ph~sicochemical properties:
i) Melting point: oil ii) NMR spectrum (CDCl3) (ppm): 1.32 (6H, s), 3.11 (2H, s), 4.54 (2H, s), 6.77 (lH, dd), 6.9-7.4 (4H, m), 7.5-7.7 (2H, m) iii) Mass spectrum (FAB) : m/z 316 (M+) Example 23 6-Cyano-3,4-dihydro-2,2-dimethyl-4-(phthalimidomethyl)-2H-1,4-benzoxazine Physicochemical properties:
i) Melting point: 147-148C
ii) Elemental analysis (for C20HI7N3O3) C (%) H (%3 N (%) Calcd.: 69.15 4.93 12.10 Found : 69.21 4.96 12.06 Lii ) NMR spectrum (CDCl3) (ppm): 1.32 (6H, s), 3.44 (2H, s), 5.23 (2~, s), 6.76 (lH, d), 7.01 (lH, dd), 7.67-7.96 (5H, m) .
- 72 ~
-:
, ,,'' , ~ a~
Example 24 Ethyl (3,4-dihydro-2,2-dimethyl~6-nitro-2H-1,4-benzoxazin-4-yl)acetate Physicochemical properties:
i) Melting point: 95-96C (ethyl acetate-n-hexane) ii) Elemental analysis (for Cl4H~sN2s) C (%) H (%) N (%) Calcd.: 57.14 6.16 9.52 Found : 57.16 6.15 9.43 iii) NMR spectrum (CDCl3) (ppm): 1.27 (3H, t), 1.36 (6H, s), 3.21 (2H, s), 4.10 (2H, s), 4.20 (2H, q), 6.77 (lH, d), 7.37 (lH, d), 7.59 (lH, dd) Example 25 Ethyl (6-cyano-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-4-yl)acetate Physicochemical properties:
i) Melting point: 52-53C
ii) Elemental analysis (for ClsHI8N23) C (%) H (%) N (%) Calcd.: 65.68 6.61 10.21 Found : 65.81 6.65 10.20 r iii) NMR spectrum (CDCl3) (ppm): 1.28 (3H, t), 1.36 (6H, s), 3.20 (2H, s), 4.01 (2H, s), 4.20 (2H, q), 6.67 (lH, d), 6.75 (lH, d), 6.95 (lH, dd) Example 26 Ethyl 2-(3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)propionate Physicochemical properties:
i) Melting point: 77-78C
ii) Elemental analysis (for ClsH2~N2o5) C (~) H (~) N(%) Calcd.: 58.43 6.54 9.09 Found : 58.41 6.47 9.13 iii) NMR spectrum (CDC13) (ppm): 1.15-1.75 (12H, m), 3.15 (2H, s), 4.20 (2H, q), 4.57 (lH, q)-, 6.80 (lH, dd), 7.50_7.75 (2HI m) Example 27 3,4-Dihydro-2,2-dimethyl-6-nitro-4-(2-vinyloxyethyl)-2H-1,4-benzoxazine Physicochemical properties:
i) Melting point: 56-56.5C
ii) Elemental analysis (for Cl4HI8N2O4) C (~) H (%) ~l (%) Calcd.: 60.42 6.52 10.07 Found . 60.37 6.44 10.00 .
. .
- ' ,~'' '~ ~ ' ' ~ rj 5d ~ r~
iii) NMR spectrum (CDCl3) (ppm): 1.35 (6H, s), 3.23 (2H, s), 3.68 (2H, t), 3.93 (2H, s), 4.05 (lH, dd), 4.21 (lH, dd), 6.47 (lH, dd), 6.80 (lH, d), 7.47-7.84 (2~, m) Example 28 3,4-Dihydro-2,2-dimethyl-4-nicotinoyl-6-nitro-2H-1,4-benzoxazine hydrochloride Physicochemical properties:
i) Melting point: 158-199C (ethanol) ii) Elemental analysis (for Cl6Hl5N3O4~HCl) C (%) H (%) N (%) Cl (%) Calcd.: 54.94 4.61 12.01 10.14 Found : 55.01 4.64 12.04 10.16 iii) NMR spectrum (DMSO-d6) (ppm): 1.28 (6H, s), 3.75 (2H, s)-, 7.13 (lH, d), 7.8-8.1 (2H, m), 8.4-8.8 (2H, m), 8.9-9.2 (2H, m), 11.1 (lH, broad s) Example 29 4-(2-Furoyl)-3,4-dihydro-2,2-dimethyl-6-ni~ro-2H-1,4-benzoxazine Physicochemical properties:
i) Melting point: 112-116.5C (ethanol) 7 5 _ ~ . . . . ..
. `. . - , : ~ . ~ :
,, -:
' . . , , : ' ,, : ' , ` .~ ,., , ~ ', , .- . , . ~' '', ' . ~ . ' .
ii) Elemental analysis (for C~5Hl4N2O5) C (%) H (%) N (%) Calcd.: 59.60 4.67 9.27 Found : 59.56 4.62 9.31 iii) NMR spectrum (CDCl3) 5 (ppm): 2.42 (6H, s), 3.84 (2H, s), 6.53 (lH, dd), 6.94 (lH, d), 7.16 (lH, dd), 7.45 (lH, dd), 7.91 (lH, dd), 8.13 (lH, d) Example 30 Ethyl trans-4-(3,4-dihydro-2,2-dimethyl-6-nitro 2H-1,4-benzoxazine-4-yl)-4-oxo-2-butenoate Physicochemical properties:
i) Melting point: 93-95C
ii) Elemental analysis (for Cl6H~8N2O6) C (%) H (%) N (%) Calcd.: 57.48 5.43 8.38 Found : 57.30 5.41 8.19 iii) NMR spectrum (DMSO-d6) (ppm): 1-24 (3H, k), 1-32 (6H, s), 3.86 (2H, s), 4.21 (2H, q), 6.74 (lH, d), 7.08 (lH, d), 7.56 (lH, d), 7.97 (lH, dd), 8.5-8.9 (lH, broad s) Example 31 3,4-Dihydro-2,2-dimethyl-6-nitro-4-ethyloxalyl-2H-1,4-benzoxazine .
:
Physicochemical properties:
i) Melting point: 80-81C
ii) Elemental analysis (for Cl4Hl6N2O6) C (%) H (%) N (%) Calcd.: 54.54 5.23 9.09 Found : 54.51 5.19 9.05 iii) N~R spectrum (CDCl3) (ppm): 1.37~1.41 (3H, m), 1.42 (3H, s), 1.45 (3H, s), 3.57 (2H x -5 , s), 3.83 (2HIx - , s), 4.36-4.46 (2H, m), 6.99 (lH, d~, 8.02 (lH, m),
i) Melting point: 68-69C (ethanol) ii) Elemental analysis (for Cl7H~7N2O3F) C (%) H (%) N (%) F -(%) Calcd.: 64.55 5.42 8.86 6.01 Found : 64.68 5.43 8.78 6.08 iii) NMR spectrum (CDCl3) (ppm): 1.38 (6H, s), 3.11 (2H, s), 4.52 (2H, s), 6.7-7.7 (7H, m) Example 16 4-(2-Benzimidazolylmethyl ? -3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine Physicochemical properties~:
i) Melting pOillt: 213-214C
ii) Elemental analysis (for Cl8H~8NI,O3) C (%) H (%) N (%) Calcd.: 63.89 5.36 16.56 Found : 63.87 5.39 16.55 iii) Mass spectrum (EI) : m/z 338 (M+) Example 17 3,4-Dihydro-2,2-dimethyl-6-nitro-4-(2-nitrobenzyl)-2H-1,4-benzoxazine Physicochemical properties:
i) Melting point: 116-118C
ii) Elemental analysis (for Cl7H~7N3O5) C (%) H (%) N (%) Calcd.: 59.47 4.99 12.24 Found : 59.31 4.98 12.26 iii) NMR spectrum (CDCl3) (ppm): 1.39 (6H, s), 3.18 (2H, s)-, 4.93 (2H, s), 6.90 (lH, d), 7.4-7.7 (5H, m), 8.1-8.2 (lH, m) Example 18 3,4-Dihydro-2,2-dimethyl-6-nitro-4-(3-nitrobenzyl)-2H-1,4-benzoxazine Physicochemical properties:
i) Melting point: 125-1~7C
, , : . : , , : . : .
:: :
- ! . : ~ ' ';''' '' . ~ ' s~
ii) Elemental analysis (for Cl7HI7N3OsoO.lH~O) C (%) H (%) N (%) Calcd.: 59.16 5.02 12.17 Found : 59.04 4.93 12.10 iii) NMR spectrum (CDCl3) (ppm): 1.20 (6H, s), 3.12 (2H, s), 4.60 (2H, s), 6.81 (lH, d), 7.4-7.7 (4H, m), 8.0-8.2 (2H, m) Example 19 3-(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)methylpyridine hydrochloride Physicochemical properties:
i) Melting point: 186~189C
ii) Elemental analysis (for Cl6Hl8N3O3Cl) C (%) H (%) N (%) Cl (%) Calcd.: 57.23 5.40 12.51 10.56 Found : 57.21 5.26 12.70 10.78 iii) NMR spectrum (DMSO-d6) (ppm): 1.33 (6H, s), 3.29 (2H, s3, 4.84 (2H, s), 6.84-6.93 (lH, m), 7.48-7.59 (2H, m), 7.91-8.06 (lH, m), 8.36-8.50 (lH, m), 8.77-8.89 (2H, m) Example 20 4-Benzyl-3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine -- , . - . .
Physicochemical properties:
i) Melting point: 92-93C
ii) Elemental analysis (for Cl~7HlaN2o3) C (%) H (%) N (%) Calcd.: 68.44 6.08 9.39 Found : 68.57 6.13 9.30 iii) NMR spectrum (CDC13) (ppm): 1.36 (6H, s), 3.06 (2H, s), 4.28 (2H, s), 6.78 (lH, d), 7.2-7.4 (5H, m), 7.5_7.7 (2H, m) - ExamPle 21 3,4-Dihydro-2,2-dimethyl-6-nitro-4-(4-nitrobenzyl)-2H-1,4-benzoxazine Physicochemical properties:
i) Melting point: 118-119C
ii) Elemental analysis (for Cl7Hl7N30s) C (%) H (%) N (%) Calcd.: 59.47 4.99 12.24 Found : 59.47 4.90 12.32 iii) NMR spectrum (CDCl3) tppm): 1.39 (6H, s), 3.13 (2H, s), 4.61 (2H, s), 6.82 (lH, d), 7.40-7.67 (4H, m), 8.13-8.28 ~2H, m) .
. . . .
., .. , : . .
.. .
s~
Example 22 4-(2-Fluorobenzyl)-3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine Ph~sicochemical properties:
i) Melting point: oil ii) NMR spectrum (CDCl3) (ppm): 1.32 (6H, s), 3.11 (2H, s), 4.54 (2H, s), 6.77 (lH, dd), 6.9-7.4 (4H, m), 7.5-7.7 (2H, m) iii) Mass spectrum (FAB) : m/z 316 (M+) Example 23 6-Cyano-3,4-dihydro-2,2-dimethyl-4-(phthalimidomethyl)-2H-1,4-benzoxazine Physicochemical properties:
i) Melting point: 147-148C
ii) Elemental analysis (for C20HI7N3O3) C (%) H (%3 N (%) Calcd.: 69.15 4.93 12.10 Found : 69.21 4.96 12.06 Lii ) NMR spectrum (CDCl3) (ppm): 1.32 (6H, s), 3.44 (2H, s), 5.23 (2~, s), 6.76 (lH, d), 7.01 (lH, dd), 7.67-7.96 (5H, m) .
- 72 ~
-:
, ,,'' , ~ a~
Example 24 Ethyl (3,4-dihydro-2,2-dimethyl~6-nitro-2H-1,4-benzoxazin-4-yl)acetate Physicochemical properties:
i) Melting point: 95-96C (ethyl acetate-n-hexane) ii) Elemental analysis (for Cl4H~sN2s) C (%) H (%) N (%) Calcd.: 57.14 6.16 9.52 Found : 57.16 6.15 9.43 iii) NMR spectrum (CDCl3) (ppm): 1.27 (3H, t), 1.36 (6H, s), 3.21 (2H, s), 4.10 (2H, s), 4.20 (2H, q), 6.77 (lH, d), 7.37 (lH, d), 7.59 (lH, dd) Example 25 Ethyl (6-cyano-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-4-yl)acetate Physicochemical properties:
i) Melting point: 52-53C
ii) Elemental analysis (for ClsHI8N23) C (%) H (%) N (%) Calcd.: 65.68 6.61 10.21 Found : 65.81 6.65 10.20 r iii) NMR spectrum (CDCl3) (ppm): 1.28 (3H, t), 1.36 (6H, s), 3.20 (2H, s), 4.01 (2H, s), 4.20 (2H, q), 6.67 (lH, d), 6.75 (lH, d), 6.95 (lH, dd) Example 26 Ethyl 2-(3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)propionate Physicochemical properties:
i) Melting point: 77-78C
ii) Elemental analysis (for ClsH2~N2o5) C (~) H (~) N(%) Calcd.: 58.43 6.54 9.09 Found : 58.41 6.47 9.13 iii) NMR spectrum (CDC13) (ppm): 1.15-1.75 (12H, m), 3.15 (2H, s), 4.20 (2H, q), 4.57 (lH, q)-, 6.80 (lH, dd), 7.50_7.75 (2HI m) Example 27 3,4-Dihydro-2,2-dimethyl-6-nitro-4-(2-vinyloxyethyl)-2H-1,4-benzoxazine Physicochemical properties:
i) Melting point: 56-56.5C
ii) Elemental analysis (for Cl4HI8N2O4) C (~) H (%) ~l (%) Calcd.: 60.42 6.52 10.07 Found . 60.37 6.44 10.00 .
. .
- ' ,~'' '~ ~ ' ' ~ rj 5d ~ r~
iii) NMR spectrum (CDCl3) (ppm): 1.35 (6H, s), 3.23 (2H, s), 3.68 (2H, t), 3.93 (2H, s), 4.05 (lH, dd), 4.21 (lH, dd), 6.47 (lH, dd), 6.80 (lH, d), 7.47-7.84 (2~, m) Example 28 3,4-Dihydro-2,2-dimethyl-4-nicotinoyl-6-nitro-2H-1,4-benzoxazine hydrochloride Physicochemical properties:
i) Melting point: 158-199C (ethanol) ii) Elemental analysis (for Cl6Hl5N3O4~HCl) C (%) H (%) N (%) Cl (%) Calcd.: 54.94 4.61 12.01 10.14 Found : 55.01 4.64 12.04 10.16 iii) NMR spectrum (DMSO-d6) (ppm): 1.28 (6H, s), 3.75 (2H, s)-, 7.13 (lH, d), 7.8-8.1 (2H, m), 8.4-8.8 (2H, m), 8.9-9.2 (2H, m), 11.1 (lH, broad s) Example 29 4-(2-Furoyl)-3,4-dihydro-2,2-dimethyl-6-ni~ro-2H-1,4-benzoxazine Physicochemical properties:
i) Melting point: 112-116.5C (ethanol) 7 5 _ ~ . . . . ..
. `. . - , : ~ . ~ :
,, -:
' . . , , : ' ,, : ' , ` .~ ,., , ~ ', , .- . , . ~' '', ' . ~ . ' .
ii) Elemental analysis (for C~5Hl4N2O5) C (%) H (%) N (%) Calcd.: 59.60 4.67 9.27 Found : 59.56 4.62 9.31 iii) NMR spectrum (CDCl3) 5 (ppm): 2.42 (6H, s), 3.84 (2H, s), 6.53 (lH, dd), 6.94 (lH, d), 7.16 (lH, dd), 7.45 (lH, dd), 7.91 (lH, dd), 8.13 (lH, d) Example 30 Ethyl trans-4-(3,4-dihydro-2,2-dimethyl-6-nitro 2H-1,4-benzoxazine-4-yl)-4-oxo-2-butenoate Physicochemical properties:
i) Melting point: 93-95C
ii) Elemental analysis (for Cl6H~8N2O6) C (%) H (%) N (%) Calcd.: 57.48 5.43 8.38 Found : 57.30 5.41 8.19 iii) NMR spectrum (DMSO-d6) (ppm): 1-24 (3H, k), 1-32 (6H, s), 3.86 (2H, s), 4.21 (2H, q), 6.74 (lH, d), 7.08 (lH, d), 7.56 (lH, d), 7.97 (lH, dd), 8.5-8.9 (lH, broad s) Example 31 3,4-Dihydro-2,2-dimethyl-6-nitro-4-ethyloxalyl-2H-1,4-benzoxazine .
:
Physicochemical properties:
i) Melting point: 80-81C
ii) Elemental analysis (for Cl4Hl6N2O6) C (%) H (%) N (%) Calcd.: 54.54 5.23 9.09 Found : 54.51 5.19 9.05 iii) N~R spectrum (CDCl3) (ppm): 1.37~1.41 (3H, m), 1.42 (3H, s), 1.45 (3H, s), 3.57 (2H x -5 , s), 3.83 (2HIx - , s), 4.36-4.46 (2H, m), 6.99 (lH, d~, 8.02 (lH, m),
9.11 (lH, broad s) Example 32 6-Cyano-3,4-dihydro-2,2-dimethyl-4-(2-oxo-3-oxolanyl)-2H-1,4-benzoxazine Physicochemical properties:
i) Meltin~ point: 144-146C (ethanol) ii) Elemental analysis (for ClsHl6N23) C (%) H (%) N (96) Calcd.: 66.16 5.92 10.29 Found : 66.03 5.93 10.21 iii) NMR spectrum (CDCl3) (ppm): 1.38 (3H, s), 1.41 (3H, s), 2.2-2.7 (2H, m), 2.99 (2H, d), 4.2-4.8 (3H, m), 6.82 (lH, d), 6.89 (lH, d), 7.05 (lH, dd) _ 77 -.
.
., , .
`
Example 33 o OH
CH 2C-~ Borane- THP CH 2CH--N0 2~ 0 ~O2~
In an argon gas stream, 1.5 g of 3,4~dihydro-2,2-dimethyl-6-nitro-3-oxo-4-phenacyl-2H-1,4-benzoxazine was added to 30 ml of a 1.0 M solution of borane in tetrahydrofuran at O - 10C.
The above solution was stirred at 70C for 1 hour, at the end of which time 5.6 ml of methanol was gradually added.
After stirring at 70C for 15 minutes, 5.6 ml of concentrated hydrochloric acid was added and the mixture was further stirred at 70C for 1 hour. The solvent was then distilled off and the residue was diluted with 30 ml of water, made alkaline with potassium carbonate, and extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and the solvent was distilled off. The residue was purified by silica gel column chromatography (eluent: ethyl acetate-n-hexane) to give 1.67 g of 3,4-dihydro-4-(2-hydroxy-2-phenylethyl)-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine as oil.
Mass spectrum (EI): m/z 328 (M~) .
' .
Example 34 C112CHOH - ~ CH2C -NOz ~ N ~ Swern ~xid ~0 In an argon gas stream, 0.7 ml of dry dimethyl sulfoxide was added gradually to a solution of 0.41 ml of oxalyl chloride in lO ml of dry methylene chloride previously cooled from -50 to -60C and the mixture was stirred at the same temperature for 2 minutes.
Then, 20 ml of a solution of 1.5 g of 3,4-dihydro-4-(2-hydroxy-2-phenylethyl)-2,2-dimethyl-6-nitro-2H-l,4 benzoxazine in dry methylene chloride was added o~er a period of 5 minutes and the mixture was stirred at the same temperature as above for 15 minutes.
To this reactlon mixture was added l.3 ml of triethylamine and, at room temperature, the mixture was diluted with 30 ml of water and extracted with methylene chloride. The extract was dried over anhydrous magnesium sulfate and the solvent was distilled off. The residue was ~; recrystallized ~rom ether to give l.31 g of 3,4-dihydro-2,2-dimethyl-6-nitro-4-phenacyl-2~1-l,4-benzoxazine melting at 125 - 128C.
~: .
:
: . `
. ~ , .
, ~"i~
Physicochemical properties:
Elemental analysis (for Cl8HI8N2O4) C (%) H (%) N (%) Calcd.: 66.25 5.56 8.58 Found : 66.16 5.62 8.47 Mass spectrum (EI) : m/z 326 (M+) Example 35-40 The compounds listed in the following table were synthesized by Process 2 as in Examples 33 and 34.
- 80 ~
~",~
H Rl7 R2 ~ N ~
H ~R5 H
Example R2 R5 R6 R7 Starting Compound OH ICH2 CO <
NO2 CH3 CH3 -CH2-CH- ~ 02N ~ ~ ~ O
. fH IH2-co-cH3 36 No2 CH3 CH3-CH2-CH-CH3 02N ~ N~o o I The compound 37 N2 CH3 CH3 -CH2-C ~ of Example 3 N
O
ll The compound 38 No2 CH3 CH3 -CH2-C-CH3 of Example 36 ~0 39 N02 CH, 5H3 ~ ~ 07N N
: I I The compound ~ 40 NO2 CH3~ CH3 ~ of Example 39 , ~ ~
:`
`;
' These compounds have the follow.ing physicochemical properties.
Example 35 3,4-Dihydro-4-[2-hydroxy-2-(2-pyridyl)ethyl]-2,2-dimethyl-6-nitro-2H~1,4-benzoxazine Mass spectrum(EI) : m/z 329 (M+) Example 36 3,4-Dihydro-4-(2-hydroxypropyl)-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine Mass spectrum (EI) : m/z 266 (Mf) Example 37 3,4-Dihydro-2,2-dimethyl-6-nitro-4-~(2-pyridylcarbonyl)methyl]-2H-1,4-benzoxazine Melting point: 106-107C
Elemental analysis (for Cl7Hl7N304) C (%) H (%) N (%) -Calcd.: 62.38 5.23 12.84 Found : 62.38 5.23 12.76 Mass spec=r m (GC-MS) : m/z 327 (M~) :' .
. :
: ' .
Example 38 4-Acetonyl-3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine Melting point: 98-99C
Elemental analysis (for Cl3H~6N2O4) C (%) H (%) N (%) Calcd.: 59.08 6.10 10.60 Found : 58.92 6.21 10.52 Mass spectrum (GC-MS) : m/z 264 (M~) Example 39 3,4-Dihydro-2,2-dimethyl-4-(2-hydroxycyclopentyl)-6-nitro-2H-1,4-benzoxazine Physicochemical propertles:
i) Elemental analysis (for Cl5H20N2O4) C (%) H (%) N (%) Calcd.: 61.63 6.90 9.58 Found : 61.60 7.00 9.53 ii) Melting point: 87-88C (n-hexane) iii~ Mass spectrum (mlz) : 292 (M+) (EI) i~) NMR spectrum (CDCl3) (ppm): 1.32 (3H, s), 1.39 (3H, s), 1.58-2.22 (6H, m), 3.26 (2H, s), 3.80 (lH, m), 4.50-4.68 (lH, m), 6.79 (lH, d), 7.59 (lH, d), 7.60 (lH, dd) .
.' ' , .
:, ', ~ , ~,~J~ 3~9 Example 40 3,4-Dihydro-2,2-dimethyl-6-nitro-4-(2-oxocyclopentyl)-2H-1,4-benzoxazine Physicochemical properties:
i) Elemental analysis (for Cl5Hl8N2O4) C (%) H (%) N (%) Calcd.: 62.06 6.25 9.65 Found : 61.84 6.38 9.52 ii) Melting point: 118-119C (ether-n-hexane) iii) Mass spectrum (m/z): 290 (M-~) (EI) iV) NMR spectrum (CDCl3) (ppm)o 1-34 (3H, s), 1.41 (3H, s), 1.75-2.60 (6H, m), 2.83 (lH, d), 2.99 (lH, d), 4.22~4.44 (lH, m), 6.79 (lH, d), 7.51 (lH, d)~ 7.61 (lH, dd) Exam~le 41 (1) NO
H
OzN ,~ ~ O~N ~N~
~ ' .: .
.
, ~ :
, :: . , :' ' , ~
' ' , , ', , : -~.J
(1) In a mixture of 34 ml of methanol and 2.07 ml of acetic acid was dissolved 3 g of 3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine. Then, a solution of 2.0 g of sodium nitrite in 6.6 ml of water was added dropwise and the mixture was stirred at room temperature overnight. The reaction mixture was neutralized with aqueous sodium hydroxide solution, concentrated under reduced pressure and extracted with chloroform. The organic layer was washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to give 3.2 g of 3,4-dihydro-2,2-dimethyl-6-nitro-4-nitroso-2H-1,4-benzoxazine.
This compound has the following physicochemical properties.
i) Melting point: 104-105C
ii) Elemental analysis (for Clo~llN34) C t%) H (%) N (%) Calcd.: 50.63 4.67 17.71 Found : 50.36 4.63 17.71 iii) NMR spectrum (CDCl3) (ppm): 1.37 (6H, s), 3.87 (2H, s), 7.06 (lH, d), 8.08 (lH, dd), 8.90 (lH, d) , ' '' ' ' .
(2) 02N ~ ~ ~ 02N ~11~
(2) In 69 ml of methanol was dissolved 2.29 g of 3,4-dihydro-2,2-dimethyl-6-nitro-4-nitroso-2H-1,4-benzoxazine and the solution was cooled on an ice bath. After addition of a solution of 1.16 g of sodium hydroxide in 8.1 ml of water to the above solution, 3.13 g of formamidinosulfinic acid was gradually added. The mixture was stirred at room temperature overnight and, then, concentrated. The concentrate was subjected to column chromatography (eluent: hexane-ethyl acetate = 9:1) to give 0.4 g of 4-amino-3j4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine Recrystallization from ether-hexane gave 0.28 g of the object compound.
This compound has the following physicochemical properties.
i) Melting point: 83-85C
ii) Elemen-tal analysis (foI Clo C (%) H (%) N (~) Calcd.: 53.81 5.87 18.82 Found : 53.75 5.80 18.93 ; .. ' ~ 86 -.
- ': . . ' ~ :
:, . .
. ,: .
~ ', '' ' :
~d ~ 3 iii) NMR spectrum (CDCl3) (ppm): 1.41 (6H, s), 3.18 (2H, s), 6.77 (lH, d), 7.66 (lH, dd), 8.06 (lH, d) (3) NH2 NHC0'^\ /^- C
0zN ~ N ~ 02N ~ N
(4) ~0 ~ ~ 02N
(3) In 4 ml of methylene chloride was dissolved 0.35 g of 4-amino-3,4-dlhydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine and the solution was cooled on an ice bath. To this solution was added 0.16 g o-f triethylamine followed by dropwise addition of a solution of 0.18 ml of 4-chlorobutyryl chloride in 1.4 ml o-f methylene chloride. ~fter 3~0 minutes, the reaction mixture was~dlluted wlth wa-~er and extracted with chloroform. The organic layer was dried o~er anhydrous magnesium sulfate and~concentrated under reduced pressure.
The concentrate was crystalllzed from ether to give 0.43 g of crude crystals of 9-chloro-N-(3,4-dlhydro-2,2-dimethyl-6-.
- a7 -.:
. ' ' ~ .
r'.~ ',J i ~
nitro-2H-1,4-benzoxazin-4-yl)butyrylamide. q~he crude crystals were used without purification in the next reaction.
(4) In 8 ml of N,N-dimethylformamide was dissolved 0.41 g of the above amide and the solution was cooled on an ice bath. Then, 0.14 g of potassium tert-butoxide was gradually added. The mixture was stirred with ice-cooling for 1 hour, after which it was diluted with water and extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and filtered. ~he filtrate was concentrated under reduced pressure and crystallized from ether. The crude crystals were recrystallized from ethanol to give 0.16 g of 3,4-dihydro-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-6-nitro-2H-1,4-benzoxazine.
This compound has the following physicochemical properties.
i) Melting point: 141-143 ii) Elemental analysis (for Cl4Hl7N3O4) C (%) H (~) N (~) Calcd.: 57.72 5.88 14.42 Found : 57.61 5.89 14.40 iii) NMR spectrum (CDCl3) (ppm): 1.41 (3H, s), 1.49 (3H, s), 2.1 2.7 (4H, m), 3.15 (lH, d), 3.4-3.8 (3H, m), 6-84 (lHt d), 7.46 (lH, d), 7.70 (lH, dd) ::
~ J~ J~L~
Example 42-44 The following compounds were synthesized by Process 3 as in Example 41.
R~ N~
Example No. R2 R3 R4 R7 Starting Compound IHCOCH2CH2CH2Cl 42CN CH3 CH3 ~ ~ O ~ O 1 . INH2 43Br CH3 CH3 -NHCOCH3 Br ~ N~
INHCOCH2CH2CH2Cl 44H CH3 ~H ~ O ~ O ~
These compounds have the following physicochemical properties.
~ - 89 -Js~
Example 42 6-Cyano-3,4-dihydro-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-2H-1,4-benzoxazine i)Melting point: 149-150C
ii) Elemental analysis (for ClsHl7N3o2) C (%) H (%) N (%) Calcd.: 66.40 6.32 15.49 Found : 66.29 6.08 15.51 iii) NMR spectrum (CDCl3) (ppm): 1.38 (3H, s), l,45 (3H, s), 2.1-2.6 (4H, m), 3.11 (lH, d), 3.4 3.7 (3H, m), 6.74-6.84 (2H, m), 7.04 (lH, dd) Example 43 N-(6-Bromo-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-4-yl)acetamide i)Melting point: 167-168C -ii) Elemental analysis (for Cl2HIsN22Br) C (%) H (%) N (%) Br (%) Calcd.: 48.18 5.05 9.36 26.71 Found : 48.14 5.01 9.29 26.51 iii) NMR spectrum (CDCl3) tppm): 1.36-1.45 (6H, m), 2.06, 2.12 (3H, s x 2), 3.16, 3.30 (2H, s x 2), 6.56-6.97 (3H, m) . ~ . , , ~ , ' ~,. ~. - ', . , , ' ~'. ' , 2 ~
Example 44 3,4-Dihydro-2,2-dimethyl-4-(2-oxo-1-pyrrodinyl)-2H-1,4-benzoxazine i) Melting point: 139-141C
ii) Elemental analysis (for C~4HI8M2O2) C (%) H (%) N (%) Calcd.: 68.27 7.37 11.37 Found : 67.75 7.44 11.26 iii) NMR spectrum (CDCl3) (ppm): 1-38 (3H, s), 1.46 (3H, s), 2.04-2.58 (4H, m), 3.0-3.6 (4H, m), 6.51-6.84 (4H, m) Example 45 ~ - ~ N~o 0zN ~ N ~ HzN
To a solution of 3.01 g of 2-(3,4-dihydro-2,2-dlmethyl-6-nitro-1,4-benzoxazin-4-yl)pyridine N-oxide in 50 ml of methanol was added an aqueous solution of 10.9 g of ammonium chloride (50 ml) at room temperature. Then, with ice-cooling, 13.1 g of zinc dust was added and the mixture was stirred at 3C for 15 hours. The insolubles were 2 ~ 9 filtered off and the filtrate was concentrated, diluted with water and extracted with chloroform. The organic layer was dried and the solvent was distilled off. The residue was chromatographed on a silica gel column and elution was carried out with chloroform-methanol (50:1). The eluate gave 1.86 g of 2-(6-amino)-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-4-yl)pyridine N-oxide. This compound has the following physicochemical properties.
i) Melting point: 200~202C
ii) Elemental analysis (for ClsHl7N3o2-o.lH2o) C (%) H (%) N (%) Calcd.: 65.97 6.35 15.39 Found : 65.94 6.35 15.39 iii) NMR spectrum (CDCl3) ~ (ppm): ]..30 (6H, s), 3.28 (2H, broad s), 3.69 (2H, s ), 6.19-7.49 (6H, m), 8.23 (lH, m) Example 46 I~N~o , ~N~ o H zN~N~ C~l3C0NI~ N~-... :
- . ~~ ., , To a solution of 0.474 g of 2-(6-amino-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-4-yl)pyridine N-oxide in 5 ml of acetic anhydride was added 3 drops of pyridine and the mixture was stirred at room temperature for 63 hours. After concentration, the residue was dissolved in chloroform, washed with saturated aqueous sodium hydrogen carbonate solution, dried and concentrated. The residue was recrystallized from chloroform-ether to give 0.285 g of 2-(6-acetamido-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-4-yl)pyridine N-oxide.
This compound has the following physicochemical properties.
i) Melting point: 290-295C (decompn.) ii) Elemental analysis (for C~7Hl9N3O3-0.1H2O) C (%) H (%) N (%) Calcd.: 64.79 6.14 13.33 Found : 64.74 6.18 13.20 iii) NMR spectrum (CDCl3) (ppm): 1.30 (6H, s), 2.04 (3H, s), 3.65 (2H, s), 6.68-7.64 (6H, m), 8.18 (lH, m) Example 47 ~1 l N~o C l13 i O z N l~ N~_ - g3 -~,J~J~ 3 The following compound was synthesi~ed in substantially the same manner as in Example 46.
2-(3,4-Dihydro-2,2-dimethyl-6-methanesulfonamido-2H-1,4-benzoxazin-4-yl)pyridine N-oxide.
i) Elemental analysis (for Cl6Hl9N304-0.5H20) C (%) H (%) N (%) S (%) Calcd.: 53.62 5.62 11.72 8.95 Found : 53.74 5.33 11.68 9.21 ii) NMR spectrum (CDCl3+DMSO-d6) (ppm): 1.28 (6H, s), 2.84 (3H, s~, 3.51 (2H, s), 6.24-8.40 (7H, m), 9.12 (lH, broad s) iii) Mass spectrum (m/z): 349 (M+) Example 48 o O CO2H
~ ~ OEt Saponification ~
02N ~ N ~ ~ OzN \ ~ N
In 2 ml of ethanol was dissolved 0.5 g of ethyl trans-4-(3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)-4-oxo-2-butenoate followed by addition of 1.5 ml of an aqueous solution of 0.06 g of sodium hydroxide. The mixture was stirred at room temperature for 2 hours. The ethanol was distilled off under reduced pressure and the residue was adjusted to pH 4 with 1 N hydrochloric acid~ The resulting , ; . . ' .,; . ., ', ' '' : ' 2~J~jr~
precipitate was recovered by filtration and washed with water and ethanol to give 0.31 g of trans-4-(3,4-dihydro-2,2-dimethyl-6-nitro-2H-l/4-benzoxazin-4-yl)-4-oxo-2-butenoic acid.
This compound has the following physicochemical properties.
i) Melting point: 222-226C
ii) Elemental analysis (for Cl4HI4N2O6) C (%) H (%) N (%) Calcd.: 54.90 4.61 9.15 Found : 54.90 4.70 9.08 iii) NMR spectrum (DMSO-d6) (ppm): 1.32 (6H, s), 3.86 (2H, s)-, 6.70 (lH, d), 7.08 (lH, d), 7.48 (lH, d), 7.96 (lH, dd), 8.4-8.8 (lH, broad s) Example 49 ~ COO~
O ~N ~ N
, .. .
.
The following compound was synthesized in substantially the same manner as in Example 48.
(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)acetic acid Physicochemical properties:
i) Melting point: 162-164C (decompn.) (hexane-ethyl acetate) ii) Elemental analysis (for Cl2Hl4N205) C (%) H (%) N (%) Calcd.: 54.13 5.30 10.52 Found : 53.95 5.22 10.58 iii) NMR spectrum (DMSO-d6) (ppm): 1.29 (6H, s), 3.24 (2H, s), 4.22 (2H, s), 6.83 (lH, d), 7.34 (lH, d), 7.50 (lH, dd), 12.84 (lH, broad s).
iii) Mass spectrum (m/z): 267 (M'~l). Fab(pos ) Example 50 O O
~ OEt ~ NHMe 02N ~ ; ~ OzN ~ N ~
To 1.00 g of ethyl (3,4-dihydro-2,2-dimethyl-6-ni-tro-2H-1,4-benzoxazin-4-yl)acetate was added 5 ml of methylamine .. , ; . :; :
. -. . .. . , , :
- , . .
,, . : . .
~3~ 3~
(40% in methanol) and the mixture was stirred at 100C for 1 hour. The reaction mixture was then concentrated under reduced pressure to give crude 2-(3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-~enzoxazin-4-yl)-N-meth~-~lacetamide. This product was washed with n-hexane-ethyl acetate to obtain 950 mg of crude crystals. Recrystallization from ethyl acetate-n-hexane gave 866 mg of the object compound.
This compound has the following physicochemical properties.
i) Melting point: 127-128C
ii) Elemental analysis (for Cl3Hl7N3O4) C (%) H ~%) N (%) Calcd.: 55.91 6.14 15.05 Found : 55.93 6.11 15.16 iii) NMR spectrum (CDCl3) (ppm): 1.40 (6X, s), 2.86 (3H, d)-, 3.18 (2H, s), 3.93 (2H, s), 6.18 (lH, broad s), 6-82 (lH, d), 7-42 (lH, d), 7.66 (lH, dd Example 51 to 55 Using the ester compounds synthesized by Process 4, the following compounds were obtained in otherwise the same manner as Example 50.
: . :
. ' : ' ~
J '~
-o Example No. R2 R5 R6 R7 Starting Compound 51 CN CH3 CH3 -CH2CONHCH3 NC ~ N ~ H2NCH3 52 N2 CH3 CH3 -CH2CONHC2H5 02N~[~N~ H2NC2H5 .. , CH2COOC2H5 53 NO2 CH3CH3 -CH2CONHCH2CH20H2 ~ N ~ H2NCH2CH20H
CEI3 CH ( CH3 ) COOC2H5 54 NO2 CH3 ~H3 CH-CONHCH302N ~ N ~ H2NCH3 o COCOOC2H5 NO2 CH3 cl3 -C~CONHCH3 02N ~ ~ H2NCH3 .
- : : ' . :' ' , ,, - ~ ' ' ` ' :
' :: . :' . ,' ' c,O ~ r E mPle 51 2-(6-Cyano-3,4-dih~dro-2,2-dimethyl-2H-1,4-benzoxazin-4-yl)-N-methylacetamide.
Physicochemical properties:
i) Melting point: 150-151C
ii) Elemental analysis (for ClbH~7N3O2) C (%) H (%) N (%) Calcd.: 64.85 6.61 16.20 Found : 64.85 6.59 16.29 iii) NMR spectrum (CDCl3) (ppm): 1.39 (6H, s), 2.87 (3~, d), 3.17 (2H, s), 3.85 (2H, s), 6.75-6.86 (2H, m), 7.05 (lH, dd) Example 52 2-(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)-N-ethylacetamide.
Physicochemical properties:
i) Melting point: 115-116C
ii) Elemental analysis (for Cl~,Hl~N3O4) C (%) H (%) N(%) Calcd.: 57.33 6.53 14.33 Found : 57.24 6.57 14.34 _ 99 _ , .
~ J ~, 9J~ ~39 iii) NMR spectrum (CDCl3) (ppm): 1.12 (3H, t), 1.40 (6H, s), 3.19 (2H, s), 3.34 (2H, m), 3.91 (2H, s), 6.17 (lH, broad s), 6.82 (lH, d), 7.44 (lH, d), 7.66 (lH, dd) Example 53 2-(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)-N-(2-hydroxyethyl)acetamide.
Physicochemical propertles:
i) Melting point: 146-147C
ii) Elemental analysis (for Cl4HlsN3s) C (%) H (%) N (%) Calcd.: 54.36 6.19 13.58 Found : 54.29 6.21 13.49 iii) NMR spectrum (CDCl3) (ppm): 1.40 (6H, s), 1.64 (lH, broad s), 3.19 (2H, s), 3.34--3.82 (4H, m), 3.93 (2H, 5j, 6.72 (lH, broad s), 6.81 (lH, d), 7.43 (lH, d), 7.64 (lH, dd) Example 54 2-(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)-N-methylpropionamide.
Physicochemical properties:
i) Melting point: 181-182C
.
... ..
~` . . ~ .
~ 3 ii) Elemental analysis (for Cl4Hl9N30") C (%) H (%) N (%) Calcd.: 57.33 6.53 14.33 ~ ound : 57.27 6.54 14.34 iii) NMR spectrum (CDCl3) (ppm): 1.38 (6H, s), 1.45 (3H, d), 2.86 (3H, d), 3.05 (2H, s), 4.43 (lH, q), 6.14 (lH, broad s), 6.83 (lH, dd), 7.50-7.75 (2H, m) Example 55 2-(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)-N-methyl-2-oxoacetamide.
Physicochemical properties:
i) Melting point: 129-130C
ii) Elemental analysis (for Cl3HI5N305) C (%) H (%) N (%) Calcd.: 53.24 5.16 14.33 Found : 53.04 5.05 14.25 iii) NMR spectrum (CDCl3) (ppm): 1-39 (6H, s), 2.95 (3H, d), 4.28 (lH, broad s), 6.93 (lH, d), 7.99 (lH, dd), 9.87 (lH, broad-s) .
- ]01 -:, . , . :
Example S6 COOII / CH :~
CON\
~C~13 02N ~ N~ 1) SOC Q 2 < C H a - ~N ~
In 6 ml of chloroform were dissolved 1.0 g of (3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-~l)acetic acid and 1.34 g of thionyl chloride followed by addition of 2 drops of pyridine. The mixture was refluxed for 5 hours, at the end of which time it was concentrated under reduced pressure to give the acid chloride as a crude product.
The above crude acid chloride was dissolved in 5 ml of chloroform and the solution was added dropwise to a mixed solution of 0.93 g of dimethylamine hydrochloride and 1.15 g of triethylamine in 20 ml of chloroform with ice-cooling.
The mlxture was then stirred at room temperature for 4 hours and concentrated. The residue was subjected to silica gel chromatography using hexane-ethyl acetate (3~ 3) as the eluent to give 0.46 g of 2-(3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)-N,N-dimethylacetamide, which was then recrystallized from ethyl acetate-hexane. This compound was found to have the following physicochemical properties.
; - 102 -~. .
: .
' i) Melting point: 179-180C
ii) Elemental analysis (for Cl4HlgN304) C (%) H (%) N (%) Calcd.: 57.33 6.53 14.33 Found : 57.26 6.48 14.28 iii) NMR spectrum (CDCl3) (ppm): 1-38 (6H, s), 2-99 (3H, s), 3.12 (3H, s), 3.23 (2H, s), 4.18 (2H, s), 6.79 (lH, d), 7.31 (lH, d), 7.60 (lH, dd) iv) Mass spectrum (m/z): 293 (M+) Example 57-58 The following compounds were synthesized in substantially the same manner as in Example 56.
Example 57 02N ~ ~/N~
~OJ~ :
2-(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)acetamide.
Physicochemical properties:
i) Melting point: 183-184C
.
``` ' ` : :
.
!
ii) Elemental analysis (for C~2HI5N304) C (%) H (%) N (%) Calcd.: 54.33 5.70 15.84 Found : 54.34 5.68 15.84 iii) NMR spectrum (CDCl3) (ppm) 1-40 (6H, s), 3-20 (2H, s), 3.93 (2H, s), 6.07 (2H, broad d), 6.81 (lH, d), 7.44 (lH, d), 7.64 (lH, dd) Example 58 ~ CONH -02N ~ N ~
2-(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)-N-phenylacetamide Physicochemical properties:
i) Melting point: 185-187C
ii) Elemental analysis (for Cl~HlgN304) C (%) H (%) N (%) Calcd.: 63.33 5.61 12.31 Found : 63.15 5.70 12.15 .
.' . . . .
~d ~
iii) NMR spectrum (CDCl3) (ppm): 1-46 (6H, s), 3-24 (2H, s), 4.03 (2H, s), 6.81-7.80 (8H, m), 9.10 (lH, broad s) Example 59 ~ OH ~ ~ <
OzN ~ N ~ (C ~ C Q ~ O ~ CH, In 10 ml of tetrahydrofuran were dissolved 0.4 g of 4-(3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)-4-oxo-2 butenoic acid, 0.3 g of dicyclohexylcarbodiimide and 0.26 g of 1-hydroxybenzo-triazole. To this solution was added 2 ml of a mixed solution of 0.1 g of dimethylamine hydrochloride and 0.13 g of triethylamine in 2 ml of tetrahydrofuran with ice-cooling. The mixture was stirred at room temperature for 3 days, after which the precipitate was filtrated off and the solvent was distilled off under reduced pressure. The residue was dissolved in ethyl acetate and the solution was washed with aqueous potassium carbonate solution and water and dried over anhydrous magnesium sulfate. The ; solvent was then distilled off under reduced pressure and the residue was purified by silica gel column chromatography.
The resulting crude crystals were ~ashed with ethyl acetate-,, , ~ , ' 7"~
hexane to give 0.26 g of 4-(3,4-dihydro-2,2-dimethyl 6-nitro~
2H-1,4-benzoxazin-4-yl)-N,N-dimethyl-4-oxo-2-butenamide.
This compound has the following physicochemical properties.
i) Melting point: 179-182C
ii) Elemental analysis (for C~6H~9N305) C (%) H (%) N (%) Calcd.: 57.65 5.75 12.61 Found : 57.55 5.96 12.21 iii) NMR spectrum (CDCl3) (ppm): 1-36 (6H, s), 3.04 (3H, s), 3.20 (3H, s), 3.80 (2H, s), 6.94 (lH, d), 7.36 (lH, d), 7.60 (lH, d) 7.98 (lH, dd) Example 60-62 The following compounds were synthesized in subslantially the same manner as in Example-59.
Example 60 CONHCH(CII 3) Z
~ 0~
2-(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)-N-isopropylacetarnide.
.. . . ..
' . ~
- , : ' , .
' ' ' . ' Physicochemical properties:
i) Melting point: 156-156.5C
ii) Elemental analysis (for Cl4H17N30z) C (%) H (%) N (%) Calcd.: 58.62 6.89 13.67 Found : 58.58 6.96 13.63 iii) NMR spectrum (CDCl3) tppm): 1-13 (6H, d), 1.40 (6H, s), 3.17 (2H, s), 3.86 (2H, s), 4.09 (lH, m), 6.81 (lH, d), 7.43 (lH, d), 7.65 (lH, dd) iv) Mass spectrum (m/z): 293 (M+) _ample 61 ~ CON
02N ~ N ~
3,4-Dihydro-2,2-dimethyl-6-nitro-4-[(1~
pyrrolydinylcarbonyl)methyl]-2H~1,4-benzoxazine.
Physicochemical.properties:
i) Melting point 165~166C
, . ' , ' '' :
" : . :
, .
~ ~ ~J ~3 ~
ii) Elemental analysis (for Cl6H21N304) C (%) H (%) N (%) Calcd.: 60.18 6.63 13.16 Found : 60.17 6.68 13.10 iii) NMR spectrum (CDCl3) (ppm): 1.38 (6H, s), 1.70-2.24 (4H, m), 3.27 (2H, s), 3.34-3.66 (4H, m), 4.08 (2H, s), 6.79 (lH, d), 7.33 (lH, d), 7.59 (lH, dd) Example 62 CONH
~ 0~
N-Benzyl-2-(3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl~acetamide.
Physicochemical properties:
i) Melting point: 133-l35C
ii) Elemental analysis (for Cl9H2lN304) C (%) H (%) N (%) Calcd.: 64.21 5.96 11.82 Found : 64.17 6.08 l1.88 ' iii) NMR spectrum (CDCl3) (ppm): 1.35 (6H,s), 3.19 (2H, s), 3.98 (2H, s), 4.50 (2H, d), 6.55 (lH, broad t), 6.81 (lH, d), 7.26 (5H, s), 7.48 (lH, d), 7.66 (lH, dd) Example 63 02N ~ ~ ~ 02N ~ ~
In 4 ml of methylene chloride was dissolved 0.33 g of 3,4-dihydro-2,2-dimethyl-6-nitro-4-(2-pyridylmethyl)-2H-1,4-benzoxazine followed by addition of 0.26 g -of m-chloroperbenzoic acid, and the mix-ture was stirred at room temperature o~ernigh-t. This reaction mixture was diluted with aqueous sodium hydrogen carbonate solution and extracted with methylene chloride. The organic layer was dried over anhydrous magnesium sulfate and fiItered. The filtrate was concentrated under reduced pressure to give crude crystals o~
2-(3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)methylpyridine N-~oxi~e. Recrystallization from ethanol-chloroform gave 0.2 g of the object compound. This compound was found to have the following physicochemical properties.
'.' -i) Melting point: 139-140C
ii) Elemental analysis (for Cl6Hl7N3O4) C (%) H (%) N (%) Calcd.: 60.94 5.43 13.33 Found : 60.69 5.47 13.18 iii) NMR spectrum (CDCl3) (ppm): 1.41 (6H, s), 3.27 (2H, s), 4.78 (2H, s), 6.83 (lH, d), 7.12-7.34 (4H, m), 7.61 (lH, dd), 8.24-8.42 (lH, m) Example 64 The following compound was syn-thesized in substantially the same manner as in Example 63.
N->0 ~ o 1 3-(6 Cyano-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-4-yl)methylpyridine N-oxide.
Physicochemical properties:
i) Melting polnt: 144-147C
.
, 3 '~ ~ ~
ii) Elemental analysis (for Cl7Hl7N3O2) C (%) H (%) N (%) Calcd.: 69.14 5.80 14.23 Found : 69.33 5.82 14.23 iii) NMR spectrum (CDCl3) (ppm): 1.37 (6H, s), 3.11 (2H, s), 4.42 (2H, s), 6.70-7.36 (5H, m), 8.08-8.18 (2H, m) Example 65 H CH 30~N~
02N~N~ NaH o~ J
C ~N ~D 2 N ~ N
H3COOC N I OJ~
In 40 ml of N,N-dimethylformamide was dissolved 3.33 g of 3,4-dihydro-2,2-dimethyl-6-nitro-2~I-I,4-benzoxazine followed by addition of 0.77 g of sodium hydride. The mixture was stirred at room temperature for 30 minutes and ice-cooled. Then, 6 ml of a solution of 2.76 g of methyl 2-chloropyrazine-3-carboxylate in N,N-dimethylformamide was added dropwise at a temperature not exceeding 5C. The reaction mixture was then stirred at room temperature for 3.5 hours, a-t the end of which time it was poured in ice-water and extracted with ethyl acetate. The extract was washed - ,.' ~ J~J'~ t~
with water and dried over anhydrous magnesium sulfate. The solvent was then distilled off under reduced pressure and the residue was purified by silica gel column chromatography.
The resulting crude crystals were recrystallized from ethanol to give 1.27 g of 3,4-dihydro-2,2-dimethyl-4-(2-methoxy-3-pyrazinyl)carbonyl-6-nitro-2H-1~4-benzoxazine. This compound was found to have the following physicochemical properties.
i) Melting point: 183-186C
ii) Elemental analysis (for Cl6H16N4O5) C (%) H (%) N (~) Calcd.: 55.81 4.68 16.27 Found : 55.96 4.55 16.09 iii) NMR spectrum (CDCl3) (ppm): 1.4-1.6 (9H, broad s), 3.90 (2H, s), 6.90 (lH, d), 7.8-8.0 (lH, broad s), 8.1-8.2 (2H, m) ~, ~
Example 66 C1 ~ ~
CH 300C ~>
02N ~o~ CH :~0 0~_ ~0) 0 2 N ~N 1--ISi (CH3) 3 CH:~OH H0 0~
O:N~N~
(1) The same procedure as Example 65 was followed to give 3,4-dihydro-4-[(2-methoxypyridln-3-yl)carbonyl]-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine.
This compound has the following physicochemical properties.
i) Melting point: 179-182C
ii) Elemental analysis (for Cl7HI7N305) ?
C (%) H (%) -N (%) Calcd.: 59.47 4.99 12.24 Found : 59.50 5.08 12.01 ~;
- 1.13 -, ~ 3 iii) NMR spectrum (CDCl3) (ppm): 1.45 (6H, s), 3.1-4.0 (5H, m), 6.90-7.26 (3H, m), 7.85-7.98 (2H, m), 8.29 (lH, dd) (2) In 6 ml of carbon tetrachloride was dissolved 0.4 g of 3,4-dihydro-~-[(2-methoxypyridin-3-yl)carbonyl]-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine followed by dropwise additlon of 0.26 g of trimethylsilyl iodide. The mixture was heated at 50C for 2 hours and, then, cooled. The reaction mixture was diluted with water and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and filtered, the filtrate was concentrated under reduced pressure, and methanol was added to the concentrate for crystallization. RecrystaIlization from ethyl acetate gave 0.31 g of 3,4-dihydro-4-[(2-hydroxypyridin-3-yl)carbonyl]-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine.
This compound has the following physicochemical properties.
i) Melting point: 183-184C
ii) Elemental analysis (for Cl6Hl5N3O5-0.8CH3COOC2~I5) C (%) H (%) N (%) Calcd.: 57.68 5.40 10.51 Found : 57.66 5.40 I0.56 iii) NMR spectrum (CDCl3) (ppm): 1.41 (6H, s), 3.70 (2H, broad s), 6.34 (lH, m), 6.94 (lH, d), 7.40-7.96 (3H, m), 8.61 (lH, m) Example 67 NC H ~ 0 ~ ~ NC ~ N ~
To 2.53 g of cyclopentanone were added 20 ml of carbon tetrachloride, 5.34 g of N-bromosuccinimide and a catalytic amount of dibenzoyl peroxide ànd the mixture was refluxed under heating for 3 hours. After-cooling, the reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The concentrate and 2.43 g of triethylamine were added to a solution of 0.38 g of 6-cyano-3,4-dihydro-2,2-dimethyl~2H-1,4-benzoxazine in 5 ml of tetrahydro~uran and the mixture was stirred at room temperature overnlght. The reaction mixture was then concentrated under reduced pressure, diluted with water and extracted with ethyl acetate. The organic layer was : separated, dried o~er anhydrous magnesium sul.fate and concentrated under reduced pressure. The residue was - 1~.5 -: , - . : ' . ,, .: ,: ~, ' :, .
. . . . . . .
, i , /J ~
chromatographed on a silica gel co]umn (eluent : hexane-ethyl acetate = 10:1 - 4:1) to give 0.3 g of crude 6-cyano-3,4-dihydro-2,2-dimethyl-4-(5-oxo-1-cyclopenten-1-yl)-2H-1,4-benzoxazine. Recrystallization from ethanol-hexane gave 0.16 g of pure product. This compound has the following physicochemical properties.
i) Melting point: 124-126C
ii) Elemental analysis (for Cl6Hl6N2O2) C (%) H (%) N (%) Calcd.: 71.62 6.01 10.44 Found : 71.52 5.99 10.30 iii) NMR spectrum (CDCl3) (ppm): 1-33 (6H, s), 2.50-2.77 (4H, m), 3.42 (2H, s), 6.84 (lH, d), 7.01-7.14 (2H, m), 7.21 (1H, t) Example 68-72 The following compounds were synthesized generally in the same manner as Example 67.
~: ' ' ' ' , ' ' ,: ' , ' o ~
Example 6 8 ~0 Br ,¢~N~
6-Bromo-3,4-dihydro-2,2-dimethyl-4-(5-oxo-1~
cyclopenten-1-yl)-2H 1,4-benzoxazine.
Physicochemical properties:
i) Melting point: 110-115C
ii) Elemental analysis (for C~5Hl6BrNO2) C (~) H (%) Br (~) N (~) Calcd.: 55.92 5.01 24.80 4.35 Found : 55.61 5.06 24.49 4.28 iii) NMR spectrum (CDCl3) (ppm): 1.26 (6H! s), 2.4-2.8 (4H, m), 3.36 (2H, s), 6.59 (lH, d), 6.74 (lH, d), 6.87 (lH,~dd), 7.11 (lH, t)~
E~ample 69 : -C 11, ~ N ~
,:
.
.. , . .. ' . . . . .
.. . . ., , , . ~ .
~ ~ f, ~ é~
3,4-Dihydro-6-methoxy~2,2-dimethyl-4-(5-oxo-1-cyclopenten-l-yl)-2H-1,4-benzoxazine.
Physicochemical properties:
i) Melting point: 95-97C
ii) Elemental analysis (for C16Hl9NO3) C (%) H (%) N (%) Calcd.: 70.31 7.01 5.12 Found : 70.17 6.90 4.92 iii) NMR spectrum (CDCl3) (ppm): 1.28 (6H, s), 2.44-2.70 (4H, m), 3.43 (2H, s), 3.69 (3H, s), 6.36 (lH, dd), 6.47 (lH, d), 6.72 (lH, d), 7.17 (lH, t) Example 70 02N ~ 1~ ~
3,4-Dihydro-2,2-dimethyl-6-nitro-4-(5-oxo-1-cyclopenten-l-yl)-2H-1,4-benzoxazine.
Physicochemical properties:
i) Melting point: 96 98C
- ~.
~2 ~3~J~
ii) Elemental analysis (for Cl5HI6N2O4^0.1H2O) C (%) H (%) N (%) Calcd.: 62.10 5.63 9.66 Found : 62.11 5.64 9.43 iii) NMR spectrum (CDCl3) (ppm): 2.33 (6H, s), 2-51-2-59 (2H~ m)~
2.64-2.75 (2H, m), 3.44 (2H, s), 6.83 (lH, dd), 7.24 (lH, t), 7.61-7.22 (2H, m) Example 71 ~0 C z H 5 ~
6-Ethyl-3,4-dihydro-2,2-dimethyl-4-(5-oxo-1-cyclopenten-1-yl)-2H-1,4-benzoxazine.
Physicochemical properties:
i) Melting point: 68-70C
ii) Elemental analysis (for Cl7H2lNO2) C (%) H(%) N (%) Calcd.: 75.25 7.80 5.16 Found : 75.30 7.95 -5.17 - 119 - ', . .. . . : , .
. - . , - ', . ~ . ' .
-.. . .
: . : ..
- : . , .:
..
iJ'';3 ~ ~
iii) NMR spectrum (CDCl3) (ppm): 1.11 (3H, t), 1.27 (6H, s), 2.54-2.72 (6H, m), 3-44 (2H~ s), 6.55-6.82 (3H, m), 7.06-7.17 (lH, t) Example 72 ~0 0zN ~ 0 ~
3,4-Dihydro-2,2-dimethyl-7-nitro-4-(5-oxo-1-cyclopenten-l-yl)-2H-1,4-benzoxazine.
Physicochemical properties:
i) Melting point: 88-89C
ii) Elemental anaIysis (for Cl5H16N2O4) C (%) H (%) N (~) Calcd.: 62.49 S.59 9.72 Found : 62.21 5.61 9.60 iii) NMR spectrum (CDCl3) (ppm): 1.35 (6H, s), 2.50-2.64 (2H, m), 2.68-2.79 (2H, m), 3.41 (2H, s), 6.68 (lH, s), 7.-35 (lH, t), 7.60-7.74 (2H, m) . :
' ' :
.. .
~ 13 ~
Example 73 NC ~ N ~ NC ~ N ~
In 15 ml of toluene were dissolved 0.5 g of 6~cyano-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazine, 0.33 g of cyclohexane-1,2-dione and a catalytic amount of p-toluenesulfonic acid and using a Dean-Stark trap, the solution was refluxed under heating for 4 hours. After cooling, the reaction mixture was washed with saturated aqueous sodium hydrogen carbor.~ate solution and aqueous sodium chloride solution and dried over anhydrous magnesium sulate and the solvent was distilled off under reduced pressure.
The residue was purified by silica gel column chromatography and the resulting crude crystals were washed with ethanol to give 0.5 g of 6-cyano-3,4-dihydro-2,2-dimethyl-4-(6-oxo-1-cyclohexen-1-yl)-2H-1,4-benzoxazine. ;
This compound has the following physicochemical properties.
.~ , .
i) Melting point: l66-l70C-, .
:' :
; .' ' ,' ' :~
2 J i.~ i~J r~ ~ ~
ii) Elemental analysis (for Cl-~H~8N2O2) C (%) H (%) N (%) Calcd.: 72.32 6.43 9.92 Found : 72.36 6.38 9.83 iii) NMR spectrum (CDCl3) (ppm): 1.34 (6H, s), 2.0-2.2 (2H, m), 2.5~2.7 (4H, m), 2.20 (2H, s), 6.60 (lH, d), 6.76 (lH, d), 6.8-7.0 (2H, m) Example 74-76 ~ he following compounds were synthesized in substantially the same manner as in Example 73.
Example 74 Me ~
NC ~ N ~
6-Cyano-3,4-dihydro-2,2-dimethyl-4-(4-methyl-5-oxo-1-cyclopenten-1-yl)-2H-1,4-benzoxazine.
Physicochemical properties:
i) Melting point: 106-108C
ii) Elemental analysis (for Cl7HI8N2O2) C (%) H (%) -N (%) Calcd.: 72.32 6.43 9.92 Found.: 72.49 6.50 9.88 `;
:
.
J ~;3 ~iJ.~
iii) NMR spectrum (CDCl3) (ppm): 1.26 (3H, d), 1.34 (6H, s), 2.1-3.1 ~3H, m), 3.43 (2H, s), 6.84 (lH, d), 7.0-7.2 (3H, m) Example 75 NC ~ N ~
6-Cyano-3,4-dihydro-2,2-dimethyl-4-(3-oxo-l-cyclopenten-1-yl)-2H-1,4-benzoxazine.
Physicochemical properties:
i) Melting point: 180-184C
i) Elemental analysis (for Cl6Hl6N2O2-0.1H2O) C (%) H (%) N (%) Calcd.: 71.15 6.05 10.37 Found : 71.23 6.10 10.10 iii) NMR spectrum (CDCl3) (ppm): 1.39 (6H, s), 2.4-2.6 (2H, m), 2.7-2.9 (2H, m), 3.55 (2H, sj, 5.73 (lH, s), 6.96 (lH, d), 7.34 (lH, dd), 7.68 (lH, d) ~ 123 -. . ~ .
~.
' ~Y~23''''3~
Example 7 6 ~s NC ~ N ~
6-Cyano-3,4-dihydro-2,2-dimethyl-4-(3-oxo-1-cyclohexen-l-yl)-2H-1,4-benzoxazine.
Physicochemical properties:
i) Melting point: 147-150C
ii) Elemental analysis (for C17Hl8Nz02) C (%) H (%) N(%) Calcd.: 72.32 6.43 9.92 Found : 72.40 6.48: 9.91 iii) NMR spectrum (CDCl3) (ppm): 1.35 (6H, s), 2.12 (2H, m), 2.44 (2H, t), 2.64 (2H, t),:3.48 (2H, s), 5.75 (lH, s), 6.93 (lH, d), 7.:23 (lH, d), 7.36 (lH, dd) Example 77 ~:
H ~ ~ Me ~ O
NC ~ l ~ ~ Me p-TsOII ~ Me O a t~luene NC ~ N
: - 124 -. ' ' . . .~
, 2~
In 2 ml of toluene were dissolved 0.5 g of 6-cyano-3,4-dihydro-2,2-dimethyl-2H-1,4 benzoxazine, 1.2 ml of 2,3-butanedione and a catalytic amount of p-toluenesulfonic acid and the mixture was stirred at 100C for 2 days. The solvent was then distilled off under reduced pressure and the residue was re-dissolved in toluene, washed with saturated aqueous sodium hydrogen carbonate solution and saturated aqueous sodium chloride solution, and dried over anhydrous magnesium sulfate. The solven-t was then distilled off and the residue was purified by silica gel column chromatography to give 0.15 g of 6-cyano-3,4-dihydro-2,2 dimethyl-4-(2,5-dimethyl-3-furyl)-2H-1,4-benzoxazine.
Physicochemical properties:
i) Melting point: 130-132C
ii) Elemental analysis (for C~7Hl8N2O2) C (%) H (%) N (%) Calcd.: 72.32 6.43 9.92 Found : 72.35 6.49 9.93 iii) NMR spectrum (CDCl3) (ppm): 1.36 (6H, s), 2.12 (3H, s), 2.24 (3H, s), 3.20 (2H, s), 5.80 (lH, s), 6.70 (lH, d), 6.76 (lH, d), 6.94 (lH, dd) Example 78-79 The following compounds were synthesized in substantially the same manner as in Example 73.
. ,,. ..... :
~t~
Example 78 ' ~
~0 02N ~Nl-3,4-Dihydro-2,2-dimethyl-6-nitro-4-(l-oxinden-2-yl)-2H-1,4-benzoxazine.
Physicochemical properties:
i) Melting point: 161-165 C
ii) Elemental analysis (for C19H~6N2O4) C (%) H (%) N (%) Calcd.: 67.85 4.79 8.33 Found : 67.89 4.90 8.22 iii) NMR spectrum (CDCl3) (ppm): 1-37 (6H, s), 3.66 (2H, s), 6.8-7.4 (6H, m), 7.76 (lH, dd), 8.04 (lH, d) :
, ~
', ~' '' ~ ' '. ' ., .
Example 79 ~~ COOC2Hs 02N ~ N~
~o~
4-(2-Ethoxycarbonylcyclopenten-1-yl)-3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine.
Physicochemical properties:
i) Melting point: 157-158C
ii) Elemental analysis (for Cl8Hz2N2O5-0-5H2O) C (%) H (%) N (%) Calcd.: 60.83 6.52 7.88 Found : 61.03 6.26 7.71 iii) NMR spectrum (CDCl3) (ppm): 1.20 (3H, t), 1.35 (6H, s), 1.76-2.09 (2H, m), 2.64-2.~4 (4H, m), 3.41 (2H, s), 4.11 (2H, q), 6.83 (lH, d), ; 7 59-7.77 (2~, m) :
.
, ' ' ' ' '' :
. ,, , ' ~' ~ , ~ ' Example 80 ~ ~ N-OMe NC ~ N ~ ' NC ~ N
In 3 ml of pyridine was dissolved 0.3 g of 6-cyano-3,4-dihydro-2,2-dimethyl-4-(5~oxo-1-cyclopenten-1-yl)-2H-1,4-benzoxazine followed by addition of 0.26 g of methoxyamine hydrochloride. The mixture was stirred at room temperature overnight and the solvent was then distilled off under reduced pressure. The residue was poured in water and extracted with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate and the solvent was distilled off under reduced pressure. Finally the residue was washed with ethanol-ether to give 0.26 g of 6-cyano-3,4-dihydro-4-(5-methoxyimino-1-cyclopenten-l-yl)-2,2-dimethyl-2H-1,4-benzoxazine.
This compound has the following physicochemical properties.
i) Melting point: 138-141C
ii) Elemental analysis (for Cl7HIgN302) C (%) H (%) N (%) Calcd.: 68.67 6.44 14.13 Found : 68.40 6.60 13.95 ;
- 128 - `~
,j , . . . . .
;, - . ` ' ' , ~J' ~ f'~
iii) NMR spectrum (CDC13) (ppm): 1.32 (6H, s), 2.4-2.8 (4H, m), 3.38 (2H, s), 3.84 (3H, s), 6.26 (lH, t), 6.78 (lH, d), 6.98 (lH, dd), 7.14 (lH, d) Exam~le 81 NC N ~ ~ OH
NC ~ N ~
In 20 ml of N,N-dimethylformamide was dissolved 1.0 g of 6-cyano-3,4-dihydro-2,2-dimethyl-2H-I,4-benzoxazine followed by addition of 0.24 g of sodium hydride. The mixture was stirred at 70C for 1 hour and-after cooling to room temperature, 0.5 ml of cyclopentene oxide was added.
The mixture was stirred at 70C for 3 hours. The reaction mixture was then allowed to cool, diluted with water and extracted with ethyl acetate. The extract was washed wlth water and aqueous sodium chloride solution and dried over anhydrous magnesium sulfate and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography and the resulting crude crystals were recrystallized from ethyl acetate-hexane to give 0.53 g - - : ' ' ' `
.
~ rl ~y ,^J r~
of 6-cyano-3,4-dihydro-4-(2-hydroxycyclopentan-1-yl)-2,2-dimethyl-2H-1,4-benzoxazine.
Physicochemical properties:
i) Melting point; 95-97C
ii) Elemental analysis (for Cl6H20N202) C (%) H (%) N (%) Calcd.: 70.56 7.40 10.29 Found : 70.40 7.46 10.23 iii) NMR spectrum (CDCl3) (ppm): 1.30 (6H, s), 1.4-2.2 (6H, m), 2.94 (2H, s), 3.8-4.3 (2H, m), 6.72 (lH, d, J=8.5 Hz), 6.92 (lH, dd, J=2.5, 8.5 Hz), 7.06 (lH, dd, J=2.5, 8.5 Hz) Example 82 ~ OH ~ O
N C ~ N 1 - --> N C ~ N
In 5 ml of methylene chloride was dissolved 0.2 ml of oxalyl chloride and at a constant temperature between -50C
and -60C, a solution prepared by dissolving 0.34 ml of dimeth~l sulfoxide in 1 ml of methylene chloride was added dropwise. The mixture was stirred for 2 minutes, after which -~
a solution of 0.54 g of 6-cyano-3,4-dihydro-2,2-dimetllyl-4-.~ .
: - .
~ r~
(2-hydroxycyclopentan-1-yl)-2H-1,4-benzoxaæine in 2 ml of methylene chloride was added dropwise. The mixture was further stirred for 15 minutes and 0.7 ml of triethylamine was added. The mixture was stirred for an additional 5 minutes, after which it was allowed to return to room temperature. The reaction mixture was diluted with 10 ml of water and extracted with methylene chloride. The extract was washed with aqueous sodium chloride solution and dried over anhydrous magnesium sulfate and the sol~ent was distilled off under reduced pressure. The residue was recovered by filtration, washed with ethanol and recrystallized from ethyl acetate to give 0.28 g of 6-cyano-3,4-dihydro-2,2-dimethyl-4-(2-oxocyclopentyl)-2H-1,4-benzoxazine.
Physicochemical properties:
i) Melting point: 172-175C
ii) Elemental analysis (for Cl6Hl8N2O2) C (%) H (%) N (%) Calcd.: 71.09 6.71 10.36 Found : 71.01 6.82 10.29 iii) NMR spectrum (CDCl3) (ppm): 1.32 (3H, s), 1.36 (3H, s), 1.7-2.6 (6H, m), 2.86 (2H, dd, J=3.5, 11.5 Hz), 4.0-4.3 (lH, broad s), 6.74 (lH, d, J=8.5 Hz), 6.80 (lH, d, J=2.5 Hz), 6.94 (lH, dd, J=2.5, 8.5 Hz) Example 83 ~ ~ BH3 0 02N ~ ~ _ _> 02N ~ N
To 9 ml of a solution of borane-tetrahydrofuran complex in tetrahydrofuran (lM) was added 1.30 g of 4-(2-furoyl)-3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine with ice-cooling. The mixture was then refluxed under heating with stirring for 2.5 hours. To this mixture was added 1.1 ml of methanol and after another hour of refluxing, the reaction mixture was poured in ice-water and extracted with ethyl acetate. The organlc layer was washed with water :
and dried over anhydrous magnesium sulfate and the solvent was distilled off. The residue was chromatographed on a silica gel column and elu-tion was carried out with hexane-toluene (2:1). The crude crystals from the eluate were recrystallized from 3 ml of ethanol to give 546 mg of 4-furfuryl-3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine.
This compound has the following physicochemical properties.
;, .
.
~ , . ' ,, 1 r~ ~
i) Melting point: 94-97C
ii) Elemental analysis (for Cl5Hl6N2O4) C (%) H (%) N (~) Calcd.: 62.49 5.59 9.72 Found : 62.44 5.51 9.76 iii) NMR spectrum (CDCl3) (ppm): 1.35 (6H, s), 3.13 (2H, s), 4.50 (2H, s), 6.3-6.4 (2H, m), 6.77 (lH, d), 3-36 (lH, t), 7.58 (lH, dd), 7.71 (lH, d) Example 84 H COOC2Hs OzN~N~ HC(OC2Hs) 3 ~ H2 < cooC2Hs CO2Et CO2Et EtO ~ -CO2Et ~ CO2Et 02N ~ N ~ + 02N ~ N~
(A) (~) A mixture of 2.08 CJ o 3j4-dihyclro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine, 2.96 g of e-thyl orthoformate and 2.40 g of diethyl malonate was stirred in a sealed tube at , 140C for 12 hours. After cooling, the solvent was distilled off and the residue was purified by silica gel column chromatography to give 0.33 g of diethyl 2-[1-(3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)ethoxymethyl]malonate (compound A) and 0.31 g of diethyl 2-(3,4-dihydro-2,2-dimethyl-6-nitro-2H 1,4-benzoxazin-4-yl)methylene malonate (compound B).
Compound A
i) Melting point: 71-74C
ii) Elemental analysis (for C20H28N2O8) C (%) H (%) N (%) Calcd.: 56.60 6.65 6.60 Found : 56.46 6.61 6.46 iii) NMR spectrum (CDCl3) (ppm)~ 1.5 (15H, m), 3.29 (2H, s), 3.72 (2H, q), 4.28 (4H, q)7 6.95 (lH, d), 7.9-8.1 (3H, m) Compound B
i) Melting point: 89-91C
ii) Elemental analysis (for Cl8H22N2O7) C (%) ~I (%) N (%) Calcd.: 57.14 5.86 7.40 Found : 56.93 5.80 7.27 iii) NMR spectrum (CDCl3) (ppm): 1.2-1.6 (12H, m), 3.36 (2H, s), 4.28 (4H, q)~ 6.95 (lH, d), 7.9-8.0 (3H, m) ', ~
, Example 85 0 ` NHMe 0~ 1 0 O z N ~ N 1- C H ~ N N ~ 0 2 N ,~ N ~ O E t In 3 ml of methylene chloride was dissolved 0.5 g of ethyl 4-(3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl) 4-oxo-2-butenoate followed by addition of 0.116 g of 40% methylamine in methanol. The mixture was stirred at room temperature for 4 days, at the end of which time the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography and the resulting crude crystals were washed with ethanol-hexane to give 0.2 g of ethyl 4-(3,4-dihydro-2,2-~dimethyl-6-nitro-2H-- 1,4-benzoxazin-4-yl)-3-methylamino-4-oxobutanoate.
This compound has the following physicochemical properties.
i) Melting poi.nt: 75-77C
ii) Elemental analysis (Cl7H23N3O6) ~ C (%) H (%) N (%) Calcd.: 55.88 6.34 -11.50 Found : 55.68 6.30 1].47 - 135 _ ` ` : :
.~ :
~: :
, ~: ~ S~) k.J ~3 iii) NMR spectrum (CDCl3) (ppm): 1.28 (3H, t), 1.36 (6H, 5), 2.42 (3H, s), 3.02 (2H, d), 3.6-3.8 (3H, m), 4-20 (2H, q), 6-90 (lH, d), 7.94 (lH, dd), 8.3-8.5 (lH, broad s) Example 86 ~0 ~0 N0z ¦
O~N ~ 0 In 5.2 ml of acetonitrile was dissolved 0.35 g of 3,4-dihydro-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-2H-1,4-benzoxazine followed by gradual addition of 0.22 g of nitronium tetxafluoroborate. The mixture was stixred for 30 minutes and, then, poured in ice-water and extracted with ethyl acetate. The organic layer was dried and concentrated under reduced pressure and the residue was chromatographed on a silica gel column. The crude crystals obtained from the eluate were recrystallized from chloroform~ether -to glve 0.07 g oE 3,4-dihydro-2,2-dimethyl-5,7 dinitro-4-(2-oxo-1-pyrrolidinyl)-2H-1,4-benzoxazine.
This compound has the following physicochemical properties.
~ .
' .
~h '~ if ~, C (%) H (~) N (%~
Calcd.: 50.00 4.80 16.66 Found : 49.40 4.76 16.Q~
iii) NMR spectrum (CDCl3~
(ppm): 1.44 (3H, s), 1.46 (3H, s), 1.92-2.44 (4H, m), 3.18-3.61 (4H, m), 7.76 (lH, d), 7.90 (lH, d~
The Eollowing compound was synthesized i~
substantially the same manner as in ~xample 4.
~xam~le 87 ~0 02N ,~
3,4-Dihydro-2,2-dimethyl-4-(2-oxo-1-piperidyl)-6-nitro-2X-1,4-benzoxazine~
ghysicochemical properties:
i) Melting point: 166-168C
ii) Elemental analysis (for Cl5HlgN3O
C(~ 3 C~lcd.: 59.01 6.27 13.76 Found: 5a.89 6.32 13.73 iii) NMR spect~um (DMSO-d6) (ppm):1.33 (3H, s), 1.40 (3X, s), 1.7-2.1 (2H, m), 2.4-2.6 ~4H, m), 3.3-3.7 (4X, m3, 6.92 (lH, d), 7.28 (lH, d), 7.59 (lH, d~
.
''- , ~ , ' ' . . .
Exampl~ A 2~29~9 ,' ~ COOC2~5 02N ~ N ~ 0 BrCHzCO2C2Hs . 02N ~ ~ ~ 0 A mixture of 6.66 g of 3,4-dihydro-2,2-dime~hyl-6-nitro~3-oxo-2H-1,4-benzoxazine, 5.51 g of ethyl bromoacetate, 4.56 g of potassium carbonate and 20 ml of ace~onitrile was ,refluxed under heating for 2.5 hours. Then, 10 ml of N,N-dimethylformamide was added and the mixture was stirred at 80C for 2 hours. To this mixture was added 2.80 g of ethyl bromoacetate. After an hour of~stirring at 80C, 2.28 g of potassium carbonate was added and the mixture was further stirred at 80C for 1 hour. The reaction mixture was then ., .. _ . .. . ..
.,,,............ . . -, , : .
,~
' ' ~ ~, . ' ' :
'- . ' ~: ' . , , ~
concentrated under reduced pressure and the residue was chromatographed on a silica gel column, elution being carried out with hexane-ethyl acetate (10:1). The crystals from the eluate were recrystallized from ethyl acetate-hexane to give 7.4 g of ethyl (3,4-dihydro-2,2-dimethyl-6-nitro-3-oxo-2H-1,4-benzoxazin-4-yl)acetate. This compound has the following physicochemical properties.
i) Melting point: 67-68C
ii) Elemental analysis (for C~4Hl6N2O6) C (%) H (%) N (%) Calcd.: 54.54 5.23 9.09 Found : 54.49 5.24 9.06 iii) NMR spectrum (CDCl3) S (ppm): 1.32 (3H, t), 1.59 (6H, s), 4.28 (2H, q), 4.69 (2H, s), 7.08 (lH, d), 7.62 (lH, d), 7.97 (lH, dd) Example B
The same procedure as Example A was followed to give the following compound.
~ C0zEt 0zN ~ N ~ 0 , .
~ .
'. ' ~ ~ S~
Ethyl (3,4-dihydro-6-nitro-3-oxo-2H-1,4-benzoxazin-4-yl)acetate Physicochemical properties:
i)Melting point: 102-103C
ii) Elemental analysis (for Cl2HI2N206) C (%) H (%) N(%) Calcd.: 51.43 4.32 10.00 Found : 51.52 4.28 10.07 iii) NMR spectrum (CDCl3) (ppm): 1.32 (3H, t), 4.28 (2H, q), 4.68 (2H, s), 4.78 (2H, s), 7.08 (lH, d), 7.62 (lH, d), 7.94 (lH, dd) Example C
H O
NO~ ~ ~ + BrCHze-NaH
in DM~ O
C~12~
I
NO2 ~ N ~ O
i.
- 139 - ~
; .
.. . .
.... . ,- : .
- : , . . .
. ~. . ,, . . ~ :
, - ' . ' ~ ' ' - ~ : . .
In an argon gas stream, 2.0 g of 3,4-dihydro-2,2-dimethyl-6-nitro-3-oxo_2H_l,4~benzoxazine was added gradually to 0.4 g of 60~ sodium hydride in oil in 40 ml of dry N,N-dimethylformamide. The mixture was stirred at room temperature for 1 hour and 2.68 g of phenacyl bromide was added. The mixture was stirred at room temperature for l hour, after which the solvent was distilled off under reduced pressure. The residue was diluted with 50 ml of water and extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated under,reduced pressure. The residue was chromatographed on a silica gel column and elution was carried out with methylene chloride-ethyl acetate. Recrystallization from ethyl acetate-ether gave 2.04 g of 3,4-dihydro-2,2-dimethyl-6-nitro-3-oxo-4-phenacyl-2H-1,4-benzoxazine.
Physicochemical properties: -i) Elemental analysis (Cl8Hl6N2O5) C (%) H (%) N (%) Calcd.: 63.53 4.74 8.23 Found : 63.61 4.72 8.05 ii) Mass spectrum (EI): m/z 340 (M+) Example D-F
The same procedure as Example C was followed to give the following compounds. - -.
' ' ' '' Example D
1l ~ -CHzC N
NO 2 ~ N ~ O
3,4-Dihydro-2 r 2-dimethyl-6-nitro-3-oxo-4-[(2-pyridylcarbonyl)methyl]-2H-1,4-benzoxazine .
Physicochemical properties:
i) Melting point: 177-178C
ii) Elemental analysis (Cl7HIsN3s) C (~) ~ (%) N (~) Calcd.: 59.82 4.43 12.31 Found : 59.87 4.45 12.21 iii) Mass spectrum (EI): m/z 341 (Mt) Example E
:
CHzCOCH3 NO~ ~ N ~ O
:~.
4-Acetonyl-3 r 4-dihydro-2;2-dimethyl-6-nitro-3-oxo:-2H~ ~:
1,4-benzoxazine :` ; '; ' " ''' ' ' ' '' , $ ~
Physicochemical properties:
i) Melting point: 136-]37C
ii) Elemental analysis (Cl3H~4N2Os) C (%) H (%) N (%) Calcd.: 56.11 5.07 10.07 Found : 56.11 5.03 10.04 iii) Mass spectrum (EI): m/z 278 (M+) Example F
~0 02N ~ N ~ 0 3,4-Dihydro-2,2-dimethyl-6-nitro-4-(2-oxocyclopentyl)-2H-1,4-benzoxazin-3-one Physicochemical properties:
i) Melting point: 141-142C
ii) Mass spectrum (EI): m/z 304 (M+) iii) NMR spectrum (CDCl3) (ppm): 1.47 (3H, s), 1.59 (3H, s), 1.80-2.96 (6H, m), 4.26 (lH, t), 7.08 (lH, d), 7.79 (lH, d), 7-96 (lH, dd) 2~7,~
~xamPle G
~, COOEt ~ CONHMe 0 2 N ~ N ~ O ~ O z N ~ N ~ O
In 1.5 ml of methylene chloride were dissolved 0.5 g of ethyl (3,4-dihydro-6-nitro-3-oxo-2H-1,4-benzoxa7in-4-yl)acetate and 0.16 g of 40% methylamine-methanol and the mixture was allowed to stand at room temperature for 3 days.
The solvent was then distilled off and the residue was recrystallized from methylene chloride-hexane to give 0.2 g of 2-(3,4-dihydro-6-nitro-3-oxo-2H~1,4-benzoxazin-4-yl)-N--methylacetamide. This compound has the following physicochemical properties.
i) Melting point: 180-185C
ii) Elemental analysis (CllHIlN3O5-0.1H2O) C (%) H (%) N (%) Calcd.: 49.48 4.23 15.74 Found : 49.32 4.25 15.73 iii) NMR spectrum (CDC13) (ppm): 2.82 (3H, d), 4.56 (2H, s), 4.78 (2H, s), 5.9-6.1 (lH, broad s), 7.06 (lH, d), 7.94 (lH, dd)j 7-98 (lH, d) .
.... .
Example H
The same procedure as Example G was followed to give the following compound.
O z N ~ N ~O
2-(3,4-Dihydro-2,2-dimethyl-6-nitro-3-oxo-2H-1,4-benzoxazin-4-yl)-N-methylacetamide Physicochemical properties:
i) Melting point: 212-214C
ii) Elemental analysis (Cl3HI5N3Os) C (%) H (%) N (%) Calcd.: 53.24 5.16 14.33 Found : 53.06 5.10 14.35 iii) NMR spectrum (CDCl3) (ppm): 1.56 (6H, s), 2.86 (3H, d), 4.54 (2H, s), 5.86 (lH, broad s), 7.06 (lH, d), 7.86-7.98 (2H, m) .
.:
' ~
Formulation Example 1 Compound of Example 1 0.1 mg Lactose 63 mg Corn starch 16 mg Magnesium stearate 0.9 mg 80 mg The compound of Example 1, lactose and corn starch are evenly mixed and wet-granulated using corn starch as the binder. Then, magnesium stearate is added and the composition is compression-molded to give tablets.
Formulation ExamPle 2 The following ingredients are filled into ampules and, after sealing by fusion, sterilized at 115C for 30 minutes.
. Composition (per milliliter) The compound of Example 1 50 ~g Sodium chloride 9 mg Distilled water for injection To make 1 ml Nhile the invention has been described in detail and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that the various changes and modifications can be made therein without departing from the spirit and scope thereof.
- 145 _
i) Meltin~ point: 144-146C (ethanol) ii) Elemental analysis (for ClsHl6N23) C (%) H (%) N (96) Calcd.: 66.16 5.92 10.29 Found : 66.03 5.93 10.21 iii) NMR spectrum (CDCl3) (ppm): 1.38 (3H, s), 1.41 (3H, s), 2.2-2.7 (2H, m), 2.99 (2H, d), 4.2-4.8 (3H, m), 6.82 (lH, d), 6.89 (lH, d), 7.05 (lH, dd) _ 77 -.
.
., , .
`
Example 33 o OH
CH 2C-~ Borane- THP CH 2CH--N0 2~ 0 ~O2~
In an argon gas stream, 1.5 g of 3,4~dihydro-2,2-dimethyl-6-nitro-3-oxo-4-phenacyl-2H-1,4-benzoxazine was added to 30 ml of a 1.0 M solution of borane in tetrahydrofuran at O - 10C.
The above solution was stirred at 70C for 1 hour, at the end of which time 5.6 ml of methanol was gradually added.
After stirring at 70C for 15 minutes, 5.6 ml of concentrated hydrochloric acid was added and the mixture was further stirred at 70C for 1 hour. The solvent was then distilled off and the residue was diluted with 30 ml of water, made alkaline with potassium carbonate, and extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and the solvent was distilled off. The residue was purified by silica gel column chromatography (eluent: ethyl acetate-n-hexane) to give 1.67 g of 3,4-dihydro-4-(2-hydroxy-2-phenylethyl)-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine as oil.
Mass spectrum (EI): m/z 328 (M~) .
' .
Example 34 C112CHOH - ~ CH2C -NOz ~ N ~ Swern ~xid ~0 In an argon gas stream, 0.7 ml of dry dimethyl sulfoxide was added gradually to a solution of 0.41 ml of oxalyl chloride in lO ml of dry methylene chloride previously cooled from -50 to -60C and the mixture was stirred at the same temperature for 2 minutes.
Then, 20 ml of a solution of 1.5 g of 3,4-dihydro-4-(2-hydroxy-2-phenylethyl)-2,2-dimethyl-6-nitro-2H-l,4 benzoxazine in dry methylene chloride was added o~er a period of 5 minutes and the mixture was stirred at the same temperature as above for 15 minutes.
To this reactlon mixture was added l.3 ml of triethylamine and, at room temperature, the mixture was diluted with 30 ml of water and extracted with methylene chloride. The extract was dried over anhydrous magnesium sulfate and the solvent was distilled off. The residue was ~; recrystallized ~rom ether to give l.31 g of 3,4-dihydro-2,2-dimethyl-6-nitro-4-phenacyl-2~1-l,4-benzoxazine melting at 125 - 128C.
~: .
:
: . `
. ~ , .
, ~"i~
Physicochemical properties:
Elemental analysis (for Cl8HI8N2O4) C (%) H (%) N (%) Calcd.: 66.25 5.56 8.58 Found : 66.16 5.62 8.47 Mass spectrum (EI) : m/z 326 (M+) Example 35-40 The compounds listed in the following table were synthesized by Process 2 as in Examples 33 and 34.
- 80 ~
~",~
H Rl7 R2 ~ N ~
H ~R5 H
Example R2 R5 R6 R7 Starting Compound OH ICH2 CO <
NO2 CH3 CH3 -CH2-CH- ~ 02N ~ ~ ~ O
. fH IH2-co-cH3 36 No2 CH3 CH3-CH2-CH-CH3 02N ~ N~o o I The compound 37 N2 CH3 CH3 -CH2-C ~ of Example 3 N
O
ll The compound 38 No2 CH3 CH3 -CH2-C-CH3 of Example 36 ~0 39 N02 CH, 5H3 ~ ~ 07N N
: I I The compound ~ 40 NO2 CH3~ CH3 ~ of Example 39 , ~ ~
:`
`;
' These compounds have the follow.ing physicochemical properties.
Example 35 3,4-Dihydro-4-[2-hydroxy-2-(2-pyridyl)ethyl]-2,2-dimethyl-6-nitro-2H~1,4-benzoxazine Mass spectrum(EI) : m/z 329 (M+) Example 36 3,4-Dihydro-4-(2-hydroxypropyl)-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine Mass spectrum (EI) : m/z 266 (Mf) Example 37 3,4-Dihydro-2,2-dimethyl-6-nitro-4-~(2-pyridylcarbonyl)methyl]-2H-1,4-benzoxazine Melting point: 106-107C
Elemental analysis (for Cl7Hl7N304) C (%) H (%) N (%) -Calcd.: 62.38 5.23 12.84 Found : 62.38 5.23 12.76 Mass spec=r m (GC-MS) : m/z 327 (M~) :' .
. :
: ' .
Example 38 4-Acetonyl-3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine Melting point: 98-99C
Elemental analysis (for Cl3H~6N2O4) C (%) H (%) N (%) Calcd.: 59.08 6.10 10.60 Found : 58.92 6.21 10.52 Mass spectrum (GC-MS) : m/z 264 (M~) Example 39 3,4-Dihydro-2,2-dimethyl-4-(2-hydroxycyclopentyl)-6-nitro-2H-1,4-benzoxazine Physicochemical propertles:
i) Elemental analysis (for Cl5H20N2O4) C (%) H (%) N (%) Calcd.: 61.63 6.90 9.58 Found : 61.60 7.00 9.53 ii) Melting point: 87-88C (n-hexane) iii~ Mass spectrum (mlz) : 292 (M+) (EI) i~) NMR spectrum (CDCl3) (ppm): 1.32 (3H, s), 1.39 (3H, s), 1.58-2.22 (6H, m), 3.26 (2H, s), 3.80 (lH, m), 4.50-4.68 (lH, m), 6.79 (lH, d), 7.59 (lH, d), 7.60 (lH, dd) .
.' ' , .
:, ', ~ , ~,~J~ 3~9 Example 40 3,4-Dihydro-2,2-dimethyl-6-nitro-4-(2-oxocyclopentyl)-2H-1,4-benzoxazine Physicochemical properties:
i) Elemental analysis (for Cl5Hl8N2O4) C (%) H (%) N (%) Calcd.: 62.06 6.25 9.65 Found : 61.84 6.38 9.52 ii) Melting point: 118-119C (ether-n-hexane) iii) Mass spectrum (m/z): 290 (M-~) (EI) iV) NMR spectrum (CDCl3) (ppm)o 1-34 (3H, s), 1.41 (3H, s), 1.75-2.60 (6H, m), 2.83 (lH, d), 2.99 (lH, d), 4.22~4.44 (lH, m), 6.79 (lH, d), 7.51 (lH, d)~ 7.61 (lH, dd) Exam~le 41 (1) NO
H
OzN ,~ ~ O~N ~N~
~ ' .: .
.
, ~ :
, :: . , :' ' , ~
' ' , , ', , : -~.J
(1) In a mixture of 34 ml of methanol and 2.07 ml of acetic acid was dissolved 3 g of 3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine. Then, a solution of 2.0 g of sodium nitrite in 6.6 ml of water was added dropwise and the mixture was stirred at room temperature overnight. The reaction mixture was neutralized with aqueous sodium hydroxide solution, concentrated under reduced pressure and extracted with chloroform. The organic layer was washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to give 3.2 g of 3,4-dihydro-2,2-dimethyl-6-nitro-4-nitroso-2H-1,4-benzoxazine.
This compound has the following physicochemical properties.
i) Melting point: 104-105C
ii) Elemental analysis (for Clo~llN34) C t%) H (%) N (%) Calcd.: 50.63 4.67 17.71 Found : 50.36 4.63 17.71 iii) NMR spectrum (CDCl3) (ppm): 1.37 (6H, s), 3.87 (2H, s), 7.06 (lH, d), 8.08 (lH, dd), 8.90 (lH, d) , ' '' ' ' .
(2) 02N ~ ~ ~ 02N ~11~
(2) In 69 ml of methanol was dissolved 2.29 g of 3,4-dihydro-2,2-dimethyl-6-nitro-4-nitroso-2H-1,4-benzoxazine and the solution was cooled on an ice bath. After addition of a solution of 1.16 g of sodium hydroxide in 8.1 ml of water to the above solution, 3.13 g of formamidinosulfinic acid was gradually added. The mixture was stirred at room temperature overnight and, then, concentrated. The concentrate was subjected to column chromatography (eluent: hexane-ethyl acetate = 9:1) to give 0.4 g of 4-amino-3j4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine Recrystallization from ether-hexane gave 0.28 g of the object compound.
This compound has the following physicochemical properties.
i) Melting point: 83-85C
ii) Elemen-tal analysis (foI Clo C (%) H (%) N (~) Calcd.: 53.81 5.87 18.82 Found : 53.75 5.80 18.93 ; .. ' ~ 86 -.
- ': . . ' ~ :
:, . .
. ,: .
~ ', '' ' :
~d ~ 3 iii) NMR spectrum (CDCl3) (ppm): 1.41 (6H, s), 3.18 (2H, s), 6.77 (lH, d), 7.66 (lH, dd), 8.06 (lH, d) (3) NH2 NHC0'^\ /^- C
0zN ~ N ~ 02N ~ N
(4) ~0 ~ ~ 02N
(3) In 4 ml of methylene chloride was dissolved 0.35 g of 4-amino-3,4-dlhydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine and the solution was cooled on an ice bath. To this solution was added 0.16 g o-f triethylamine followed by dropwise addition of a solution of 0.18 ml of 4-chlorobutyryl chloride in 1.4 ml o-f methylene chloride. ~fter 3~0 minutes, the reaction mixture was~dlluted wlth wa-~er and extracted with chloroform. The organic layer was dried o~er anhydrous magnesium sulfate and~concentrated under reduced pressure.
The concentrate was crystalllzed from ether to give 0.43 g of crude crystals of 9-chloro-N-(3,4-dlhydro-2,2-dimethyl-6-.
- a7 -.:
. ' ' ~ .
r'.~ ',J i ~
nitro-2H-1,4-benzoxazin-4-yl)butyrylamide. q~he crude crystals were used without purification in the next reaction.
(4) In 8 ml of N,N-dimethylformamide was dissolved 0.41 g of the above amide and the solution was cooled on an ice bath. Then, 0.14 g of potassium tert-butoxide was gradually added. The mixture was stirred with ice-cooling for 1 hour, after which it was diluted with water and extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate and filtered. ~he filtrate was concentrated under reduced pressure and crystallized from ether. The crude crystals were recrystallized from ethanol to give 0.16 g of 3,4-dihydro-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-6-nitro-2H-1,4-benzoxazine.
This compound has the following physicochemical properties.
i) Melting point: 141-143 ii) Elemental analysis (for Cl4Hl7N3O4) C (%) H (~) N (~) Calcd.: 57.72 5.88 14.42 Found : 57.61 5.89 14.40 iii) NMR spectrum (CDCl3) (ppm): 1.41 (3H, s), 1.49 (3H, s), 2.1 2.7 (4H, m), 3.15 (lH, d), 3.4-3.8 (3H, m), 6-84 (lHt d), 7.46 (lH, d), 7.70 (lH, dd) ::
~ J~ J~L~
Example 42-44 The following compounds were synthesized by Process 3 as in Example 41.
R~ N~
Example No. R2 R3 R4 R7 Starting Compound IHCOCH2CH2CH2Cl 42CN CH3 CH3 ~ ~ O ~ O 1 . INH2 43Br CH3 CH3 -NHCOCH3 Br ~ N~
INHCOCH2CH2CH2Cl 44H CH3 ~H ~ O ~ O ~
These compounds have the following physicochemical properties.
~ - 89 -Js~
Example 42 6-Cyano-3,4-dihydro-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-2H-1,4-benzoxazine i)Melting point: 149-150C
ii) Elemental analysis (for ClsHl7N3o2) C (%) H (%) N (%) Calcd.: 66.40 6.32 15.49 Found : 66.29 6.08 15.51 iii) NMR spectrum (CDCl3) (ppm): 1.38 (3H, s), l,45 (3H, s), 2.1-2.6 (4H, m), 3.11 (lH, d), 3.4 3.7 (3H, m), 6.74-6.84 (2H, m), 7.04 (lH, dd) Example 43 N-(6-Bromo-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-4-yl)acetamide i)Melting point: 167-168C -ii) Elemental analysis (for Cl2HIsN22Br) C (%) H (%) N (%) Br (%) Calcd.: 48.18 5.05 9.36 26.71 Found : 48.14 5.01 9.29 26.51 iii) NMR spectrum (CDCl3) tppm): 1.36-1.45 (6H, m), 2.06, 2.12 (3H, s x 2), 3.16, 3.30 (2H, s x 2), 6.56-6.97 (3H, m) . ~ . , , ~ , ' ~,. ~. - ', . , , ' ~'. ' , 2 ~
Example 44 3,4-Dihydro-2,2-dimethyl-4-(2-oxo-1-pyrrodinyl)-2H-1,4-benzoxazine i) Melting point: 139-141C
ii) Elemental analysis (for C~4HI8M2O2) C (%) H (%) N (%) Calcd.: 68.27 7.37 11.37 Found : 67.75 7.44 11.26 iii) NMR spectrum (CDCl3) (ppm): 1-38 (3H, s), 1.46 (3H, s), 2.04-2.58 (4H, m), 3.0-3.6 (4H, m), 6.51-6.84 (4H, m) Example 45 ~ - ~ N~o 0zN ~ N ~ HzN
To a solution of 3.01 g of 2-(3,4-dihydro-2,2-dlmethyl-6-nitro-1,4-benzoxazin-4-yl)pyridine N-oxide in 50 ml of methanol was added an aqueous solution of 10.9 g of ammonium chloride (50 ml) at room temperature. Then, with ice-cooling, 13.1 g of zinc dust was added and the mixture was stirred at 3C for 15 hours. The insolubles were 2 ~ 9 filtered off and the filtrate was concentrated, diluted with water and extracted with chloroform. The organic layer was dried and the solvent was distilled off. The residue was chromatographed on a silica gel column and elution was carried out with chloroform-methanol (50:1). The eluate gave 1.86 g of 2-(6-amino)-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-4-yl)pyridine N-oxide. This compound has the following physicochemical properties.
i) Melting point: 200~202C
ii) Elemental analysis (for ClsHl7N3o2-o.lH2o) C (%) H (%) N (%) Calcd.: 65.97 6.35 15.39 Found : 65.94 6.35 15.39 iii) NMR spectrum (CDCl3) ~ (ppm): ]..30 (6H, s), 3.28 (2H, broad s), 3.69 (2H, s ), 6.19-7.49 (6H, m), 8.23 (lH, m) Example 46 I~N~o , ~N~ o H zN~N~ C~l3C0NI~ N~-... :
- . ~~ ., , To a solution of 0.474 g of 2-(6-amino-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-4-yl)pyridine N-oxide in 5 ml of acetic anhydride was added 3 drops of pyridine and the mixture was stirred at room temperature for 63 hours. After concentration, the residue was dissolved in chloroform, washed with saturated aqueous sodium hydrogen carbonate solution, dried and concentrated. The residue was recrystallized from chloroform-ether to give 0.285 g of 2-(6-acetamido-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-4-yl)pyridine N-oxide.
This compound has the following physicochemical properties.
i) Melting point: 290-295C (decompn.) ii) Elemental analysis (for C~7Hl9N3O3-0.1H2O) C (%) H (%) N (%) Calcd.: 64.79 6.14 13.33 Found : 64.74 6.18 13.20 iii) NMR spectrum (CDCl3) (ppm): 1.30 (6H, s), 2.04 (3H, s), 3.65 (2H, s), 6.68-7.64 (6H, m), 8.18 (lH, m) Example 47 ~1 l N~o C l13 i O z N l~ N~_ - g3 -~,J~J~ 3 The following compound was synthesi~ed in substantially the same manner as in Example 46.
2-(3,4-Dihydro-2,2-dimethyl-6-methanesulfonamido-2H-1,4-benzoxazin-4-yl)pyridine N-oxide.
i) Elemental analysis (for Cl6Hl9N304-0.5H20) C (%) H (%) N (%) S (%) Calcd.: 53.62 5.62 11.72 8.95 Found : 53.74 5.33 11.68 9.21 ii) NMR spectrum (CDCl3+DMSO-d6) (ppm): 1.28 (6H, s), 2.84 (3H, s~, 3.51 (2H, s), 6.24-8.40 (7H, m), 9.12 (lH, broad s) iii) Mass spectrum (m/z): 349 (M+) Example 48 o O CO2H
~ ~ OEt Saponification ~
02N ~ N ~ ~ OzN \ ~ N
In 2 ml of ethanol was dissolved 0.5 g of ethyl trans-4-(3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)-4-oxo-2-butenoate followed by addition of 1.5 ml of an aqueous solution of 0.06 g of sodium hydroxide. The mixture was stirred at room temperature for 2 hours. The ethanol was distilled off under reduced pressure and the residue was adjusted to pH 4 with 1 N hydrochloric acid~ The resulting , ; . . ' .,; . ., ', ' '' : ' 2~J~jr~
precipitate was recovered by filtration and washed with water and ethanol to give 0.31 g of trans-4-(3,4-dihydro-2,2-dimethyl-6-nitro-2H-l/4-benzoxazin-4-yl)-4-oxo-2-butenoic acid.
This compound has the following physicochemical properties.
i) Melting point: 222-226C
ii) Elemental analysis (for Cl4HI4N2O6) C (%) H (%) N (%) Calcd.: 54.90 4.61 9.15 Found : 54.90 4.70 9.08 iii) NMR spectrum (DMSO-d6) (ppm): 1.32 (6H, s), 3.86 (2H, s)-, 6.70 (lH, d), 7.08 (lH, d), 7.48 (lH, d), 7.96 (lH, dd), 8.4-8.8 (lH, broad s) Example 49 ~ COO~
O ~N ~ N
, .. .
.
The following compound was synthesized in substantially the same manner as in Example 48.
(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)acetic acid Physicochemical properties:
i) Melting point: 162-164C (decompn.) (hexane-ethyl acetate) ii) Elemental analysis (for Cl2Hl4N205) C (%) H (%) N (%) Calcd.: 54.13 5.30 10.52 Found : 53.95 5.22 10.58 iii) NMR spectrum (DMSO-d6) (ppm): 1.29 (6H, s), 3.24 (2H, s), 4.22 (2H, s), 6.83 (lH, d), 7.34 (lH, d), 7.50 (lH, dd), 12.84 (lH, broad s).
iii) Mass spectrum (m/z): 267 (M'~l). Fab(pos ) Example 50 O O
~ OEt ~ NHMe 02N ~ ; ~ OzN ~ N ~
To 1.00 g of ethyl (3,4-dihydro-2,2-dimethyl-6-ni-tro-2H-1,4-benzoxazin-4-yl)acetate was added 5 ml of methylamine .. , ; . :; :
. -. . .. . , , :
- , . .
,, . : . .
~3~ 3~
(40% in methanol) and the mixture was stirred at 100C for 1 hour. The reaction mixture was then concentrated under reduced pressure to give crude 2-(3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-~enzoxazin-4-yl)-N-meth~-~lacetamide. This product was washed with n-hexane-ethyl acetate to obtain 950 mg of crude crystals. Recrystallization from ethyl acetate-n-hexane gave 866 mg of the object compound.
This compound has the following physicochemical properties.
i) Melting point: 127-128C
ii) Elemental analysis (for Cl3Hl7N3O4) C (%) H ~%) N (%) Calcd.: 55.91 6.14 15.05 Found : 55.93 6.11 15.16 iii) NMR spectrum (CDCl3) (ppm): 1.40 (6X, s), 2.86 (3H, d)-, 3.18 (2H, s), 3.93 (2H, s), 6.18 (lH, broad s), 6-82 (lH, d), 7-42 (lH, d), 7.66 (lH, dd Example 51 to 55 Using the ester compounds synthesized by Process 4, the following compounds were obtained in otherwise the same manner as Example 50.
: . :
. ' : ' ~
J '~
-o Example No. R2 R5 R6 R7 Starting Compound 51 CN CH3 CH3 -CH2CONHCH3 NC ~ N ~ H2NCH3 52 N2 CH3 CH3 -CH2CONHC2H5 02N~[~N~ H2NC2H5 .. , CH2COOC2H5 53 NO2 CH3CH3 -CH2CONHCH2CH20H2 ~ N ~ H2NCH2CH20H
CEI3 CH ( CH3 ) COOC2H5 54 NO2 CH3 ~H3 CH-CONHCH302N ~ N ~ H2NCH3 o COCOOC2H5 NO2 CH3 cl3 -C~CONHCH3 02N ~ ~ H2NCH3 .
- : : ' . :' ' , ,, - ~ ' ' ` ' :
' :: . :' . ,' ' c,O ~ r E mPle 51 2-(6-Cyano-3,4-dih~dro-2,2-dimethyl-2H-1,4-benzoxazin-4-yl)-N-methylacetamide.
Physicochemical properties:
i) Melting point: 150-151C
ii) Elemental analysis (for ClbH~7N3O2) C (%) H (%) N (%) Calcd.: 64.85 6.61 16.20 Found : 64.85 6.59 16.29 iii) NMR spectrum (CDCl3) (ppm): 1.39 (6H, s), 2.87 (3~, d), 3.17 (2H, s), 3.85 (2H, s), 6.75-6.86 (2H, m), 7.05 (lH, dd) Example 52 2-(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)-N-ethylacetamide.
Physicochemical properties:
i) Melting point: 115-116C
ii) Elemental analysis (for Cl~,Hl~N3O4) C (%) H (%) N(%) Calcd.: 57.33 6.53 14.33 Found : 57.24 6.57 14.34 _ 99 _ , .
~ J ~, 9J~ ~39 iii) NMR spectrum (CDCl3) (ppm): 1.12 (3H, t), 1.40 (6H, s), 3.19 (2H, s), 3.34 (2H, m), 3.91 (2H, s), 6.17 (lH, broad s), 6.82 (lH, d), 7.44 (lH, d), 7.66 (lH, dd) Example 53 2-(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)-N-(2-hydroxyethyl)acetamide.
Physicochemical propertles:
i) Melting point: 146-147C
ii) Elemental analysis (for Cl4HlsN3s) C (%) H (%) N (%) Calcd.: 54.36 6.19 13.58 Found : 54.29 6.21 13.49 iii) NMR spectrum (CDCl3) (ppm): 1.40 (6H, s), 1.64 (lH, broad s), 3.19 (2H, s), 3.34--3.82 (4H, m), 3.93 (2H, 5j, 6.72 (lH, broad s), 6.81 (lH, d), 7.43 (lH, d), 7.64 (lH, dd) Example 54 2-(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)-N-methylpropionamide.
Physicochemical properties:
i) Melting point: 181-182C
.
... ..
~` . . ~ .
~ 3 ii) Elemental analysis (for Cl4Hl9N30") C (%) H (%) N (%) Calcd.: 57.33 6.53 14.33 ~ ound : 57.27 6.54 14.34 iii) NMR spectrum (CDCl3) (ppm): 1.38 (6H, s), 1.45 (3H, d), 2.86 (3H, d), 3.05 (2H, s), 4.43 (lH, q), 6.14 (lH, broad s), 6.83 (lH, dd), 7.50-7.75 (2H, m) Example 55 2-(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)-N-methyl-2-oxoacetamide.
Physicochemical properties:
i) Melting point: 129-130C
ii) Elemental analysis (for Cl3HI5N305) C (%) H (%) N (%) Calcd.: 53.24 5.16 14.33 Found : 53.04 5.05 14.25 iii) NMR spectrum (CDCl3) (ppm): 1-39 (6H, s), 2.95 (3H, d), 4.28 (lH, broad s), 6.93 (lH, d), 7.99 (lH, dd), 9.87 (lH, broad-s) .
- ]01 -:, . , . :
Example S6 COOII / CH :~
CON\
~C~13 02N ~ N~ 1) SOC Q 2 < C H a - ~N ~
In 6 ml of chloroform were dissolved 1.0 g of (3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-~l)acetic acid and 1.34 g of thionyl chloride followed by addition of 2 drops of pyridine. The mixture was refluxed for 5 hours, at the end of which time it was concentrated under reduced pressure to give the acid chloride as a crude product.
The above crude acid chloride was dissolved in 5 ml of chloroform and the solution was added dropwise to a mixed solution of 0.93 g of dimethylamine hydrochloride and 1.15 g of triethylamine in 20 ml of chloroform with ice-cooling.
The mlxture was then stirred at room temperature for 4 hours and concentrated. The residue was subjected to silica gel chromatography using hexane-ethyl acetate (3~ 3) as the eluent to give 0.46 g of 2-(3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)-N,N-dimethylacetamide, which was then recrystallized from ethyl acetate-hexane. This compound was found to have the following physicochemical properties.
; - 102 -~. .
: .
' i) Melting point: 179-180C
ii) Elemental analysis (for Cl4HlgN304) C (%) H (%) N (%) Calcd.: 57.33 6.53 14.33 Found : 57.26 6.48 14.28 iii) NMR spectrum (CDCl3) (ppm): 1-38 (6H, s), 2-99 (3H, s), 3.12 (3H, s), 3.23 (2H, s), 4.18 (2H, s), 6.79 (lH, d), 7.31 (lH, d), 7.60 (lH, dd) iv) Mass spectrum (m/z): 293 (M+) Example 57-58 The following compounds were synthesized in substantially the same manner as in Example 56.
Example 57 02N ~ ~/N~
~OJ~ :
2-(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)acetamide.
Physicochemical properties:
i) Melting point: 183-184C
.
``` ' ` : :
.
!
ii) Elemental analysis (for C~2HI5N304) C (%) H (%) N (%) Calcd.: 54.33 5.70 15.84 Found : 54.34 5.68 15.84 iii) NMR spectrum (CDCl3) (ppm) 1-40 (6H, s), 3-20 (2H, s), 3.93 (2H, s), 6.07 (2H, broad d), 6.81 (lH, d), 7.44 (lH, d), 7.64 (lH, dd) Example 58 ~ CONH -02N ~ N ~
2-(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)-N-phenylacetamide Physicochemical properties:
i) Melting point: 185-187C
ii) Elemental analysis (for Cl~HlgN304) C (%) H (%) N (%) Calcd.: 63.33 5.61 12.31 Found : 63.15 5.70 12.15 .
.' . . . .
~d ~
iii) NMR spectrum (CDCl3) (ppm): 1-46 (6H, s), 3-24 (2H, s), 4.03 (2H, s), 6.81-7.80 (8H, m), 9.10 (lH, broad s) Example 59 ~ OH ~ ~ <
OzN ~ N ~ (C ~ C Q ~ O ~ CH, In 10 ml of tetrahydrofuran were dissolved 0.4 g of 4-(3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)-4-oxo-2 butenoic acid, 0.3 g of dicyclohexylcarbodiimide and 0.26 g of 1-hydroxybenzo-triazole. To this solution was added 2 ml of a mixed solution of 0.1 g of dimethylamine hydrochloride and 0.13 g of triethylamine in 2 ml of tetrahydrofuran with ice-cooling. The mixture was stirred at room temperature for 3 days, after which the precipitate was filtrated off and the solvent was distilled off under reduced pressure. The residue was dissolved in ethyl acetate and the solution was washed with aqueous potassium carbonate solution and water and dried over anhydrous magnesium sulfate. The ; solvent was then distilled off under reduced pressure and the residue was purified by silica gel column chromatography.
The resulting crude crystals were ~ashed with ethyl acetate-,, , ~ , ' 7"~
hexane to give 0.26 g of 4-(3,4-dihydro-2,2-dimethyl 6-nitro~
2H-1,4-benzoxazin-4-yl)-N,N-dimethyl-4-oxo-2-butenamide.
This compound has the following physicochemical properties.
i) Melting point: 179-182C
ii) Elemental analysis (for C~6H~9N305) C (%) H (%) N (%) Calcd.: 57.65 5.75 12.61 Found : 57.55 5.96 12.21 iii) NMR spectrum (CDCl3) (ppm): 1-36 (6H, s), 3.04 (3H, s), 3.20 (3H, s), 3.80 (2H, s), 6.94 (lH, d), 7.36 (lH, d), 7.60 (lH, d) 7.98 (lH, dd) Example 60-62 The following compounds were synthesized in subslantially the same manner as in Example-59.
Example 60 CONHCH(CII 3) Z
~ 0~
2-(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)-N-isopropylacetarnide.
.. . . ..
' . ~
- , : ' , .
' ' ' . ' Physicochemical properties:
i) Melting point: 156-156.5C
ii) Elemental analysis (for Cl4H17N30z) C (%) H (%) N (%) Calcd.: 58.62 6.89 13.67 Found : 58.58 6.96 13.63 iii) NMR spectrum (CDCl3) tppm): 1-13 (6H, d), 1.40 (6H, s), 3.17 (2H, s), 3.86 (2H, s), 4.09 (lH, m), 6.81 (lH, d), 7.43 (lH, d), 7.65 (lH, dd) iv) Mass spectrum (m/z): 293 (M+) _ample 61 ~ CON
02N ~ N ~
3,4-Dihydro-2,2-dimethyl-6-nitro-4-[(1~
pyrrolydinylcarbonyl)methyl]-2H~1,4-benzoxazine.
Physicochemical.properties:
i) Melting point 165~166C
, . ' , ' '' :
" : . :
, .
~ ~ ~J ~3 ~
ii) Elemental analysis (for Cl6H21N304) C (%) H (%) N (%) Calcd.: 60.18 6.63 13.16 Found : 60.17 6.68 13.10 iii) NMR spectrum (CDCl3) (ppm): 1.38 (6H, s), 1.70-2.24 (4H, m), 3.27 (2H, s), 3.34-3.66 (4H, m), 4.08 (2H, s), 6.79 (lH, d), 7.33 (lH, d), 7.59 (lH, dd) Example 62 CONH
~ 0~
N-Benzyl-2-(3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl~acetamide.
Physicochemical properties:
i) Melting point: 133-l35C
ii) Elemental analysis (for Cl9H2lN304) C (%) H (%) N (%) Calcd.: 64.21 5.96 11.82 Found : 64.17 6.08 l1.88 ' iii) NMR spectrum (CDCl3) (ppm): 1.35 (6H,s), 3.19 (2H, s), 3.98 (2H, s), 4.50 (2H, d), 6.55 (lH, broad t), 6.81 (lH, d), 7.26 (5H, s), 7.48 (lH, d), 7.66 (lH, dd) Example 63 02N ~ ~ ~ 02N ~ ~
In 4 ml of methylene chloride was dissolved 0.33 g of 3,4-dihydro-2,2-dimethyl-6-nitro-4-(2-pyridylmethyl)-2H-1,4-benzoxazine followed by addition of 0.26 g -of m-chloroperbenzoic acid, and the mix-ture was stirred at room temperature o~ernigh-t. This reaction mixture was diluted with aqueous sodium hydrogen carbonate solution and extracted with methylene chloride. The organic layer was dried over anhydrous magnesium sulfate and fiItered. The filtrate was concentrated under reduced pressure to give crude crystals o~
2-(3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)methylpyridine N-~oxi~e. Recrystallization from ethanol-chloroform gave 0.2 g of the object compound. This compound was found to have the following physicochemical properties.
'.' -i) Melting point: 139-140C
ii) Elemental analysis (for Cl6Hl7N3O4) C (%) H (%) N (%) Calcd.: 60.94 5.43 13.33 Found : 60.69 5.47 13.18 iii) NMR spectrum (CDCl3) (ppm): 1.41 (6H, s), 3.27 (2H, s), 4.78 (2H, s), 6.83 (lH, d), 7.12-7.34 (4H, m), 7.61 (lH, dd), 8.24-8.42 (lH, m) Example 64 The following compound was syn-thesized in substantially the same manner as in Example 63.
N->0 ~ o 1 3-(6 Cyano-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-4-yl)methylpyridine N-oxide.
Physicochemical properties:
i) Melting polnt: 144-147C
.
, 3 '~ ~ ~
ii) Elemental analysis (for Cl7Hl7N3O2) C (%) H (%) N (%) Calcd.: 69.14 5.80 14.23 Found : 69.33 5.82 14.23 iii) NMR spectrum (CDCl3) (ppm): 1.37 (6H, s), 3.11 (2H, s), 4.42 (2H, s), 6.70-7.36 (5H, m), 8.08-8.18 (2H, m) Example 65 H CH 30~N~
02N~N~ NaH o~ J
C ~N ~D 2 N ~ N
H3COOC N I OJ~
In 40 ml of N,N-dimethylformamide was dissolved 3.33 g of 3,4-dihydro-2,2-dimethyl-6-nitro-2~I-I,4-benzoxazine followed by addition of 0.77 g of sodium hydride. The mixture was stirred at room temperature for 30 minutes and ice-cooled. Then, 6 ml of a solution of 2.76 g of methyl 2-chloropyrazine-3-carboxylate in N,N-dimethylformamide was added dropwise at a temperature not exceeding 5C. The reaction mixture was then stirred at room temperature for 3.5 hours, a-t the end of which time it was poured in ice-water and extracted with ethyl acetate. The extract was washed - ,.' ~ J~J'~ t~
with water and dried over anhydrous magnesium sulfate. The solvent was then distilled off under reduced pressure and the residue was purified by silica gel column chromatography.
The resulting crude crystals were recrystallized from ethanol to give 1.27 g of 3,4-dihydro-2,2-dimethyl-4-(2-methoxy-3-pyrazinyl)carbonyl-6-nitro-2H-1~4-benzoxazine. This compound was found to have the following physicochemical properties.
i) Melting point: 183-186C
ii) Elemental analysis (for Cl6H16N4O5) C (%) H (%) N (~) Calcd.: 55.81 4.68 16.27 Found : 55.96 4.55 16.09 iii) NMR spectrum (CDCl3) (ppm): 1.4-1.6 (9H, broad s), 3.90 (2H, s), 6.90 (lH, d), 7.8-8.0 (lH, broad s), 8.1-8.2 (2H, m) ~, ~
Example 66 C1 ~ ~
CH 300C ~>
02N ~o~ CH :~0 0~_ ~0) 0 2 N ~N 1--ISi (CH3) 3 CH:~OH H0 0~
O:N~N~
(1) The same procedure as Example 65 was followed to give 3,4-dihydro-4-[(2-methoxypyridln-3-yl)carbonyl]-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine.
This compound has the following physicochemical properties.
i) Melting point: 179-182C
ii) Elemental analysis (for Cl7HI7N305) ?
C (%) H (%) -N (%) Calcd.: 59.47 4.99 12.24 Found : 59.50 5.08 12.01 ~;
- 1.13 -, ~ 3 iii) NMR spectrum (CDCl3) (ppm): 1.45 (6H, s), 3.1-4.0 (5H, m), 6.90-7.26 (3H, m), 7.85-7.98 (2H, m), 8.29 (lH, dd) (2) In 6 ml of carbon tetrachloride was dissolved 0.4 g of 3,4-dihydro-~-[(2-methoxypyridin-3-yl)carbonyl]-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine followed by dropwise additlon of 0.26 g of trimethylsilyl iodide. The mixture was heated at 50C for 2 hours and, then, cooled. The reaction mixture was diluted with water and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and filtered, the filtrate was concentrated under reduced pressure, and methanol was added to the concentrate for crystallization. RecrystaIlization from ethyl acetate gave 0.31 g of 3,4-dihydro-4-[(2-hydroxypyridin-3-yl)carbonyl]-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine.
This compound has the following physicochemical properties.
i) Melting point: 183-184C
ii) Elemental analysis (for Cl6Hl5N3O5-0.8CH3COOC2~I5) C (%) H (%) N (%) Calcd.: 57.68 5.40 10.51 Found : 57.66 5.40 I0.56 iii) NMR spectrum (CDCl3) (ppm): 1.41 (6H, s), 3.70 (2H, broad s), 6.34 (lH, m), 6.94 (lH, d), 7.40-7.96 (3H, m), 8.61 (lH, m) Example 67 NC H ~ 0 ~ ~ NC ~ N ~
To 2.53 g of cyclopentanone were added 20 ml of carbon tetrachloride, 5.34 g of N-bromosuccinimide and a catalytic amount of dibenzoyl peroxide ànd the mixture was refluxed under heating for 3 hours. After-cooling, the reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The concentrate and 2.43 g of triethylamine were added to a solution of 0.38 g of 6-cyano-3,4-dihydro-2,2-dimethyl~2H-1,4-benzoxazine in 5 ml of tetrahydro~uran and the mixture was stirred at room temperature overnlght. The reaction mixture was then concentrated under reduced pressure, diluted with water and extracted with ethyl acetate. The organic layer was : separated, dried o~er anhydrous magnesium sul.fate and concentrated under reduced pressure. The residue was - 1~.5 -: , - . : ' . ,, .: ,: ~, ' :, .
. . . . . . .
, i , /J ~
chromatographed on a silica gel co]umn (eluent : hexane-ethyl acetate = 10:1 - 4:1) to give 0.3 g of crude 6-cyano-3,4-dihydro-2,2-dimethyl-4-(5-oxo-1-cyclopenten-1-yl)-2H-1,4-benzoxazine. Recrystallization from ethanol-hexane gave 0.16 g of pure product. This compound has the following physicochemical properties.
i) Melting point: 124-126C
ii) Elemental analysis (for Cl6Hl6N2O2) C (%) H (%) N (%) Calcd.: 71.62 6.01 10.44 Found : 71.52 5.99 10.30 iii) NMR spectrum (CDCl3) (ppm): 1-33 (6H, s), 2.50-2.77 (4H, m), 3.42 (2H, s), 6.84 (lH, d), 7.01-7.14 (2H, m), 7.21 (1H, t) Example 68-72 The following compounds were synthesized generally in the same manner as Example 67.
~: ' ' ' ' , ' ' ,: ' , ' o ~
Example 6 8 ~0 Br ,¢~N~
6-Bromo-3,4-dihydro-2,2-dimethyl-4-(5-oxo-1~
cyclopenten-1-yl)-2H 1,4-benzoxazine.
Physicochemical properties:
i) Melting point: 110-115C
ii) Elemental analysis (for C~5Hl6BrNO2) C (~) H (%) Br (~) N (~) Calcd.: 55.92 5.01 24.80 4.35 Found : 55.61 5.06 24.49 4.28 iii) NMR spectrum (CDCl3) (ppm): 1.26 (6H! s), 2.4-2.8 (4H, m), 3.36 (2H, s), 6.59 (lH, d), 6.74 (lH, d), 6.87 (lH,~dd), 7.11 (lH, t)~
E~ample 69 : -C 11, ~ N ~
,:
.
.. , . .. ' . . . . .
.. . . ., , , . ~ .
~ ~ f, ~ é~
3,4-Dihydro-6-methoxy~2,2-dimethyl-4-(5-oxo-1-cyclopenten-l-yl)-2H-1,4-benzoxazine.
Physicochemical properties:
i) Melting point: 95-97C
ii) Elemental analysis (for C16Hl9NO3) C (%) H (%) N (%) Calcd.: 70.31 7.01 5.12 Found : 70.17 6.90 4.92 iii) NMR spectrum (CDCl3) (ppm): 1.28 (6H, s), 2.44-2.70 (4H, m), 3.43 (2H, s), 3.69 (3H, s), 6.36 (lH, dd), 6.47 (lH, d), 6.72 (lH, d), 7.17 (lH, t) Example 70 02N ~ 1~ ~
3,4-Dihydro-2,2-dimethyl-6-nitro-4-(5-oxo-1-cyclopenten-l-yl)-2H-1,4-benzoxazine.
Physicochemical properties:
i) Melting point: 96 98C
- ~.
~2 ~3~J~
ii) Elemental analysis (for Cl5HI6N2O4^0.1H2O) C (%) H (%) N (%) Calcd.: 62.10 5.63 9.66 Found : 62.11 5.64 9.43 iii) NMR spectrum (CDCl3) (ppm): 2.33 (6H, s), 2-51-2-59 (2H~ m)~
2.64-2.75 (2H, m), 3.44 (2H, s), 6.83 (lH, dd), 7.24 (lH, t), 7.61-7.22 (2H, m) Example 71 ~0 C z H 5 ~
6-Ethyl-3,4-dihydro-2,2-dimethyl-4-(5-oxo-1-cyclopenten-1-yl)-2H-1,4-benzoxazine.
Physicochemical properties:
i) Melting point: 68-70C
ii) Elemental analysis (for Cl7H2lNO2) C (%) H(%) N (%) Calcd.: 75.25 7.80 5.16 Found : 75.30 7.95 -5.17 - 119 - ', . .. . . : , .
. - . , - ', . ~ . ' .
-.. . .
: . : ..
- : . , .:
..
iJ'';3 ~ ~
iii) NMR spectrum (CDCl3) (ppm): 1.11 (3H, t), 1.27 (6H, s), 2.54-2.72 (6H, m), 3-44 (2H~ s), 6.55-6.82 (3H, m), 7.06-7.17 (lH, t) Example 72 ~0 0zN ~ 0 ~
3,4-Dihydro-2,2-dimethyl-7-nitro-4-(5-oxo-1-cyclopenten-l-yl)-2H-1,4-benzoxazine.
Physicochemical properties:
i) Melting point: 88-89C
ii) Elemental anaIysis (for Cl5H16N2O4) C (%) H (%) N (~) Calcd.: 62.49 S.59 9.72 Found : 62.21 5.61 9.60 iii) NMR spectrum (CDCl3) (ppm): 1.35 (6H, s), 2.50-2.64 (2H, m), 2.68-2.79 (2H, m), 3.41 (2H, s), 6.68 (lH, s), 7.-35 (lH, t), 7.60-7.74 (2H, m) . :
' ' :
.. .
~ 13 ~
Example 73 NC ~ N ~ NC ~ N ~
In 15 ml of toluene were dissolved 0.5 g of 6~cyano-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazine, 0.33 g of cyclohexane-1,2-dione and a catalytic amount of p-toluenesulfonic acid and using a Dean-Stark trap, the solution was refluxed under heating for 4 hours. After cooling, the reaction mixture was washed with saturated aqueous sodium hydrogen carbor.~ate solution and aqueous sodium chloride solution and dried over anhydrous magnesium sulate and the solvent was distilled off under reduced pressure.
The residue was purified by silica gel column chromatography and the resulting crude crystals were washed with ethanol to give 0.5 g of 6-cyano-3,4-dihydro-2,2-dimethyl-4-(6-oxo-1-cyclohexen-1-yl)-2H-1,4-benzoxazine. ;
This compound has the following physicochemical properties.
.~ , .
i) Melting point: l66-l70C-, .
:' :
; .' ' ,' ' :~
2 J i.~ i~J r~ ~ ~
ii) Elemental analysis (for Cl-~H~8N2O2) C (%) H (%) N (%) Calcd.: 72.32 6.43 9.92 Found : 72.36 6.38 9.83 iii) NMR spectrum (CDCl3) (ppm): 1.34 (6H, s), 2.0-2.2 (2H, m), 2.5~2.7 (4H, m), 2.20 (2H, s), 6.60 (lH, d), 6.76 (lH, d), 6.8-7.0 (2H, m) Example 74-76 ~ he following compounds were synthesized in substantially the same manner as in Example 73.
Example 74 Me ~
NC ~ N ~
6-Cyano-3,4-dihydro-2,2-dimethyl-4-(4-methyl-5-oxo-1-cyclopenten-1-yl)-2H-1,4-benzoxazine.
Physicochemical properties:
i) Melting point: 106-108C
ii) Elemental analysis (for Cl7HI8N2O2) C (%) H (%) -N (%) Calcd.: 72.32 6.43 9.92 Found.: 72.49 6.50 9.88 `;
:
.
J ~;3 ~iJ.~
iii) NMR spectrum (CDCl3) (ppm): 1.26 (3H, d), 1.34 (6H, s), 2.1-3.1 ~3H, m), 3.43 (2H, s), 6.84 (lH, d), 7.0-7.2 (3H, m) Example 75 NC ~ N ~
6-Cyano-3,4-dihydro-2,2-dimethyl-4-(3-oxo-l-cyclopenten-1-yl)-2H-1,4-benzoxazine.
Physicochemical properties:
i) Melting point: 180-184C
i) Elemental analysis (for Cl6Hl6N2O2-0.1H2O) C (%) H (%) N (%) Calcd.: 71.15 6.05 10.37 Found : 71.23 6.10 10.10 iii) NMR spectrum (CDCl3) (ppm): 1.39 (6H, s), 2.4-2.6 (2H, m), 2.7-2.9 (2H, m), 3.55 (2H, sj, 5.73 (lH, s), 6.96 (lH, d), 7.34 (lH, dd), 7.68 (lH, d) ~ 123 -. . ~ .
~.
' ~Y~23''''3~
Example 7 6 ~s NC ~ N ~
6-Cyano-3,4-dihydro-2,2-dimethyl-4-(3-oxo-1-cyclohexen-l-yl)-2H-1,4-benzoxazine.
Physicochemical properties:
i) Melting point: 147-150C
ii) Elemental analysis (for C17Hl8Nz02) C (%) H (%) N(%) Calcd.: 72.32 6.43 9.92 Found : 72.40 6.48: 9.91 iii) NMR spectrum (CDCl3) (ppm): 1.35 (6H, s), 2.12 (2H, m), 2.44 (2H, t), 2.64 (2H, t),:3.48 (2H, s), 5.75 (lH, s), 6.93 (lH, d), 7.:23 (lH, d), 7.36 (lH, dd) Example 77 ~:
H ~ ~ Me ~ O
NC ~ l ~ ~ Me p-TsOII ~ Me O a t~luene NC ~ N
: - 124 -. ' ' . . .~
, 2~
In 2 ml of toluene were dissolved 0.5 g of 6-cyano-3,4-dihydro-2,2-dimethyl-2H-1,4 benzoxazine, 1.2 ml of 2,3-butanedione and a catalytic amount of p-toluenesulfonic acid and the mixture was stirred at 100C for 2 days. The solvent was then distilled off under reduced pressure and the residue was re-dissolved in toluene, washed with saturated aqueous sodium hydrogen carbonate solution and saturated aqueous sodium chloride solution, and dried over anhydrous magnesium sulfate. The solven-t was then distilled off and the residue was purified by silica gel column chromatography to give 0.15 g of 6-cyano-3,4-dihydro-2,2 dimethyl-4-(2,5-dimethyl-3-furyl)-2H-1,4-benzoxazine.
Physicochemical properties:
i) Melting point: 130-132C
ii) Elemental analysis (for C~7Hl8N2O2) C (%) H (%) N (%) Calcd.: 72.32 6.43 9.92 Found : 72.35 6.49 9.93 iii) NMR spectrum (CDCl3) (ppm): 1.36 (6H, s), 2.12 (3H, s), 2.24 (3H, s), 3.20 (2H, s), 5.80 (lH, s), 6.70 (lH, d), 6.76 (lH, d), 6.94 (lH, dd) Example 78-79 The following compounds were synthesized in substantially the same manner as in Example 73.
. ,,. ..... :
~t~
Example 78 ' ~
~0 02N ~Nl-3,4-Dihydro-2,2-dimethyl-6-nitro-4-(l-oxinden-2-yl)-2H-1,4-benzoxazine.
Physicochemical properties:
i) Melting point: 161-165 C
ii) Elemental analysis (for C19H~6N2O4) C (%) H (%) N (%) Calcd.: 67.85 4.79 8.33 Found : 67.89 4.90 8.22 iii) NMR spectrum (CDCl3) (ppm): 1-37 (6H, s), 3.66 (2H, s), 6.8-7.4 (6H, m), 7.76 (lH, dd), 8.04 (lH, d) :
, ~
', ~' '' ~ ' '. ' ., .
Example 79 ~~ COOC2Hs 02N ~ N~
~o~
4-(2-Ethoxycarbonylcyclopenten-1-yl)-3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine.
Physicochemical properties:
i) Melting point: 157-158C
ii) Elemental analysis (for Cl8Hz2N2O5-0-5H2O) C (%) H (%) N (%) Calcd.: 60.83 6.52 7.88 Found : 61.03 6.26 7.71 iii) NMR spectrum (CDCl3) (ppm): 1.20 (3H, t), 1.35 (6H, s), 1.76-2.09 (2H, m), 2.64-2.~4 (4H, m), 3.41 (2H, s), 4.11 (2H, q), 6.83 (lH, d), ; 7 59-7.77 (2~, m) :
.
, ' ' ' ' '' :
. ,, , ' ~' ~ , ~ ' Example 80 ~ ~ N-OMe NC ~ N ~ ' NC ~ N
In 3 ml of pyridine was dissolved 0.3 g of 6-cyano-3,4-dihydro-2,2-dimethyl-4-(5~oxo-1-cyclopenten-1-yl)-2H-1,4-benzoxazine followed by addition of 0.26 g of methoxyamine hydrochloride. The mixture was stirred at room temperature overnight and the solvent was then distilled off under reduced pressure. The residue was poured in water and extracted with ethyl acetate. The extract was washed with water and dried over anhydrous magnesium sulfate and the solvent was distilled off under reduced pressure. Finally the residue was washed with ethanol-ether to give 0.26 g of 6-cyano-3,4-dihydro-4-(5-methoxyimino-1-cyclopenten-l-yl)-2,2-dimethyl-2H-1,4-benzoxazine.
This compound has the following physicochemical properties.
i) Melting point: 138-141C
ii) Elemental analysis (for Cl7HIgN302) C (%) H (%) N (%) Calcd.: 68.67 6.44 14.13 Found : 68.40 6.60 13.95 ;
- 128 - `~
,j , . . . . .
;, - . ` ' ' , ~J' ~ f'~
iii) NMR spectrum (CDC13) (ppm): 1.32 (6H, s), 2.4-2.8 (4H, m), 3.38 (2H, s), 3.84 (3H, s), 6.26 (lH, t), 6.78 (lH, d), 6.98 (lH, dd), 7.14 (lH, d) Exam~le 81 NC N ~ ~ OH
NC ~ N ~
In 20 ml of N,N-dimethylformamide was dissolved 1.0 g of 6-cyano-3,4-dihydro-2,2-dimethyl-2H-I,4-benzoxazine followed by addition of 0.24 g of sodium hydride. The mixture was stirred at 70C for 1 hour and-after cooling to room temperature, 0.5 ml of cyclopentene oxide was added.
The mixture was stirred at 70C for 3 hours. The reaction mixture was then allowed to cool, diluted with water and extracted with ethyl acetate. The extract was washed wlth water and aqueous sodium chloride solution and dried over anhydrous magnesium sulfate and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography and the resulting crude crystals were recrystallized from ethyl acetate-hexane to give 0.53 g - - : ' ' ' `
.
~ rl ~y ,^J r~
of 6-cyano-3,4-dihydro-4-(2-hydroxycyclopentan-1-yl)-2,2-dimethyl-2H-1,4-benzoxazine.
Physicochemical properties:
i) Melting point; 95-97C
ii) Elemental analysis (for Cl6H20N202) C (%) H (%) N (%) Calcd.: 70.56 7.40 10.29 Found : 70.40 7.46 10.23 iii) NMR spectrum (CDCl3) (ppm): 1.30 (6H, s), 1.4-2.2 (6H, m), 2.94 (2H, s), 3.8-4.3 (2H, m), 6.72 (lH, d, J=8.5 Hz), 6.92 (lH, dd, J=2.5, 8.5 Hz), 7.06 (lH, dd, J=2.5, 8.5 Hz) Example 82 ~ OH ~ O
N C ~ N 1 - --> N C ~ N
In 5 ml of methylene chloride was dissolved 0.2 ml of oxalyl chloride and at a constant temperature between -50C
and -60C, a solution prepared by dissolving 0.34 ml of dimeth~l sulfoxide in 1 ml of methylene chloride was added dropwise. The mixture was stirred for 2 minutes, after which -~
a solution of 0.54 g of 6-cyano-3,4-dihydro-2,2-dimetllyl-4-.~ .
: - .
~ r~
(2-hydroxycyclopentan-1-yl)-2H-1,4-benzoxaæine in 2 ml of methylene chloride was added dropwise. The mixture was further stirred for 15 minutes and 0.7 ml of triethylamine was added. The mixture was stirred for an additional 5 minutes, after which it was allowed to return to room temperature. The reaction mixture was diluted with 10 ml of water and extracted with methylene chloride. The extract was washed with aqueous sodium chloride solution and dried over anhydrous magnesium sulfate and the sol~ent was distilled off under reduced pressure. The residue was recovered by filtration, washed with ethanol and recrystallized from ethyl acetate to give 0.28 g of 6-cyano-3,4-dihydro-2,2-dimethyl-4-(2-oxocyclopentyl)-2H-1,4-benzoxazine.
Physicochemical properties:
i) Melting point: 172-175C
ii) Elemental analysis (for Cl6Hl8N2O2) C (%) H (%) N (%) Calcd.: 71.09 6.71 10.36 Found : 71.01 6.82 10.29 iii) NMR spectrum (CDCl3) (ppm): 1.32 (3H, s), 1.36 (3H, s), 1.7-2.6 (6H, m), 2.86 (2H, dd, J=3.5, 11.5 Hz), 4.0-4.3 (lH, broad s), 6.74 (lH, d, J=8.5 Hz), 6.80 (lH, d, J=2.5 Hz), 6.94 (lH, dd, J=2.5, 8.5 Hz) Example 83 ~ ~ BH3 0 02N ~ ~ _ _> 02N ~ N
To 9 ml of a solution of borane-tetrahydrofuran complex in tetrahydrofuran (lM) was added 1.30 g of 4-(2-furoyl)-3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine with ice-cooling. The mixture was then refluxed under heating with stirring for 2.5 hours. To this mixture was added 1.1 ml of methanol and after another hour of refluxing, the reaction mixture was poured in ice-water and extracted with ethyl acetate. The organlc layer was washed with water :
and dried over anhydrous magnesium sulfate and the solvent was distilled off. The residue was chromatographed on a silica gel column and elu-tion was carried out with hexane-toluene (2:1). The crude crystals from the eluate were recrystallized from 3 ml of ethanol to give 546 mg of 4-furfuryl-3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine.
This compound has the following physicochemical properties.
;, .
.
~ , . ' ,, 1 r~ ~
i) Melting point: 94-97C
ii) Elemental analysis (for Cl5Hl6N2O4) C (%) H (%) N (~) Calcd.: 62.49 5.59 9.72 Found : 62.44 5.51 9.76 iii) NMR spectrum (CDCl3) (ppm): 1.35 (6H, s), 3.13 (2H, s), 4.50 (2H, s), 6.3-6.4 (2H, m), 6.77 (lH, d), 3-36 (lH, t), 7.58 (lH, dd), 7.71 (lH, d) Example 84 H COOC2Hs OzN~N~ HC(OC2Hs) 3 ~ H2 < cooC2Hs CO2Et CO2Et EtO ~ -CO2Et ~ CO2Et 02N ~ N ~ + 02N ~ N~
(A) (~) A mixture of 2.08 CJ o 3j4-dihyclro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazine, 2.96 g of e-thyl orthoformate and 2.40 g of diethyl malonate was stirred in a sealed tube at , 140C for 12 hours. After cooling, the solvent was distilled off and the residue was purified by silica gel column chromatography to give 0.33 g of diethyl 2-[1-(3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)ethoxymethyl]malonate (compound A) and 0.31 g of diethyl 2-(3,4-dihydro-2,2-dimethyl-6-nitro-2H 1,4-benzoxazin-4-yl)methylene malonate (compound B).
Compound A
i) Melting point: 71-74C
ii) Elemental analysis (for C20H28N2O8) C (%) H (%) N (%) Calcd.: 56.60 6.65 6.60 Found : 56.46 6.61 6.46 iii) NMR spectrum (CDCl3) (ppm)~ 1.5 (15H, m), 3.29 (2H, s), 3.72 (2H, q), 4.28 (4H, q)7 6.95 (lH, d), 7.9-8.1 (3H, m) Compound B
i) Melting point: 89-91C
ii) Elemental analysis (for Cl8H22N2O7) C (%) ~I (%) N (%) Calcd.: 57.14 5.86 7.40 Found : 56.93 5.80 7.27 iii) NMR spectrum (CDCl3) (ppm): 1.2-1.6 (12H, m), 3.36 (2H, s), 4.28 (4H, q)~ 6.95 (lH, d), 7.9-8.0 (3H, m) ', ~
, Example 85 0 ` NHMe 0~ 1 0 O z N ~ N 1- C H ~ N N ~ 0 2 N ,~ N ~ O E t In 3 ml of methylene chloride was dissolved 0.5 g of ethyl 4-(3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl) 4-oxo-2-butenoate followed by addition of 0.116 g of 40% methylamine in methanol. The mixture was stirred at room temperature for 4 days, at the end of which time the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography and the resulting crude crystals were washed with ethanol-hexane to give 0.2 g of ethyl 4-(3,4-dihydro-2,2-~dimethyl-6-nitro-2H-- 1,4-benzoxazin-4-yl)-3-methylamino-4-oxobutanoate.
This compound has the following physicochemical properties.
i) Melting poi.nt: 75-77C
ii) Elemental analysis (Cl7H23N3O6) ~ C (%) H (%) N (%) Calcd.: 55.88 6.34 -11.50 Found : 55.68 6.30 1].47 - 135 _ ` ` : :
.~ :
~: :
, ~: ~ S~) k.J ~3 iii) NMR spectrum (CDCl3) (ppm): 1.28 (3H, t), 1.36 (6H, 5), 2.42 (3H, s), 3.02 (2H, d), 3.6-3.8 (3H, m), 4-20 (2H, q), 6-90 (lH, d), 7.94 (lH, dd), 8.3-8.5 (lH, broad s) Example 86 ~0 ~0 N0z ¦
O~N ~ 0 In 5.2 ml of acetonitrile was dissolved 0.35 g of 3,4-dihydro-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-2H-1,4-benzoxazine followed by gradual addition of 0.22 g of nitronium tetxafluoroborate. The mixture was stixred for 30 minutes and, then, poured in ice-water and extracted with ethyl acetate. The organic layer was dried and concentrated under reduced pressure and the residue was chromatographed on a silica gel column. The crude crystals obtained from the eluate were recrystallized from chloroform~ether -to glve 0.07 g oE 3,4-dihydro-2,2-dimethyl-5,7 dinitro-4-(2-oxo-1-pyrrolidinyl)-2H-1,4-benzoxazine.
This compound has the following physicochemical properties.
~ .
' .
~h '~ if ~, C (%) H (~) N (%~
Calcd.: 50.00 4.80 16.66 Found : 49.40 4.76 16.Q~
iii) NMR spectrum (CDCl3~
(ppm): 1.44 (3H, s), 1.46 (3H, s), 1.92-2.44 (4H, m), 3.18-3.61 (4H, m), 7.76 (lH, d), 7.90 (lH, d~
The Eollowing compound was synthesized i~
substantially the same manner as in ~xample 4.
~xam~le 87 ~0 02N ,~
3,4-Dihydro-2,2-dimethyl-4-(2-oxo-1-piperidyl)-6-nitro-2X-1,4-benzoxazine~
ghysicochemical properties:
i) Melting point: 166-168C
ii) Elemental analysis (for Cl5HlgN3O
C(~ 3 C~lcd.: 59.01 6.27 13.76 Found: 5a.89 6.32 13.73 iii) NMR spect~um (DMSO-d6) (ppm):1.33 (3H, s), 1.40 (3X, s), 1.7-2.1 (2H, m), 2.4-2.6 ~4H, m), 3.3-3.7 (4X, m3, 6.92 (lH, d), 7.28 (lH, d), 7.59 (lH, d~
.
''- , ~ , ' ' . . .
Exampl~ A 2~29~9 ,' ~ COOC2~5 02N ~ N ~ 0 BrCHzCO2C2Hs . 02N ~ ~ ~ 0 A mixture of 6.66 g of 3,4-dihydro-2,2-dime~hyl-6-nitro~3-oxo-2H-1,4-benzoxazine, 5.51 g of ethyl bromoacetate, 4.56 g of potassium carbonate and 20 ml of ace~onitrile was ,refluxed under heating for 2.5 hours. Then, 10 ml of N,N-dimethylformamide was added and the mixture was stirred at 80C for 2 hours. To this mixture was added 2.80 g of ethyl bromoacetate. After an hour of~stirring at 80C, 2.28 g of potassium carbonate was added and the mixture was further stirred at 80C for 1 hour. The reaction mixture was then ., .. _ . .. . ..
.,,,............ . . -, , : .
,~
' ' ~ ~, . ' ' :
'- . ' ~: ' . , , ~
concentrated under reduced pressure and the residue was chromatographed on a silica gel column, elution being carried out with hexane-ethyl acetate (10:1). The crystals from the eluate were recrystallized from ethyl acetate-hexane to give 7.4 g of ethyl (3,4-dihydro-2,2-dimethyl-6-nitro-3-oxo-2H-1,4-benzoxazin-4-yl)acetate. This compound has the following physicochemical properties.
i) Melting point: 67-68C
ii) Elemental analysis (for C~4Hl6N2O6) C (%) H (%) N (%) Calcd.: 54.54 5.23 9.09 Found : 54.49 5.24 9.06 iii) NMR spectrum (CDCl3) S (ppm): 1.32 (3H, t), 1.59 (6H, s), 4.28 (2H, q), 4.69 (2H, s), 7.08 (lH, d), 7.62 (lH, d), 7.97 (lH, dd) Example B
The same procedure as Example A was followed to give the following compound.
~ C0zEt 0zN ~ N ~ 0 , .
~ .
'. ' ~ ~ S~
Ethyl (3,4-dihydro-6-nitro-3-oxo-2H-1,4-benzoxazin-4-yl)acetate Physicochemical properties:
i)Melting point: 102-103C
ii) Elemental analysis (for Cl2HI2N206) C (%) H (%) N(%) Calcd.: 51.43 4.32 10.00 Found : 51.52 4.28 10.07 iii) NMR spectrum (CDCl3) (ppm): 1.32 (3H, t), 4.28 (2H, q), 4.68 (2H, s), 4.78 (2H, s), 7.08 (lH, d), 7.62 (lH, d), 7.94 (lH, dd) Example C
H O
NO~ ~ ~ + BrCHze-NaH
in DM~ O
C~12~
I
NO2 ~ N ~ O
i.
- 139 - ~
; .
.. . .
.... . ,- : .
- : , . . .
. ~. . ,, . . ~ :
, - ' . ' ~ ' ' - ~ : . .
In an argon gas stream, 2.0 g of 3,4-dihydro-2,2-dimethyl-6-nitro-3-oxo_2H_l,4~benzoxazine was added gradually to 0.4 g of 60~ sodium hydride in oil in 40 ml of dry N,N-dimethylformamide. The mixture was stirred at room temperature for 1 hour and 2.68 g of phenacyl bromide was added. The mixture was stirred at room temperature for l hour, after which the solvent was distilled off under reduced pressure. The residue was diluted with 50 ml of water and extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated under,reduced pressure. The residue was chromatographed on a silica gel column and elution was carried out with methylene chloride-ethyl acetate. Recrystallization from ethyl acetate-ether gave 2.04 g of 3,4-dihydro-2,2-dimethyl-6-nitro-3-oxo-4-phenacyl-2H-1,4-benzoxazine.
Physicochemical properties: -i) Elemental analysis (Cl8Hl6N2O5) C (%) H (%) N (%) Calcd.: 63.53 4.74 8.23 Found : 63.61 4.72 8.05 ii) Mass spectrum (EI): m/z 340 (M+) Example D-F
The same procedure as Example C was followed to give the following compounds. - -.
' ' ' '' Example D
1l ~ -CHzC N
NO 2 ~ N ~ O
3,4-Dihydro-2 r 2-dimethyl-6-nitro-3-oxo-4-[(2-pyridylcarbonyl)methyl]-2H-1,4-benzoxazine .
Physicochemical properties:
i) Melting point: 177-178C
ii) Elemental analysis (Cl7HIsN3s) C (~) ~ (%) N (~) Calcd.: 59.82 4.43 12.31 Found : 59.87 4.45 12.21 iii) Mass spectrum (EI): m/z 341 (Mt) Example E
:
CHzCOCH3 NO~ ~ N ~ O
:~.
4-Acetonyl-3 r 4-dihydro-2;2-dimethyl-6-nitro-3-oxo:-2H~ ~:
1,4-benzoxazine :` ; '; ' " ''' ' ' ' '' , $ ~
Physicochemical properties:
i) Melting point: 136-]37C
ii) Elemental analysis (Cl3H~4N2Os) C (%) H (%) N (%) Calcd.: 56.11 5.07 10.07 Found : 56.11 5.03 10.04 iii) Mass spectrum (EI): m/z 278 (M+) Example F
~0 02N ~ N ~ 0 3,4-Dihydro-2,2-dimethyl-6-nitro-4-(2-oxocyclopentyl)-2H-1,4-benzoxazin-3-one Physicochemical properties:
i) Melting point: 141-142C
ii) Mass spectrum (EI): m/z 304 (M+) iii) NMR spectrum (CDCl3) (ppm): 1.47 (3H, s), 1.59 (3H, s), 1.80-2.96 (6H, m), 4.26 (lH, t), 7.08 (lH, d), 7.79 (lH, d), 7-96 (lH, dd) 2~7,~
~xamPle G
~, COOEt ~ CONHMe 0 2 N ~ N ~ O ~ O z N ~ N ~ O
In 1.5 ml of methylene chloride were dissolved 0.5 g of ethyl (3,4-dihydro-6-nitro-3-oxo-2H-1,4-benzoxa7in-4-yl)acetate and 0.16 g of 40% methylamine-methanol and the mixture was allowed to stand at room temperature for 3 days.
The solvent was then distilled off and the residue was recrystallized from methylene chloride-hexane to give 0.2 g of 2-(3,4-dihydro-6-nitro-3-oxo-2H~1,4-benzoxazin-4-yl)-N--methylacetamide. This compound has the following physicochemical properties.
i) Melting point: 180-185C
ii) Elemental analysis (CllHIlN3O5-0.1H2O) C (%) H (%) N (%) Calcd.: 49.48 4.23 15.74 Found : 49.32 4.25 15.73 iii) NMR spectrum (CDC13) (ppm): 2.82 (3H, d), 4.56 (2H, s), 4.78 (2H, s), 5.9-6.1 (lH, broad s), 7.06 (lH, d), 7.94 (lH, dd)j 7-98 (lH, d) .
.... .
Example H
The same procedure as Example G was followed to give the following compound.
O z N ~ N ~O
2-(3,4-Dihydro-2,2-dimethyl-6-nitro-3-oxo-2H-1,4-benzoxazin-4-yl)-N-methylacetamide Physicochemical properties:
i) Melting point: 212-214C
ii) Elemental analysis (Cl3HI5N3Os) C (%) H (%) N (%) Calcd.: 53.24 5.16 14.33 Found : 53.06 5.10 14.35 iii) NMR spectrum (CDCl3) (ppm): 1.56 (6H, s), 2.86 (3H, d), 4.54 (2H, s), 5.86 (lH, broad s), 7.06 (lH, d), 7.86-7.98 (2H, m) .
.:
' ~
Formulation Example 1 Compound of Example 1 0.1 mg Lactose 63 mg Corn starch 16 mg Magnesium stearate 0.9 mg 80 mg The compound of Example 1, lactose and corn starch are evenly mixed and wet-granulated using corn starch as the binder. Then, magnesium stearate is added and the composition is compression-molded to give tablets.
Formulation ExamPle 2 The following ingredients are filled into ampules and, after sealing by fusion, sterilized at 115C for 30 minutes.
. Composition (per milliliter) The compound of Example 1 50 ~g Sodium chloride 9 mg Distilled water for injection To make 1 ml Nhile the invention has been described in detail and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that the various changes and modifications can be made therein without departing from the spirit and scope thereof.
- 145 _
Claims (16)
1. A benzoxazine derivative of the formula (I):
(I) wherein R1, R2, R3 and R4, which may be the same or different, each independently represents a hydrogen atom, a halogen atom, a lower alkyl group, a halo-substituted lower alkyl group, a lower alkoxy group, a cyano group, a nitro group, an amino group, a lower alkanoylamino group, a lower alkylsulfonylamino group, a lower alkylsulfonyl group, or an arylsulfonyl group;
R5 and R6, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group;
R7 represents a hydroxy-lower alkyl group, a carbocyclic group which may optionally be substituted, a heterocyclic group which may optionally be substituted, a group of the formula -A1-R8, a group of the formula , a group of the formula , or a group of the formula ;
A1 represents a lower alkylene group or a hydroxy-lower alkylene group;
R8 represents an aryl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, or a lower alkenyloxy group, when A1 represents a non-substituted lower alkylene, R3 does not represent a phenyl group;
A2 represents a lower alkylene group;
R9 represents a lower alkyl group, an aryl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, a hydroxy group, a lower alkoxy group, an amino group, a mono- or di-lower alkylamino group, a hydroxy-lower alkylamino group, an aralkylamino group, or an arylamino group;
A3 represents a single bond, a lower alkylene group which may optionally be substituted, or a lower alkenylene group;
R10 represents a heterocyclic group which may optionally be substituted, a carboxyl group, a lower alkoxycarbonyl group, a carbamoyl group, a mono- or di-lower alkylaminocarbonyl group, an amino group, or a mono- or di-lower alkylamino group;
A4 represents a lower alkylene group which may optionally be substituted by a hydroxy or lower alkoxy group;
and R11 and R12, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group:
or a pharmaceutically acceptable salt thereof.
(I) wherein R1, R2, R3 and R4, which may be the same or different, each independently represents a hydrogen atom, a halogen atom, a lower alkyl group, a halo-substituted lower alkyl group, a lower alkoxy group, a cyano group, a nitro group, an amino group, a lower alkanoylamino group, a lower alkylsulfonylamino group, a lower alkylsulfonyl group, or an arylsulfonyl group;
R5 and R6, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group;
R7 represents a hydroxy-lower alkyl group, a carbocyclic group which may optionally be substituted, a heterocyclic group which may optionally be substituted, a group of the formula -A1-R8, a group of the formula , a group of the formula , or a group of the formula ;
A1 represents a lower alkylene group or a hydroxy-lower alkylene group;
R8 represents an aryl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, or a lower alkenyloxy group, when A1 represents a non-substituted lower alkylene, R3 does not represent a phenyl group;
A2 represents a lower alkylene group;
R9 represents a lower alkyl group, an aryl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, a hydroxy group, a lower alkoxy group, an amino group, a mono- or di-lower alkylamino group, a hydroxy-lower alkylamino group, an aralkylamino group, or an arylamino group;
A3 represents a single bond, a lower alkylene group which may optionally be substituted, or a lower alkenylene group;
R10 represents a heterocyclic group which may optionally be substituted, a carboxyl group, a lower alkoxycarbonyl group, a carbamoyl group, a mono- or di-lower alkylaminocarbonyl group, an amino group, or a mono- or di-lower alkylamino group;
A4 represents a lower alkylene group which may optionally be substituted by a hydroxy or lower alkoxy group;
and R11 and R12, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group:
or a pharmaceutically acceptable salt thereof.
2. A compound as claimed in Claim 1, wherein R7 is an N-oxide form and/or lower alkyl-substituted nitrogen-containing heterocyclic group, an oxo-substituted nitrogen-containing heterocyclic group, an oxo-substituted carbocyclic group, a group of the formula -Al-R8 in which A1 and R8 as defined above, or a group of the formula in which A2 and R9 are as defined above.
3. A compound as claimed in Claim 1, wherein one of R2 and R3 is a nitro group, a cyano group, or a halogen atom and the other is a hydrogen atom or a nitro group and wherein R7 is a 1-oxo-2-pyridil group, a 6-methyl-1-oxo-2-pyridil group, a 2-oxo-1-pyrrolidinyl group, a (1-oxo-2-pyridil)methyl group, a 2-oxocyclopentyl group, a 5-oxo-1-cyclopenten-1-yl group, an acetonyl group, a phenacyl group, a carbamoylmethyl group, an N-methylaminocarbonylmethyl group or an N,N-dimethylaminocarbonylmethyl group.
4. A compound as claimed in Claim 3, said compound being 2-(3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)pyridine N-oxide.
5. A compound as claimed in Claim 3, said compound being 2-(6-cyano-3,4-dihydro-2,2-dimethyl-2H-1,4-benzoxazin-4-yl)pyridine N-oxide.
6. A compound as claimed in Claim 3, said compound being 2-(3,4-dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)-6-methylpyridine N-oxide.
7. A compound of the formula (II):
(II) wherein R1', R2', R3' and R4', which may be the same or different, each independently represents a hydrogen atom, a halogen atom, a cyano group, or a nitro group;
R5 and R6, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group;
R7a represents a carbocyclic group which may optionally be substituted by an oxo group, or a group of the formula ;
A2 represents a lower alkylene group; and R9a represents a lower alkyl group, an aryl group which may optionally be substituted by one or more halogen atoms or nitro groups, a nitrogen-containing heterocyclic group which may optionally be substituted by at least one of an oxo group and a lower alkyl group, inclusive of the N-oxide form thereof, a hydroxy group, a lower alkoxy group, an amino group, a mono- or di-lower alkylamino group, a hydroxy-lower alkylamino group, an aralkylamino group, or an arylamino group:
or a salt thereof.
(II) wherein R1', R2', R3' and R4', which may be the same or different, each independently represents a hydrogen atom, a halogen atom, a cyano group, or a nitro group;
R5 and R6, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group;
R7a represents a carbocyclic group which may optionally be substituted by an oxo group, or a group of the formula ;
A2 represents a lower alkylene group; and R9a represents a lower alkyl group, an aryl group which may optionally be substituted by one or more halogen atoms or nitro groups, a nitrogen-containing heterocyclic group which may optionally be substituted by at least one of an oxo group and a lower alkyl group, inclusive of the N-oxide form thereof, a hydroxy group, a lower alkoxy group, an amino group, a mono- or di-lower alkylamino group, a hydroxy-lower alkylamino group, an aralkylamino group, or an arylamino group:
or a salt thereof.
8. A compound as claimed in Claim 7, wherein R7a is a 2-oxocyclopentyl group, a 5-oxo-1-cyclopenten-1-yl group, an acetonyl group, a phenacyl group, a carbamoylmethyl group, an N-methylaminocarbonylmethyl group, or an N,N-dimethylaminocarbonylmethyl group:
or a salt thereof.
or a salt thereof.
3. A compound of the formula (III):
(III) wherein R1', R2', R3' and R4', which may be the same or different, each independently represents a hydrogen atom, a halogen atom, a cyano group, or a nitro group;
R5 and R6, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group; and R13 represents a nitroso group or an amino group:
and a salt thereof.
(III) wherein R1', R2', R3' and R4', which may be the same or different, each independently represents a hydrogen atom, a halogen atom, a cyano group, or a nitro group;
R5 and R6, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group; and R13 represents a nitroso group or an amino group:
and a salt thereof.
10. A pharmaceutical composition which comprises a benzoxazine derivative of the formula (I):
(I) wherein R1, R2, R3 and R4, which may be the same or different, each independently represents a hydrogen atom, a halogen atom, a lower alkyl group, a halo-substituted lower alkyl group, a lower alkoxy group, a cyano group, a nitro group, an amino group, a lower alkanoylamino group, a lower alkylsulfonylamino group, a lower alkylsulfonyl group, or an arylsulfonyl group;
R5 and R6, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group;
R7 represents a hydroxy-lower alkyl group, a carbocyclic group which may optionally be substituted, a heterocyclic group which may optionally be substituted, a group of the formula -A1-R8, a group of the formula , a group of the formula , or a group of the formula ;
A1 represents a lower alkylene group or a hydroxy-lower alkylene group;
R8 represents an aryl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, or a lower alkenyloxy group;
A2 represents a lower alkylene group;
R9 represents a lower alkyl group, an aryl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, a hydroxy group, a lower alkoxy group, an amino group, a mono- or di-lower alkylamino group, a hydroxy-lower alkylamino group, an aralkylamino group, or an arylamino group;
A3 represents a single bond, a lower alkylene group which may optionally be substituted, or a lower alkenylene group;
R10 represents a heterocyclic group which may optionally be substituted, a carboxyl group, a lower alkoxycarbonyl group, a carbamoyl group, a mono- or di-lower alkylaminocarbonyl group, an amino group, or a mono- or di-lower alkylamino group;
A4 represents a lower alkylene group which may optionally be substituted by a hydroxy or lower alkoxy group;
and R11 and R12, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group:
or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
(I) wherein R1, R2, R3 and R4, which may be the same or different, each independently represents a hydrogen atom, a halogen atom, a lower alkyl group, a halo-substituted lower alkyl group, a lower alkoxy group, a cyano group, a nitro group, an amino group, a lower alkanoylamino group, a lower alkylsulfonylamino group, a lower alkylsulfonyl group, or an arylsulfonyl group;
R5 and R6, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group;
R7 represents a hydroxy-lower alkyl group, a carbocyclic group which may optionally be substituted, a heterocyclic group which may optionally be substituted, a group of the formula -A1-R8, a group of the formula , a group of the formula , or a group of the formula ;
A1 represents a lower alkylene group or a hydroxy-lower alkylene group;
R8 represents an aryl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, or a lower alkenyloxy group;
A2 represents a lower alkylene group;
R9 represents a lower alkyl group, an aryl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, a hydroxy group, a lower alkoxy group, an amino group, a mono- or di-lower alkylamino group, a hydroxy-lower alkylamino group, an aralkylamino group, or an arylamino group;
A3 represents a single bond, a lower alkylene group which may optionally be substituted, or a lower alkenylene group;
R10 represents a heterocyclic group which may optionally be substituted, a carboxyl group, a lower alkoxycarbonyl group, a carbamoyl group, a mono- or di-lower alkylaminocarbonyl group, an amino group, or a mono- or di-lower alkylamino group;
A4 represents a lower alkylene group which may optionally be substituted by a hydroxy or lower alkoxy group;
and R11 and R12, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group:
or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
11. A process for producing a benzoxazine derivative of the formula (Ic):
(Ic) or a salt thereof, which comprises reacting an N-free benzoxazine derivative of the formula (IV):
(IV) with a halide, a sulfonate or an ester of the formula (V):
R7c-Y1 (V) wherein, in formulas (Ic), (IV) and (V), R1, R2, R3 and R4, which may be the same or different, each independently represents a hydrogen atom, a halogen atom, a lower alkyl group, a halo-substituted lower alkyl group, a lower alkoxy group, a cyano group, a nitro group, an amino group, a lower alkanoylamino group, a lower alkylsulfonylamino group, a lower alkylsulfonyl group, or an arylsulfonyl group;
R5 and R6, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group;
R7c represents a heterocyclic group which is available for bonding through a ring-forming carbon atom (not a hetero atom) and may optionally have a substituent or substituents, a group of the formula -A1c-R8c; a group of the formula , a group of the formula , and a group of the formula ;
A1c represents a lower alkylene group;
R8c represents an aryl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, or a lower alkenyloxy group, when A1c represents a non-substituted lower alkylene, R8c does not represent a phenyl group;
A2 represents a lower alkylene group;
R9 represents a lower alkyl group, an aryl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, a hydroxy group, a lower alkoxy group, an amino group, a mono- or di-lower alkylamino group, an aralkylamino group, or an arylamino group;
A3c represents a single bond, a lower alkylene or lower alkenylene group;
R10 represents a heterocyclic group which may optionally be substituted, a carboxyl group, a lower alkoxycarbonyl group, a carbamoyl group, a mono- or di-lower alkylaminocarbonyl group, an amino group, or a mono- or di-lower alkylamino group;
R14 represents a hydrogen atom, a lower alkyl group, or a lower alkoxycarbonyl group;
R15 and R16, which may be the same or different, each independently represents a lower alkyl group or combinedly represent a lower alkylene group, an o-phenylene group, or a carbonyl group to form a ring;
Z1 represents a carbonyl group, a methylene group, or a carbinol group; and Y1 represents a halogen atom, an alkyl or aryl sulfonyloxy group, or an ester residue.
(Ic) or a salt thereof, which comprises reacting an N-free benzoxazine derivative of the formula (IV):
(IV) with a halide, a sulfonate or an ester of the formula (V):
R7c-Y1 (V) wherein, in formulas (Ic), (IV) and (V), R1, R2, R3 and R4, which may be the same or different, each independently represents a hydrogen atom, a halogen atom, a lower alkyl group, a halo-substituted lower alkyl group, a lower alkoxy group, a cyano group, a nitro group, an amino group, a lower alkanoylamino group, a lower alkylsulfonylamino group, a lower alkylsulfonyl group, or an arylsulfonyl group;
R5 and R6, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group;
R7c represents a heterocyclic group which is available for bonding through a ring-forming carbon atom (not a hetero atom) and may optionally have a substituent or substituents, a group of the formula -A1c-R8c; a group of the formula , a group of the formula , and a group of the formula ;
A1c represents a lower alkylene group;
R8c represents an aryl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, or a lower alkenyloxy group, when A1c represents a non-substituted lower alkylene, R8c does not represent a phenyl group;
A2 represents a lower alkylene group;
R9 represents a lower alkyl group, an aryl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, a hydroxy group, a lower alkoxy group, an amino group, a mono- or di-lower alkylamino group, an aralkylamino group, or an arylamino group;
A3c represents a single bond, a lower alkylene or lower alkenylene group;
R10 represents a heterocyclic group which may optionally be substituted, a carboxyl group, a lower alkoxycarbonyl group, a carbamoyl group, a mono- or di-lower alkylaminocarbonyl group, an amino group, or a mono- or di-lower alkylamino group;
R14 represents a hydrogen atom, a lower alkyl group, or a lower alkoxycarbonyl group;
R15 and R16, which may be the same or different, each independently represents a lower alkyl group or combinedly represent a lower alkylene group, an o-phenylene group, or a carbonyl group to form a ring;
Z1 represents a carbonyl group, a methylene group, or a carbinol group; and Y1 represents a halogen atom, an alkyl or aryl sulfonyloxy group, or an ester residue.
12. A process for producing a benzoxazine derivative of the formula (Ie):
(Ie) or a salt thereof, which comprises reducing an 3-oxo-4-substituted carbonylalkylbenzoxazine derivative of the formula (IIa-1):
(IIa-1) and, when desired, further oxidizing the resulting hydroxyalkyl group-containing benzoxazine derivative of the formula (Id):
(Id) wherein, in formulas (Ie), (IIa-1) and (Id), R1, R2, R3 and R4, which may be the same or different, each independently represents a hydrogen atom, a halogen atom, a lower alkyl group, a halo-substituted lower alkyl group, a lower alkoxy group, a cyano group, a nitro group, an amino group, a lower alkanoylamino group, a lower alkylsulfonylamino group, a lower alkylsulfonyl group, or an arylsulfonyl group;
R5 and R6, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group;
R7a-1 represents a group of the formula or a group of the formula ;
A2 represents a lower alkylene group;
R9 represents a lower alkyl group, an aryl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, a hydroxy group, a lower alkoxy group, an amino group, a mono- or di-lower alkylamino group, an aralkylamino group, or an arylamino group;
R14 represents a hydrogen atom or a lower alkyl group, or a lower alkoxycarbonyl group;
R15 and R16, which may be the same or different, each independently represents a lower alkyl group or combinedly represent a lower alkylene, o-phenylene or carbonyl group to form a ring;
A5 represents a group represented by A2 or a group of the formula in which R14 and R15 are as defined above;
R17 represents a group represented by R9 or R16 which are as defined above.
(Ie) or a salt thereof, which comprises reducing an 3-oxo-4-substituted carbonylalkylbenzoxazine derivative of the formula (IIa-1):
(IIa-1) and, when desired, further oxidizing the resulting hydroxyalkyl group-containing benzoxazine derivative of the formula (Id):
(Id) wherein, in formulas (Ie), (IIa-1) and (Id), R1, R2, R3 and R4, which may be the same or different, each independently represents a hydrogen atom, a halogen atom, a lower alkyl group, a halo-substituted lower alkyl group, a lower alkoxy group, a cyano group, a nitro group, an amino group, a lower alkanoylamino group, a lower alkylsulfonylamino group, a lower alkylsulfonyl group, or an arylsulfonyl group;
R5 and R6, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group;
R7a-1 represents a group of the formula or a group of the formula ;
A2 represents a lower alkylene group;
R9 represents a lower alkyl group, an aryl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, a hydroxy group, a lower alkoxy group, an amino group, a mono- or di-lower alkylamino group, an aralkylamino group, or an arylamino group;
R14 represents a hydrogen atom or a lower alkyl group, or a lower alkoxycarbonyl group;
R15 and R16, which may be the same or different, each independently represents a lower alkyl group or combinedly represent a lower alkylene, o-phenylene or carbonyl group to form a ring;
A5 represents a group represented by A2 or a group of the formula in which R14 and R15 are as defined above;
R17 represents a group represented by R9 or R16 which are as defined above.
13. A process for producing a benzoxazine derivative of the formula (If):
(If) or a salt thereof, which comprises subjecting a haloalkanoylaminobenzoxazine derivative of the formula (X):
(X) to cyclization, wherein, in formulas (If) and (X), R1, R2, R3 and R4, which may be the same or different, each independently represents a hydrogen atom, a halogen atom, a lower alkyl group, a halo-substituted lower alkyl group, a lower alkoxy group, a cyano group, a nitro group, an amino group, a lower alkanoylamino group, a lower alkylsulfonylamino group, a lower alkylsulfonyl group, or an arylsulfonyl group;
R5 and R6, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group;
R18 represents a halo-substituted propyl or a halo-substituted butyl group; and A6 represents a tri- or tetramethylene group.
(If) or a salt thereof, which comprises subjecting a haloalkanoylaminobenzoxazine derivative of the formula (X):
(X) to cyclization, wherein, in formulas (If) and (X), R1, R2, R3 and R4, which may be the same or different, each independently represents a hydrogen atom, a halogen atom, a lower alkyl group, a halo-substituted lower alkyl group, a lower alkoxy group, a cyano group, a nitro group, an amino group, a lower alkanoylamino group, a lower alkylsulfonylamino group, a lower alkylsulfonyl group, or an arylsulfonyl group;
R5 and R6, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group;
R18 represents a halo-substituted propyl or a halo-substituted butyl group; and A6 represents a tri- or tetramethylene group.
14. A process for producing an aminocarbonyl group-containing benzoxazine derivative of the formula (Ih):
(Ih) or a salt thereof, which comprises reacting a carboxylic acid of the formula (Ig):
(Ig) or a reactive derivative thereof with an amine of the formula (XI):
(XI) wherein, in formulas (Ih), (Ig) and (XI), R1, R2, R3 and R4, which may be the same or different, each independently represents a hydrogen atom, a halogen atom, a lower alkyl group, a halo-substituted lower alkyl group, a lower alkoxy group, a cyano group, a nitro group, an amino group, a lower alkanoylamino group, a lower alkylsulfonylamino group, a lower alkylsulfonyl group, or an arylsulfonyl group;
R5 and R6, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group;
A7 represents a lower alkylene group or a group of the formula ;
A3 represents a single bond, a lower alkylene group which may optionally be substituted, or a lower alkenylene group;
R19 and R20, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group or combinedly form a heterocyclic group which may optionally be substituted.
(Ih) or a salt thereof, which comprises reacting a carboxylic acid of the formula (Ig):
(Ig) or a reactive derivative thereof with an amine of the formula (XI):
(XI) wherein, in formulas (Ih), (Ig) and (XI), R1, R2, R3 and R4, which may be the same or different, each independently represents a hydrogen atom, a halogen atom, a lower alkyl group, a halo-substituted lower alkyl group, a lower alkoxy group, a cyano group, a nitro group, an amino group, a lower alkanoylamino group, a lower alkylsulfonylamino group, a lower alkylsulfonyl group, or an arylsulfonyl group;
R5 and R6, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group;
A7 represents a lower alkylene group or a group of the formula ;
A3 represents a single bond, a lower alkylene group which may optionally be substituted, or a lower alkenylene group;
R19 and R20, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group or combinedly form a heterocyclic group which may optionally be substituted.
15. A process for producing an N-oxide form heterocycle-substituted benzoxazine derivative of the formula (Ij):
(Ij) or a salt thereof, which comprises oxidizing a compound of the formula (Ii):
(Ii) wherein, in formulas (Ij) and (Ii), R1, R2, R3 and R4, which may be the same or different, each independently represents a hydrogen atom, a halogen atom, a lower alkyl group, a halo-substituted lower alkyl group, a lower alkoxy group, a cyano group, a nitro group, an amino group, a lower alkanoylamino group, a lower alkylsulfonylamino group, a lower alkylsulfonyl group, or an arylsulfonyl group;
R5 and R6, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group;
A8 represents a single bond, a group represented by A1, or a group of the formula:
;
A1 represents a lower alkylene group or a hydroxy-lower alkylene group;
A3 represents a single bond, a lower alkylene group which may optionally be substituted, or a lower alkenylene group; and represents a nitrogen-containing monocyclic or bicyclic heteroaromatic group which may optionally be substituted.
(Ij) or a salt thereof, which comprises oxidizing a compound of the formula (Ii):
(Ii) wherein, in formulas (Ij) and (Ii), R1, R2, R3 and R4, which may be the same or different, each independently represents a hydrogen atom, a halogen atom, a lower alkyl group, a halo-substituted lower alkyl group, a lower alkoxy group, a cyano group, a nitro group, an amino group, a lower alkanoylamino group, a lower alkylsulfonylamino group, a lower alkylsulfonyl group, or an arylsulfonyl group;
R5 and R6, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group;
A8 represents a single bond, a group represented by A1, or a group of the formula:
;
A1 represents a lower alkylene group or a hydroxy-lower alkylene group;
A3 represents a single bond, a lower alkylene group which may optionally be substituted, or a lower alkenylene group; and represents a nitrogen-containing monocyclic or bicyclic heteroaromatic group which may optionally be substituted.
16. A process for producing a benzoxazine derivative of the formula (Ik):
(Ik) or a salt thereof, which comprises reacting an N-free benzoxazine derivative of the formula (IV):
(IV) with a dihalide or diketone of the formula (XII):
(XII) wherein, in formulas (Ik), (IV) and (XII), R1, R2, R3 and R4, which may be the same or different, each independently represents a hydrogen atom, a halogen atom, a lower alkyl group, a halo-substituted lower alkyl group, a lower alkoxy group, a cyano group, a nitro group, an amino group, a lower alkanoylamino group, a lower alkylsulfonylamino group, a lower alkylsulfonyl group, or an arylsulfonyl group;
R5 and R6, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group;
Y2 represents a halogen atom or, when taken together with Y3, represents a carbonyl oxygen atom;
Y3 represents a halogen atom or, when taken together with Y2, represents a carbonyl oxygen atom, or a hydrogen atom when Y4 is a halogen atom; and Y4 represents a hydrogen atom when Y2 and Y3 are both halogen atoms or combinedly represent a carbonyl oxygen atom, or represents a halogen atom when Y2 is a halogen atom and Y3 is a hydrogen atom;
R14 represents a hydrogen atom or a lower alkyl or lower alkoxycarbonyl group; and R15 and R16, which may be the same or different, each independently represents a lower alkyl group or combinedly represent a lower alkylene or o-phenylene group or a carbonyl group (when Y2 is a halogen atom) to form a ring.
(Ik) or a salt thereof, which comprises reacting an N-free benzoxazine derivative of the formula (IV):
(IV) with a dihalide or diketone of the formula (XII):
(XII) wherein, in formulas (Ik), (IV) and (XII), R1, R2, R3 and R4, which may be the same or different, each independently represents a hydrogen atom, a halogen atom, a lower alkyl group, a halo-substituted lower alkyl group, a lower alkoxy group, a cyano group, a nitro group, an amino group, a lower alkanoylamino group, a lower alkylsulfonylamino group, a lower alkylsulfonyl group, or an arylsulfonyl group;
R5 and R6, which may be the same or different, each independently represents a hydrogen atom or a lower alkyl group;
Y2 represents a halogen atom or, when taken together with Y3, represents a carbonyl oxygen atom;
Y3 represents a halogen atom or, when taken together with Y2, represents a carbonyl oxygen atom, or a hydrogen atom when Y4 is a halogen atom; and Y4 represents a hydrogen atom when Y2 and Y3 are both halogen atoms or combinedly represent a carbonyl oxygen atom, or represents a halogen atom when Y2 is a halogen atom and Y3 is a hydrogen atom;
R14 represents a hydrogen atom or a lower alkyl or lower alkoxycarbonyl group; and R15 and R16, which may be the same or different, each independently represents a lower alkyl group or combinedly represent a lower alkylene or o-phenylene group or a carbonyl group (when Y2 is a halogen atom) to form a ring.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP29072789 | 1989-11-08 | ||
JP1-290727 | 1989-11-08 | ||
JP31592689 | 1989-12-05 | ||
JP1-315926 | 1989-12-05 | ||
JP34293789 | 1989-12-28 | ||
JP1-342937 | 1989-12-28 | ||
JP1-208485 | 1990-08-06 | ||
JP20848590A JPH04102517A (en) | 1990-08-06 | 1990-08-06 | Automatic bow-tie tying machine |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2029569A1 true CA2029569A1 (en) | 1991-05-09 |
Family
ID=27476412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002029569A Abandoned CA2029569A1 (en) | 1989-11-08 | 1990-11-08 | Benzoxazine derivatives and pharmaceutical compositions containing the same |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2029569A1 (en) |
-
1990
- 1990-11-08 CA CA002029569A patent/CA2029569A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR950007757B1 (en) | Benzoxazine derivatives, their preparation and pharmaceutical compositions containing them | |
US5756496A (en) | Amide derivatives having 5HT1D-antagonist activity | |
US4524206A (en) | 1-Heteroaryl-4-(2,5-pyrrolidinedion-1-yl)alkyl)piperazine derivatives | |
CA1317955C (en) | 3-¬4(1-substituted-4-piperazinyl)butyl|-4- thiazolidinones a process for their preparation and their use as medicaments | |
US5359068A (en) | Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one | |
AU4513999A (en) | Nitrate salts of antihypertensive medicines | |
US4490369A (en) | Benzazepine derivatives, their pharmaceutical compositions and method of use | |
CZ20024199A3 (en) | Substituted 1-aminoalkyl lactams and their use as muscarine receptor antagonist | |
SE465928B (en) | 1,2,4-TRIAZOLONE COMPOUNDS WITH ANTIDEPRESSIVE ACTIVITY, PROCEDURES FOR PREPARING THESE AND A PHARMACEUTICAL COMPOSITION | |
JPH0641455B2 (en) | Pyridazinone derivative | |
CA2518403A1 (en) | Quinolinone/benzoxazinone derivatives and uses thereof | |
US5420126A (en) | 3,4-dihydro-2H-1,4-benzoxazine derivatives and pharmaceutical compositions containing the same | |
US4960778A (en) | Benzoxazolinone compounds | |
EP0549666A1 (en) | NEW AMINOBENZOSULTAM DERIVATIVES AND THEIR USE AS A LIPOXYGENASE INHIBITOR. | |
US5179111A (en) | Imidazole derivatives | |
AU692862B2 (en) | Aryl and heteroaryl alkoxynaphthalene derivatives | |
CA2029569A1 (en) | Benzoxazine derivatives and pharmaceutical compositions containing the same | |
US5753682A (en) | Imidazole lipoxygenase inhibitors | |
CA1278573C (en) | Dihydropyridines | |
US5574033A (en) | Heterocyclic compound and cardiotonic agent containing the same as effective component | |
US5773448A (en) | Pharmaceutical compounds | |
CA2021340C (en) | Cyclic vinylogous n-hydroxy-n-methylureas useful as 5-lipoxygenase inhibitors | |
US5071863A (en) | 4,5,6,7-trisubstituted benzoxazolones | |
US5278158A (en) | Oxazinobenzazole compounds | |
CA1215711A (en) | 3-(ureidocyclohexylamino)-propane-1,2-diol- derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |